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The role of transmembrane mucin protein MUC1 in anoikis 
and EGFR activation of human epithelial cancer cells 
 
MUC1 is a large, heavily glycosylated transmembrane mucin protein expressed on 
the apical membrane of normal epithelial cells. In epithelial cancer cells, however, 
MUC1 is overexpressed, abnormally glycosylated and loses its apical polarization, 
becoming expressed over the entire cell surface.   
Galectin-3, a β-galactoside-binding protein expressed by many types of human cells, 
is a natural ligand for MUC1. Recent studies by ourselves and others have revealed 
that the interaction between galectin-3 and MUC1 induces MUC1 cell surface 
polarization and the exposure of underlying smaller cell surface adhesion molecules. 
This leads to increased cancer cell homotypic aggregation and cancer cell 
(heterotypic) adhesion to vascular endothelium.  
Recently, mucin-1 (MUC1) was reported to be associated with epidermal growth 
factor receptor (EGFR) in epithelial cells. EGFR is a receptor tyrosine kinase involved 
in the regulation of multiple cellular process, including tumour proliferation and 
metastasis. Changes in MUC1, galectin-3 and EGFR expression have all, individually 
or in combination, been associated with poor cancer prognosis and increased tumour 
metastasis. Resistance of cancer cells to anoikis, a fundamental cellular process for 
maintaining tissue homeostasis, is a pre-requisite for metastasis. The aim of this 
study was to investigate the impact of MUC1 expression and the MUC1 interaction 
with galectin-3 and EGFR on EGFR activation and anoikis in epithelial cancer cells.  
It was found in this study, that overexpression of MUC1 in epithelial cells prevents 
initiation of anoikis in response to loss of adhesion. This effect was found to be 
attributed to both MUC1 extracellular and intracellular domains with predominant 
effect from the MUC1 extracellular domain. Reduction of MUC1 O-glycosylation by 
stable shRNA suppression of core 1 gal-transferase (C1GT) reduced MUC1-mediated 
resistance to anoikis in human colon cancer cells HCT116 and SW620. It was also 
found that MUC1 expression enhanced EGF-induced EGFR activation in human breast 
and colon cancer cells. Both the MUC1 extracellular and intracellular domains 
contribute to EGFR activation, again with the predominant contribution from the 
MUC1 extracellular domain. Thus, binding of galectin-3 to the MUC1 extracellular 
domain induces MUC1 cell surface polarization and increases MUC1–EGFR 
interaction, leading to increased EGFR homo-/hetero-dimerization and activation. 
These discoveries provide insight into the impact of MUC1 overexpression and MUC1 
O-glycosylation on cancer cell behaviour in cancer progression and metastasis and 
may aid future development of novel therapeutic strategies for cancer treatment.  
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Abbreviation 
AKT     Protein Kinase B 
APAF 1     Apoptotic protease activating factor 1 
AREG        Amphiregulin 
BCA                                                           Bicinchoninic acid 
BCL2     B-cell lymphoma 2 
BH3 domain protein      BCL2 homology domain 3 
Bid     BH3 interacting-domain  
t-Bid                  Truncated Bid 
BRCA 1                                                     Breast cancer gene 1 
BRCA 2                                                     Breast cancer gene 2 
BSA     Bovine serum albumin 
BTC      Betacellulin 
C1GT      Core 1 Gal-transferase 
C3GnT     Core 3 GlcN Ac-transferase 
CRD      Carbohydrate recognition domain 
DAG      Diacylglycerol 
DiL stain                                                   1,1'-dioctadecyl-3,3,3'3'-              
                                                                   tetramethylindocarbocyanine perchlorate           
DISC      Death inducing signalling complex 
ECM     Extracellular Matrix 
EGF     Epidermal growth factor 
EGFR     Epidermal growth factor receptor(ErbB1) 
EPI      Epigen 
EREG      Epiregulin 
ERK      Extracellular signal–regulated kinases 
FAK     Focal adhesion kinase 
FADD       Fas associated death domain 
Fas-L     Fas ligand 
bFGF         Basic fibroblast growth factor 
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FLIP      FLICE-like inhibitory protein 
Gal                                                            Galactose 
Gal3F     Full form galectin-3 with both N and C terminal 
Gal3C     Truncated galectin-3 without N terminal 
GlcNAc                                                     N-Acetyl glucosamine 
GalNAc     N-acetyl-galactosamine 
ppGalNAc-Ts      Polypeptide GalNAc-transferases 
GRB2      Growth factor receptor binding protein 2 
GSL-II     Griffonia (Bandeiraea) Simplicifolia Lectin II 
HB-EGF    Heparin-binding EGF-like growth factor 
HIF 1     Hypoxia-inducible factor 1 
HIF 2     Hypoxia-inducible factor 2 
HGF     Hepatocyte growth factor 
HMOX 1                                                   Heme oxygenase 1 
HMOX 2                                                   Heme oxygenase 2 
cIAP 1                                                       Cellular inhibitor of apoptosis protein 1 
cIAP 2                                                       Cellular inhibitor of apoptosis protein 2 
ILK     Integrin-linked protein kinase 
IP3                       1,4,5-triphosphate 
MAPK      Mitogen-activated protein kinases 
MEK 1      Mitogen-activated protein kinase kinase 1  
MEK 2      Mitogen-activated protein kinase kinase  2  
MYBL2         v-myb myeloblastosis viral oncogene homolog-                
like 2 
NF-kB Nuclear factor kappa-light-chain-enhancer of 
activated B cells 
OMM       Outer mitochondrial membrane 
PERK                                                               Phosphorylated Extracellular signal–regulated     
                                                                  kinases 
PERP     p53-effector related to pmp22 
PI Propidium Iodide  
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PI3K Phosphatidylinositol-4,5-bisphosphate 3-
kinase   
PIP2      Phosphatidylinositol-4,5-bisphosphate 
PIP3      Phosphatidylinositol-3,4,5-triphosphate 
PKB                      Protein kinase B 
PKC      Protein kinase C 
PNA     Peanut Agglutinin 
PON2                                                        Paraoxonase 2 
PS     Phosphatidylserine 
PTEN     Phosphatase and tensin homolog 
SH2      Src homology 2 
sialyl-Tn    Neu5Ac β1,6GalNAcα 
SMA     α-smooth muscle actin 
sos     Son of sevenless 
SOS1      Son of sevenless 1 
SRC      Src homology and collagen 
ST7                                                            Suppressor of tumorigenicity protein 7 
ST14                                                               Suppressor of tumorigenicity protein 14 
ST6GalNAc-T                        GalNAc α 2,6  Sialyltransferase II 
TGF     Transforming growth factor 
TGF-α     Transforming growth factor-α 
TKI     Tyrosine kinase inhibitors 
TNF-α     Tumour necrosis factor α 
TNF RI/ TNF RSF Tumor necrosis factor receptor superfamily 
mTOR      Mammalian target of rapamycin 
TRAIL                                                        TNF-related apoptosis-inducing ligand 
XIAP                                                          X-linked inhibitor of apoptosis protein 
VNTR                 Variable number tandem repeat 
VVA     Vicia Villosa Lectin 
ZEB1                                Zinc finger E-box-binding homeobox 1  
ZEB2                                Zinc finger E-box-binding homeobox 2  
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1.1 Epithelial cancer  
1.1.1 Epidemiology 
Cancer can be defined as a disease where a group of cells disregard the normal rules 
of cell division and tissue homeostasis. Normal cells adhere to strict cellular signals 
that dictate whether a cell should divide, differentiate or undergo apoptosis. Cancer 
cells develop a certain degree of autonomy from these signals and are able to divide 
and proliferate independently. It is the uncontrolled cellular division, dissemination, 
survival and proliferation of these tumour cells that leads to poor prognosis and 
complications associated with cancer. 
Epithelial cancers, also known as carcinomas, are currently the most prevalent cancer 
being diagnosed across Europe (1). In the UK alone, epithelial cancer originating in 
lung, bowel, breast and prostate together accounted for almost half (46%) of all 
cancer deaths in the UK in 2014 (2, 3). Tumour metastasis is the primary reason for 
cancer-related death. Although the mortality rate for all neoplasms has been falling 
over the last 2 decades, cancer-associated complications still remains the major 
cause of death in the UK (4). 
 
1.1.2 Molecular basis of cancer 
Nonlethal genetic damage is the initiator of carcinogenesis in the majority of 
epithelial cancers. Such genetic damage can generally be acquired from a variety of 
sources, such as carcinogens, radiation, viruses, tobacco smoking or it could be 
inherited in the germline. The genetic hypothesis of cancer implies that a tumour is 
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formed by the clonal expansion of a single precursor cell that has incurred genetic 
damage (5, 6). In the majority of tumours, four classes of normal regulatory genes 
are generally altered, which collectively confers growth and survival advantages of 
the tumour cells over normal cells. These are the growth promoting proto-
oncogenes, the growth inhibiting tumour suppressor genes, genes that regulate 
programmed cell death (apoptosis), and genes that are involved in DNA repair (5). 
Oncogenes are genes that promote autonomous cell growth in cancer cells. They are 
derived by mutations in proto-oncogenes and are characterised by the ability to 
promote cell growth in the absence of normal growth promoting signals (7). The 
mutant allele of a proto-oncogenes is considered dominant because it transforms 
cells despite the presence of a normal counterparts. Since 1970s, dozens of 
oncogenes have been reported and characterized, with human epidermal growth 
factor receptor 2 (HER-2/neu erbB-2), telomerase reverse transcriptase (hTERT), RAS 
and SRC being some of the major oncogenes reported in epithelial cancers (8, 9). 
Tumor suppressor genes normally functions as an inhibitor against cancer 
development. Mutation leading to loss of function or insufficient expression of tumor 
suppressor genes leads to cancer progression. In contrast to oncogenes, which are 
generally dominant, the tumour suppressor family of genes are sometime referred 
as recessive oncogenes, as both alleles must be damaged to render a loss of 
protection against tumour transformation (10, 11). However, recently haplo-
insufficiency has also been noted (12, 13), whereby loss of a single allele of a tumour 
suppressor gene has been shown to promote transformation. Key examples of 
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tumour suppressor genes include the retinoblastoma protein RB and p53. Other 
examples of tumour suppressor genes include ST7, ST14 and PTEN. 
Genes that regulate apoptosis may be dominant or recessive (5). A wide variety of 
proteins control extrinsic and intrinsic apoptosis which will be discussed later. In 
short, there are sets of pro- and anti- apoptotic proteins whose activation and 
expression is tightly controlled in normal cells. In tumour cells, this balance is shifted 
towards promotion of anti-apoptotic protein. This is achieved via direct promotion 
in the activation of key anti-apoptotic proteins and/or suppression of key pro-
apoptotic proteins. An example of this can be seen in seen in gastric cancer,  where 
there is a downregulation in the expression level of the pro-apoptotic protein FAS, a 
key component of extrinsic apoptosis pathways (14) while at the same time there is 
an increase in the expression of  anti-apoptotic FLICE-like inhibitory protein (FLIP), an 
inhibitor of FAS-mediated apoptosis (15).   
Structural damage to DNA is remarkably common. Fortunately, normal cells have an 
in-house DNA repair mechanism that seeks out these structural damages to the DNA 
molecule and exerts a targeted fix.  Mutations to genes responsible for DNA repair 
have been reported in a variety of cancers including breast, colon, pancreatic and 
prostate cancer (16-18). Such mutations do not directly transform cells by affecting 
proliferation or apoptosis. Instead, they have an indirect effect whereby they 
influence the ability of an organism to repair non-lethal damage to their genes 
including proto oncogenes, tumour suppressor genes and genes that regulate 
apoptosis. A prolonged disability in the DNA repair genes can predispose a cell to 
widespread mutations in the genome and eventually to neoplastic transformation. 
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Breast cancer 1 (BRCA1) and breast cancer 2 (BRCA2) genes have been identified to 
play a key role in the DNA repair process, and their alterations are strongly associated 
with the morbidity of in a variety of epithelial cancers (17-19). 
Carcinogenesis is a multistep process at both the phenotypic and the genetic level. 
The nonlethal genetic damage leads to initial mutation in the cells, which if not 
repaired, leads to mutation accumulation and acquisition of greater malignant 
potential. Even though most malignant tumours are initially monoclonal, by the time 
they are clinically detected, the tumour cells are extremely heterogenous (5). 
Tumour heterogeneity plays a key role in several acquired phenotypic attributes of a 
developing tumour such as excessive growth, local invasiveness and the ability to 
form distant metastasis – collectively termed the hallmarks of cancer 
 
 1.1.3 Essential alterations for malignant transformation in epithelial 
cancer 
 A key paper published by Douglas Hanahan and Robert Weinberg initially identified 
six biological capabilities acquired during the multistep development of human 
tumours (20). Termed hallmarks of cancer these capabilities include 1) self-sustained 
proliferative signalling without external stimuli, 2) insensitivity to growth inhibitory 
signals, 3) mechanisms to evade apoptosis 4) limitless replication potential leading 
to immortality, 5) ability to maintain sustained angiogenesis and neovascularization 
and, 6) the ability to invade and metastasize.  In an updated publication in 2011 (21), 
Weinberg and Hanahan proposed four new hallmarks: 1) abnormal metabolic 
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pathways, 2) evading the immune system, 3) genome instability and 4) inflammation 
(21) leading to overall ten hallmarks of cancer.   
 
Figure 1.1: The ten hallmarks of cancer. The figure illustrates the ten biological 
capabilities acquired during the multistep development of human tumours and  
adapted from (21) (permission acquired from Cell, licence no 4296971476301) 
 
Genome instability is the underlying cause for the acquisition of these hallmarks.   
Furthermore, conceptual progress in the last two decades has identified two 
emerging hallmarks of cancer— altered energy metabolism of tumour cells and the 
ability to evade immune-mediated destruction (21). Additionally, more and more 
research is pointing towards the significance of the tumour microenvironment and 
inflammation in the acquisition of tumour transformation and metastasis.  
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Better understanding of the widespread applicability of these concepts has a 
potential to identify new undiscovered mechanisms that can eventually lead to new 
means of treating human cancer. Keeping with the genetic instability noted in most 
cancer cells, previous work done by our lab and others has identified that epithelial 
cancer cells show an overexpression of cell surface mucin protein MUC1 (22-25). 
MUC1 overexpression has been shown to promote tumour cells ability to invade and 
metastasise (23, 25, 26), one of the hallmarks of cancer mentioned above. The 
thinking behind this thesis has been to explore if MUC1 expression allows tumour 
cells in acquisition of further tumour-associated phenotype.  
1.2 Mucins    
MUC1 belongs to the mucin family of proteins. The mucin family of proteins are large, 
heavily glycosylated and are often expressed by epithelia of respiratory, 
gastrointestinal and reproductive tracts (27). Over the years, the different mucin 
members have been categorised as secretory or membrane-bound mucins. Secretory 
mucins are primarily gel-forming as they coat the epithelial surface and function as a 
protective barrier for underlying mucosal surface. Membrane-bound mucins could 
potentially act as a second line of defence, however recently they have been shown 
to engage in signal transduction events (28, 29). Of the known mucins to date, the 
secretory family of mucins include MUC2, MUC5AC, MUC5B, MUC6 and MUC7, 
MUC9 and MUC19 whereas the membrane-bound mucins include MUC1, MUC3, 
MUC4, MUC11, MUC12, MUC13, MUC15, MUC16, MUC17 and MUC20.  In addition 
to playing a physical barrier to underlying mucosa, mucins also have an essential role 
in lubrication, chemical sensing and molecular configuration of extracellular matrix 
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(ECM) as well as having a role in relaying and facilitating extracellular stimulus into 
cell signalling (30-32). 
1.2.1 MUC1 structure 
The MUC1 gene encodes a single polypeptide chain which is autoproteolytically 
cleaved into two peptide fragments; the longer N terminal (MUC1-N) and the shorter 
C terminal (MUC1-C) (33, 34). Extracellularly the two subunits remain associated 
through stable hydrogen bonds. MUC1-N includes a proline, theronine and serine 
rich VNTR (variable number of tandem repeat) region encoded by highly polymorphic 
exons encoding for multiple 20-21 amino acid sequence repeats (35). In northern 
Europeans, VNTR is composed of 20-120 repeats with 40-80 repeats being most 
common (36). 
In normal cells, MUC1 is extensively 0-glycosylated and moderately N-glycosylated 
with glycosylation contributing to 50- 90% of total weight of MUC1. Based on cell 
type, the number of tandem repeats in the VNTR and the amount of glycosylation, 
the weight of MUC1 can vary between 250-500 kDa. The majority of MUC1 O-
glycosylation happens in the serine and threonine rich VNTR region. There are 5 
potential sites for MUC1 N-glycosylation, 4 of which reside in degenerate sequence 
of MUC1 which bears subtle sequence similarity to the VNTR region and one in the 
extracellular domain of MUC1-C (37) (Figure 1.2). 
MUC1-C is short, comprising a 58-amino acid extracellular domain, a 28-amino acid 
transmembrane domain (TMD), and a 72-amino acid cytoplasmic tail (CT) (Figure 1A). 
The intracellular tail of MUC1 has 22 potential phosphorylation sites which have been 
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shown to have a key role in cell signalling (32, 38-40). Based on the N-glycosylation 
state of the ECD, the molecular weight of MUC1-C can vary from 17 to 25 kDa (37). 
 
 
  
                              
Figure 1.2: Schematic representation of structure of MUC1 adapted from (37) 
(permission acquired from Cell, licence no 4296980503660) 
 
1.2.2 MUC1 glycosylation 
The glycosylation pattern of MUC1 varies depending upon the tissue-specific 
expression of the glycosyltransferases (33). Potentially five types of glycans can be 
produced by a cell ranging from N-linked glycosylation, O-linked glycosylation, 
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phosphor-serine glycosylation, c-linked glycosylation and glypiation. Of these, the N-
glycosylation and the O-glycosylation dominates in MUC1. The N-glycosylation of 
MUC1 is vital for protein folding, sorting, secretion and apical expression in polarized 
cells whereas O-glycosylation correlates with its biological properties (41).  In normal 
cells, MUC1 is heavily glycosylated, with the peptide core masked by the sugar chains 
that shield it from undergoing proteolytic cleavage by environmental enzymes. 
Additionally, glycosylation also stabilizes mucins at the cell surface by preventing 
them from undergoing clathrin-mediated endocytosis (42). 
The process by which MUC1 O-glycosylation occurs is well characterised, although 
relatively little is known about its regulation (43-46). The biosynthesis process starts 
with the addition of N-acetyl-galactosamine (GalNAc) to the serine (Ser) or threonine 
(Thr) residues, present extensively in MUC1 VNTR region, to form the initial O-linked 
GalNAcα-Ser/Thr structure (Tn antigen) catalysed by one or two of a large family of 
up to 20 distinct UDP-N-acetyl-α-D-galactosamine polypeptide GalNAc-transferases 
(ppGalNAc-Ts) (43, 47).  This first step of biosynthesis for O-linked mucin type glycans 
is believed to start in an inter ER-Golgi compartment and finish in the Golgi 
apparatus. Following the formation of Tn antigen, the GalNAc residue can be 
modified by either addition of a Gal residue catalysed by the Core 1 Gal-transferase 
(C1GT) or  with addition of a GlcNAc residue catalysed by the Core 3 GlcNAc-
transferase (C3GnT) or with addition of a sialic acid residue by a sialyl-transferase 
(ST6GalNAc-T) to form Core 1 structure, Galβ1,3GalNAcα- [Thomsen-Friedenreich 
(TF) antigen], Core 3 structure of GlcNAcβ1,3GalNAcα- and Neu5Acβ1,6GalNAcα- 
(sialyl-Tn), respectively (48-52). The formation of sialyl-Tn terminates the sugar chain 
whilst the TF and Core 3 structures can be further acted on by other 
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glycosyltransferases in a stepwise fashion to yield up to 8 core complex glycosylation 
structures (53). It has recently been found that C3GnT, ST6GalNAc-T and C1GT 
directly compete with each other for accessibility to Tn structure and that 
suppression of one of these transferases leads to increased activity of others (54). 
 
1.2.3 Physiological role of MUC1 
Mucins have numerous functions in the body, especially in epithelial cells where their 
high degree of glycosylation provides lubrication, prevents dehydration and offers 
protection against proteolysis. Mucins in epithelial cells also have a role in protection 
against microbial challenge by acting as a physical barrier and inhibiting microbial 
access to the cell surface. (55, 56) Bacterial adhesins have been shown to bind mucin 
carbohydrate at the cell surface (57, 58), implicating a role of mucins as a barrier to 
potential infections.   
Additionally, MUC1 in particular has been shown to modulate cell-cell and cell-ECM 
interaction (59, 60) and it has been proposed that MUC1 overexpression may 
promote metastasis via its interference with these interactions (61, 62). The number 
of tandem repeats in the MUC1 extracellular domain plays a crucial role in such 
interactions, as it has been shown that a reduction in VNTR makes MUC1 ineffective 
inhibitors of cell-cell and cell-ECM interactions (63, 64). 
MUC1 intracellular domain, with its 22 potential phosphorylation sites, has been 
implicated in various cell signalling (65). Many intracellular signalling proteins have 
been reported to interact with the MUC1 intracellular domain, e.g. including PI3K, 
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Shc, PLC1, c-Src, Grb-2, p53, IKKβ, IKKγ, β-catenin, HSP90 and HSP70 (66). Interaction 
of the MUC1 cytoplasmic tail with β-catenin, son of sevenless (SOS) and Growth 
factor receptor-bound protein 2 (Grb2), has been shown to have a role in cell growth 
and wnt signalling in HEK 293 and gastric epithelial cells (67, 68).  
 
MUC1 has also been shown to have a role in protecting the endometrium from 
microbial attack and MUC1 needs to be down-regulated to allow embryo 
implantation (69, 70). In MUC1 null mice, loss of MUC1 leads to chronic infection and 
inflammation of the uterus (69) yet blastocysts are only able to attach to the uterine 
wall in these mice when MUC1 overexpression is minimised (70). Indeed, MUC1 
expression in mice is lost throughout the uterine epithelia by day 4 of pregnancy 
when the uterus is receptive to blastocyst attachment (71, 72). A similar effect is 
noted in the rabbit uterus, where although MUC1 expression is generally increased 
over the receptive phase, a local loss of MUC1 is noticed at implantation sites (73). 
In vitro studies indicate that human blastocysts produce factors that lead to local 
MUC1 loss on monolayers of human uterine epithelia (74). 
Studies in tumour cells have highlighted that the type and the amount of MUC1 
expressed in cancer cells modulate immune response to these cells. MUC1 is often 
less extensively glycosylated in tumour cells, exposing the physiologically inaccessible 
tumour specific epitopes that may trigger an immune response (75, 76). However, 
MUC1 has also been shown to supress immune surveillance of tumour cells (77, 78), 
highlighting both an immunostimulatory and an immunosuppressive function of 
MUC1. 
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1.2.4 MUC1 in epithelial cancers 
In physiological conditions, MUC1 expression is limited to the apical surfaces of the 
cell and MUC1 itself is heavily glycosylated. In cancer cells, this apical polarisation is 
lost and MUC1 is overly expressed and abnormally (less) glycosylated; leading to the 
exposure of oncofoetal antigens which would normally be 'covered' by the sugar 
chain (79). A high level of MUC1-N at the cell surface is known to interfere with cell-
cell and cell-extracellular matrix and is associated with increased malignancy (80, 81). 
Furthermore, since the typical length of the N terminal extends more than 10-fold 
beyond the length of a typical cell surface molecule, the over-expression of MUC1 in 
tumour cells causes it to act as a physical barrier to chemotherapeutic drugs and to 
the cells of the immune system.  
 
1.2.5 MUC1 extracellular domain and altered glycosylation in cancer 
MUC1 is a heterodimer that is co-translationally processed into two polypeptides, 
MUC1 extracellular domain (MUC1 ECD) and MUC1 transmembrane domain (MUC1- 
CD), which itself consists of a small stem region extracellularly, a transmembrane 
part, and a 72 amino acid long cytoplasmic tail (figure 1.2). The MUC1-ECD is linked 
to the stem region of MUC1-CD via non-covalent interactions. The MUC1 
extracellular domain, as mentioned previously, is heavily glycosylated, and this 
glycosylation contributes to a significant part of the molecular weight of the entire 
MUC1 molecule.  
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Many epithelial tumours have been shown to exhibit aberrant O-glycosylation (82-
84). The alteration in tumour glycosylation is mainly through three mechanisms. 
Firstly, neo synthesis or incomplete synthesis (85) may lead to increased expression 
of core 1 based structures, such as T, Tn or sialyl-Tn (86-88). These structures ae 
typically absent in healthy cells however in tumour cells increased expression of 
these truncated structure is driven mainly by alteration in expression, location and 
availability of molecular chaperone (Cosmc) of GalNAc-Ts (89-91).  Secondly, 
hypermethylation of Cosmc gene also significantly contributes to aberrant O-
glycosylation (92, 93). Finally, the relative positioning of the glycosyltransferases 
within the Golgi can lead to different O-glycosylation. Work by Kellokompu and 
colleagues (94, 95) and by Campbell and colleagues (96, 97)  has shown that Golgi 
derangement occurs in epithelial cancers and can be mimicked by agents that block 
normal Golgi acidification, in both cases leading to increased formation of oncofetal 
carbohydrate antigens.  
Phenotypically, overexpression of truncated mucin O-glycans is associated with 
increased aggressiveness and enhanced metastatic behaviour in a variety of cancers 
(87, 92, 98). These effects are, in parts, due to changes in the binding properties of 
key secreted and cell surface proteins that modulate interaction between tumour 
cells and the extracellular environment (e.g selectin and integrin) (98)  and the direct 
effect on receptor-ligand interactions that alter signal transduction in affected cells. 
Re-expression of enzymes that maintain and extend the carbohydrate chain, such as 
Cosmc and core-3-synthase, seems to decrease these aggressive effects, as seen in 
pancreatic cancer cells (99).  
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Extracellularly, altered glycosylation significantly influences the interaction of 
tumor cells with their immediate surrounding. One example is the interaction with 
immune cells. Altered glycosylation of mucins often evokes an immune response 
in the body, as evident by increased circulating antibodies against various epitopes 
of MUC1 in patients with advanced metastasis (100, 101). Currently, these 
aberrant glycosylations are being explored as a potential target for 
immunotherapies, including the design of chimeric antigen receptor T cell against 
Tn on MUC1 (102, 103). 
 
The altered glycosylation state of MUC1 also has a role in tumour metastatic 
spread. Expression of carbohydrate structures sialyl-LewisX and sialyl-LewisA on 
MUC1 enable the binding of MUC1 to both E-selectin and intercellular adhesion 
molecule (ICAM)-1 (104). As selectins play a critical role in immune cell rolling and 
extravasation from vasculature and subsequent trafficking through tissues, such 
interactions in MUC1 are also proposed to similarly have an effect in tumor cell 
extravasation, invasion, and metastasis (105). 
 
Additionally, MUC1- ICAM1 interaction has been found to alter the metastatic 
phenotype of the cancer cell itself. It has been found that following interaction with 
ICAM-1, Src interacts with MUC1-CD, an interaction that promotes Src-mediated 
cytoskeletal rearrangement (106, 107). The Src family of nonreceptor tyrosine 
kinases have long been regarded as key mediators of metastatic progression (108). 
Interaction between MUC1 and Src induces pro-migratory Rac-1 and Cdc42-
dependent actin reorganization at the sites of contact with endothelial cells, thereby 
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promoting an invasive phenotype in tumour cells (106). In addition, a truncated 
version of MUC1 consisting of only the external stem region, the transmembrane 
region and the transmembrane domain was shown to be sufficient to induce 
epithelial mesenchymal transition (EMT) in mouse mammary carcinoma cells, 
through interaction of MUC1 extracellular domain, ICAM1 and E-selectin (109). 
Collectively, these studies demonstrate that the MUC1 extracellular domain, through 
its altered glycosylation in cancer cells, can drive metastatic spread, as well as 
intracellular interactions that promote migratory behaviours.  
 
1.2.6 MUC1 intracellular domain in epithelial cancer 
The intracellular domain of MUC1, MUC1-CT, has been heavily studied for its 
potential role in tumour promotion. With 22 phosphorylation sites in the cytoplasmic 
tail, the intracellular domain of MUC1 forms a key kinase recognition site and binds 
to several kinases such as c-SRC (110) EGFR or (ErbB) family (111), glycogen 
synthetase kinase 3b (GSK3b) (112), and protein kinase C delta (113). As well as 
kinase interaction, the MUC1 cytoplasmic tail has been known to interact with key 
apoptosis proteins such as β catenin (114), heat shock proteins (HSP) such as HSP70 
and HSP90 (115). MUC1-CT interaction with β catenin and p53 has been shown to 
prevent mitochondria- mediated apoptosis in response to DNA damage (116). MUC1-
CT is also able to translocate to the nucleus in association with β-catenin (114) where 
it has been shown to supress e-cadherin expression, while promoting expression of 
epithelial mesenchymal transition (EMT) promotors Snail, Slug and Twist (117). As a 
result of this, β catenin association with cadherins at adherin junctions is 
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compromised and this, together with increased expression of EMT promoters, 
promotes MUC1-mediated anchorage-independent growth.  
Aberrant glucose metabolism is a cancer hallmark that facilitates cell survival. MUC1-
CT has been shown to mediate the expression of genes involved in glucose uptake 
and metabolism in orthotopic implantation models of pancreatic cancer (118). In this 
manner, MUC1-CT molecules can directly facilitate tumour cell survival and 
proliferation by upregulating glucose uptake and metabolism. While all the gene and 
protein targets for MUC1-CT are yet to mapped, its cytoplasmic interactions and 
nuclear localization have been correlated with poor prognosis, tumour-node-
metastasis staging, increased EMT and lower survival.  
MUC1 CT has also been linked with altered expression of growth factors such as 
connective tissue growth factor (CTGF), Platelet derived growth factor A (PDGF-A) 
and PDGF-B that promote tumour cell proliferation via MAPK and PI3K/AKT pathways 
(40, 119-122). In addition, recent research has indicated that MUC1-CT may also 
inhibit the apoptotic function of BAX through interaction with the BH3 domain (123), 
suggesting that over-expression of MUC1 may increase the pro-survival signal leading 
to anoikis resistance.  
 
1.3 Anoikis 
Anoikis is a Greek term, meaning “homelessness” or “loss of home”. First used in cell 
biology by Stephen M Frisch in 1994, the term refers to apoptosis induced by absent 
or inappropriate cell-cell/cell-matrix contact (124). One of the key aspect of 
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multicellularity is cellular growth and differentiation in correct context within a tissue 
to ensure tissue homeostasis. Cells within a tissue sense their location through 
specific interactions with the extracellular matrix (ECM) as well as with neighbouring 
cells. Cell death-induced via anoikis therefore, ensures tissue homeostasis by 
determining that any displaced cells undergo apoptosis; thereby preventing them 
from re-attaching at a secondary site and undergoing dysplastic growth. There are 
several cell surface molecules which sense cellular adhesion to cell and/or 
extracellular matrix and convert them into intracellular signals leading to eventual 
generation of pro- or anti-apoptotic signals. At any given time, the fate of a cell is 
dependent on which of these two, pro or anti-apoptotic signals, dominate. Anoikis 
therefore is a physiological process in development and tissue homeostasis and is 
often deregulated in disease (125, 126).  
Anoikis has been described in many cell types; however, it now appears that not all 
cell types induce anoikis via similar pathways. Regardless of the pathways involved, 
the end result always leads to the activation of effector caspases and DNA 
fragmentation. In keeping with classical apoptosis, anoikis could either follow the 
intrinsic pathway, which involves the mitochondrial membrane and release of 
cytochrome C, or the extrinsic pathway, which is initiated at the cell surface via death 
receptors (126, 127). Both these pathways are heavily regulated by sets of proteins 
which, depending on their roles, can either be classified as pro- or anti-apoptotic 
proteins. The pro-apoptotic proteins involve the Bax, Bak, BoK (multi BH3 domain 
proteins) or Bid, Bik, Bmf, Noxa, Bad, Bim and Puma (BH3-only proteins) while Bcl-2, 
Bcl-XL and myeloid cell leukaemia sequence (Mcl-1) are the major anti-apoptotic 
proteins (128). In addition to these, several molecules have been discovered (Bad,Bix, 
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Noxa, Puma) which act as apoptotic sensitizers (129, 130). It is the activation, over-
expression or inhibition of either set of these pro- and anti-apoptotic proteins that 
eventually determines the fate of the cell under anoikis conditions (131-134).  
 
1.3.1 Intrinsic pathway 
The intrinsic pathway is triggered in response to several pro-apoptotic signals, 
including DNA damage and endoplasmic reticulum stress (135), where the eventual 
executioner caspase (caspase-3, caspase-7) activation is due to increased 
mitochondrial membrane permeability (131, 135). In this pathway, following a pro-
apoptotic signal, Bax and Bak translocate from the cytosol to the outer mitochondrial 
membrane (OMM), where their oligomerization leads to disruption of OMM integrity 
leading to increased OMM permeabilization leading in turn to increased cytochrome 
C release in the cytosol (136, 137). In addition to the OMM pore forming activity, 
both Bax and Bak have been shown to accelerate the opening of voltage dependent 
anion channels (138, 139), thus further destabilizing mitochondrial permeabilization 
and increasing cytochrome c release.  Cytochrome c released in the cytosol interacts 
with pro-caspase-9 and cofactor apoptosis protease activating factor (APAF1) to form 
an ‘apoptosome’ (140). The apoptosome assembly cleaves pro-capase-9 into 
activated caspase-9 which subsequently leads to activation of effector caspase-3 and 
eventual proteolysis of caspase targets (140, 141) 
The BH3 domain proteins play a critical role in the cascade of events leading up to 
intrinsic anoikis (142). Cell detachment from ECM leads to downward signalling and 
activation of Bid and Bim, termed “activators” of intrinsic anoikis (143). Bim is 
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normally sequestered in an inactive state in the dynein cytoskeletal complex. Loss of 
cell attachment leads to Bim release and accumulation in the mitochondria where it 
directly facilitates the formation of Bax/Bak oligomers (144). Cell detachment also 
leads to Bim accumulation through inhibition of its degradation; typically facilitated 
by integrin-mediated phosphorylation of Bim via ERK, PI3K and AKT (145, 146).  
As well as anoikis activators, some of the BH3 group of proteins also act as anoikis 
“sensitizers”. These proteins do not directly activate Bax and Bak oligomerization, 
nor do they contribute to Bim or Bid activation; yet they have a pro-apoptotic 
function as they inactivate the anti-apoptotic functions of the Bcl-2 group of proteins 
(129, 147, 148). Proteins such a Bad, Bik, Bmf, Noxa, Puma and Hrk are typical anoikis 
sensitizers (130, 131, 149). Their action ensures that the Bcl-2 members of anti-
apoptotic proteins, which can inhibit Bax/Bak oligomerization on outer 
mitochondrial membrane as well as Bim and Bid activation, are inactivated; thus 
leading to the accumulation of pro-apoptotic signals.  
Recent research has also pointed to the involvement of other members of BH3-only 
family in anoikis of different cell histotypes. For example, Noxa and Puma, 
transcriptionally regulated by p-53 have been shown to have an effect in fibroblast 
anoikis (150, 151). Furthermore in epithelial cells, the Bcl-2 modifying factor (Bmf) 
has been identified to have a similar role as an 'apoptosis sensitiser', where it 
neutralizes Bcl-2, leading to cytochrome C release and anoikis execution (151). 
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1.3.2 Extrinsic pathway 
The extrinsic pathway also leads to anoikis execution. This differs from intrinsic 
anoikis, initially in the way the extrinsic pathway is activated and via the pathway’s 
ability to recruit effector caspases without mitochondrial involvement. The signal is 
initiated when extracellular death ligands such as Fas ligand (FasL) or tumour necrosis 
factor α (TNF-α) bind to their respective receptors resulting in the assembly of death-
inducing signalling complex (DISC) intracellularly (149). Through the action of Fas-
associated death domain (FADD), DISC is able to aggregate several molecules of 
caspase 8 which then auto-activate themselves (152).  Auto-activated caspase-8 then 
proteolytically activates caspase-3 and 7, leading to substrate proteolysis and cell 
death (143, 153) (type I extrinsic anoikis) or they can cleave the BH3-only protein Bid 
to form truncated-Bid (t-Bid) (154) which then has an effect on mitochondrial 
permeability and cytochrome c release (type II extrinsic anoikis). T-Bid therefore 
converges the extrinsic anoikis pathway towards the intrinsic pathway [Figure 1.3]. 
Loss of adhesion to the extracellular matrix leads to an increased expression of both 
the Fas and FasL, while FLIP, an endogenous inhibitor of Fas-mediated anoikis is 
reduced (155).  Furthermore, the cell rounding following detachment can induce 
extrinsic anoikis mainly through relocatization and activation of Fas (156).  Finally, 
activation of death receptor could be secondary to mitochondrial release thereby 
creating further crosstalk between intrinsic and extrinsic pathways (157).   
Activation of caspase-3 is the common event of both the intrinsic and extrinsic anoikis 
pathways. Caspase 3 initiates the downstream proteolytic cascade and also has a role 
on reducing the effect of the pro-survival signal.  Whether a cell undergoes anoikis 
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via intrinsic or extrinsic pathway depends on the cell type. With regards to epithelial 
cells, some studies have suggested that the initiating event is the activation of death 
receptor, as over-expression of a dominant-negative form of FADD, which blocks 
caspase-8 recruitment to DISC, inhibits anoikis (158, 159). However, in these studies 
extracellular inhibitors of death receptor (in the form of soluble extracellular portions 
of the receptor, which can sequester the ligand), failed to inhibit anoikis. 
Furthermore, the detachment-induced activation of caspase-8 was inhibited by Bcl-
2 over-expression, suggesting that perhaps caspase-8 activation is dependent on 
mitochondrial membrane permeability and the release of cytochrome C.  
                 
 
Figure 1.3: The intrinsic and extrinsic pathways of anoikis. Intrinsic pathway signal 
initiates at the cell surface, possibly due to breakdown of ECM contact with integrin. 
The net result is oligomer formation in the outer mitochondrial membrane and 
release of cytochrome C. The extrinsic pathway begins at the death receptor on the 
cell surface, which subsequently activates caspase- 8. Both intrinsic and extrinsic 
pathways lead to the activation of effector caspase, caspase-3, and direct proteolysis 
of targets and apoptotic death. Figure adapted from (131) (permission acquired from 
Journal of Pathology, licence no 4296980918248) 
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1.3.3 Physiological protection from anoikis 
Not all cells undergo anoikis when detached. Certain cells, such as the epithelial cells 
under migration, mesenchymal cells (160), haematopoietic cells and leukocytes (161) 
evade anoikis physiologically via various mechanisms, some of which are discussed 
here. 
As mentioned already, cell adhesion to permissive ECM proteins and its immediate 
neighbouring cells are key determinant of anoikis initiation. The cell surface adhesion 
molecules such as integrins, cadherins and selectins monitor a cell’s position with its 
immediate surrounding and play a key role in modulating key downstream effector 
molecules such as the FAK (162), Src kinase (163), PI3K/AKT (164), MPAK (165) and 
integrin-linked kinase (ILK) (166).  Altered expression and improper activation of 
these molecules has been shown to interfere with anoikis (167-169), and it is 
therefore not surprising that some of these molecules are unregulated and have an 
enhanced activation in malignant cells (170-172). Formation of focal adhesion and 
subsequent activation of FAK is a key effect of integrin mediated surveillance of cell-
ECM contact (149, 169, 173). Activated FAK affects multiple critical cellular processes 
such as cell survival, proliferation, motility and differentiation. The activated FAK also 
enables the recruitment of other scaffold and signalling molecules to the focal 
adhesion sites, consequently activating downstream cell survival signalling. PI3K and 
its downstream target protein kinase B (PKB/AKT) (174, 175), MAPK pathway (176), 
ILK (177, 178) and caveolin-1 have all been known to be activated, directly or 
indirectly by FAK; all of which influence anoikis regulation.  
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As well as cell-ECM contact, cell-cell contact mediated by cadherins are also able to 
support cell survival. Cadherins are a family of proteins that allow homo and 
heterotypic calcium-dependent anchorage between neighbouring cells (179, 180). 
This anchorage plays a crucial role in cell survival and ensures anoikis resistance. 
Indeed, it has been reported that blockage of E-cadherin binding induces anoikis 
(181, 182), while overexpression of β-catenin, a downstream regulator of cadherin 
signalling, elicits anoikis resistance in epithelial cells (183). Cadherins are able to 
promote cell survival in a PI3K/AKT dependent fashion (181) and are also able to 
indirectly interact with integrins (184, 185). Some integrins, notably α2β1 and α3β1, 
can localise to cell-cell contact and can mediate cell survival despite loss of ECM 
adhesion (186). In addition to cadherins, cell-cell adherion mediated by NCAM and L- 
and P- selectins have also been shown to trigger cell survival signalling such as FAK, 
Src, PI3K/Akt and MAPK, all of which can have can supress cell death (187-189). 
Haemopoetic stem cells and leukocytes are unique because these are non-adherent 
cells, able to avoid anoikis. These cells can move in a protease independent manner 
across matrix barrier through adaptations of cell shape and being able to squeeze 
through small gaps. The weak interaction with ECM allows these cells to move in high 
velocity. Since these cells are unable to effectively use integrin mediated focal 
adhesions or cadherin mediated adherins junctions, they are unable to ensure a 
continuous pro-survival signal seen in adhering cells. In these cells, it is proposed that 
the anoikis resistance occurs mainly due to increased presence of several cytokines 
such as interleukin-2, (IL-2), IL-7, IL-15 and interferon-α which override the pro 
apoptotic signal from BH3 only proteins (149). Further support for this hypothesis 
comes from the fact that in quiescent T-cells, the withdrawal of these cytokines leads 
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to Bim accumulation, Bcl-XL downregulation and a final commitment to anoikis (149). 
The possible role of cytokines in anoikis regulation, emphasises the complexity of the 
pathways and highlights that multiple mechanism may be at play at any given time 
to determine the overall fate of a cell under anoikis conditions.  
Epithelial cells avoid anoikis during cell migration. Migrating cells use mesenchymal 
motility that is characterised by cell elongation, ECM proteolysis and focal contact 
(190, 191). Integrins are heavily involved in this process as they activate focal kinase, 
which not only leads to PI3k activation and an eventual build up of pro-survival 
signals, but it also initiates mesenchymal motility (191, 192).  Mesenchymal motility 
has been linked to pro-survival signals and epithelial mesenchymal transition (EMT) 
is one of the pre-requisites for metastasis (193-195).  
Lastly, coordination between autophagy and anoikis resistance of epithelial cells is 
recently emerging (196-199). Following detachment, the detached cell show a 
reduction in EGFR expression (200) which, due to inhibition of pro survival PI3K and 
AKT pathways, leads to a marked reduction in ATP level (201). Autophagy in this 
context is a temporary solution to provide the necessary energy till the cell 
reattaches (196, 202). There are 4 ways a cell can undergo autophagy; 
macroautophagy, microautophagy, chaperone mediated autophagy and mitophagy. 
The key protein  involved in this pathway is Beclin-1, which itself is an autophagic 
protein but also modulates the anti-apoptotic role of of Bcl-2 and Bcl-XL (203), and 
ERKs (204, 205). Autophagy allows epithelial cells to survive temporarily, given that 
they re-adhere onto the ECM in a timely fashion (206, 207), and it is likely a previously 
unrecognized tool used by circulating cancer cells to survive anoikis, thereby 
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facilitating tumour cell dormancy though nutrient recovery, as well as dissemination 
of metastases. 
 
1.3.4 Anoikis resistance in cancer 
Unlike normal cells, cancer cells do not require adhesion to ECM to grow and 
proliferate. This ability has important implications in metastatic processes where 
cancer cells must survive and migrate in the absence of proper ECM contact. In this 
scenario, anoikis resistance is a molecular prerequisite for the metastatic spread of 
cancer (149, 208).  
The general strategy which allows early stage tumour cells to evade anoikis is to 
selectively activate pathways responsible for proliferation and cell survival, such as 
those transduced by PI3K (209, 210), MEK/ERK (211-213) and NF-kB (214). Depending 
on the tumour cell, this ability can be acquired either through a direct activation of 
the pathways themselves or via inactivation of pathway inhibitors. In some cases, 
tumour cells acquire an autocrine growth factor loop, whereby they are able to 
activate the growth factor in a ligand-independent manner, thus activating the pro-
survival pathways (215, 216). Various growth factors such as basic fibroblast growth 
factor (bFGF) (217), HGF (218), EGFR (219) and TGF (220) have been shown to be 
abnormally activated in a variety of epithelial cancer cells  to aid cell proliferation, 
survival and migration. Furthermore, tumour cells are also able to exploit the 
physiological anti-anoikis mechanisms, mentioned above, and are able to resist 
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anoikis by altering their integrin expression, undergoing EMT and adapting their 
metabolism through autophagy.  
Given their role in promoting anti-apoptotic signals via activation of various kinases 
and ligand independent activation of growth factors, as mentioned above, a change 
in pattern of integrin expression have been reported in many anoikis-resistant cancer 
cells (169, 221, 222). Analysis of integrin expression profiles reveals that normal 
epithelial cells predominantly express integrins α2β1, α3β1 and α6β1 (133, 149, 223). 
Hyperproliferating epithelial cells over-express both αvβ5 and αvβ6 integrins (224, 
225)  and the anoikis-resistant squamous carcinoma predominantly over-expresses 
αvβ6 (226). This integrin switch to αvβ6 contributes to acquisition of an anoikis-
resistant phenotype (227). Physiologically, integrin β6 is expressed during 
embryogenesis in a subset of epithelial cells of kidney, lung and skin but is 
undetectable in adults (224). However high level of integrin β6 has been reported in 
several types of carcinoma cells (228, 229). Along with β6, increased and altered 
expression of integrin β3 and integrin β4 have also been shown to resist anoikis and 
increase cancer cell invasiveness (230, 231). 
A key physiological process exploited by tumour cells is epithelial-mesenchymal 
transition (EMT). During EMT cancer cells are able to activate pathways that leads to 
a  downregulation of cell-cell adhesion molecules such as E-cadherins and γ-catenin 
while at the same time an increased expression of mesenchymal markers such as 
vimentin, fibronectin, α-smooth muscle actin (SMA), N-cadherin as well as to the 
activation of matrix metalloproteinases (149). This enables the epithelial derived cells 
with a motile and highly invasive phenotype, ultimately facilitating metastatic 
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spread. It is now generally accepted that anoikis resistance is correlated with the 
acquisition of the mesenchymal phenotype (193, 195, 232, 233). This is possible 
because the key players in EMT such as Snail (234), ZEB1/2 (235), Twist (236, 237), 
NF-kB(238) and HIF1/2 (239)  are collectively able to upregulate the pro survival 
signal (such as upregulation of Bcl-2 family proteins and increased activation of 
PI3K/AKT) while downregulating the pro-apoptotic proteins such as p53-effector 
related to pmp22 (PERP), p21, Bim, Bax and Noxa (149, 234).  
Compelling evidence suggests that oxidative stress and hypoxia experienced by 
rapidly diving cancer cells further contributes to anoikis resistance (239-241). 
Caveolin-1, an activator of the AKT pathway, has been reported to be upregulated in 
increased hypoxic state and has been implicated to have a direct role in anoikis 
resistance and anchorage-independent growth (242-244). Furthermore oxidative 
stress has been shown to modulate the activation of Akt and MAPK signalling 
pathways (245, 246), as well as the activity of redox sensitive transcription factors 
such as  NF-kB, HIF-1/2, p53, AP-1, Nrf2,  thereby contributing to increased pro-
survival signals (247, 248). Furthermore, hypoxia promotes EMT in a variety of 
carcinoma cells including melanoma, breast, prostate and colon cancers (249, 250),  
thereby further assisting anoikis resistance. 
As well as the examples given above, there are many molecules and proteins such 
PTEN (251), Ras (252), Tyrosine kinase receptor B (253), ZEB transcription factor 
(254), that have been identified as having a role in anoikis resistance. The majority of 
these proteins/molecules work by either promoting the pro-survival signals via 
mechanisms already described (whereby they facilitate anoikis resistance by either 
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increasing the Bcl-2: Bax ratio, having an effect on the PI3k/AKT pathway or 
simulating the pro-survival kinases) or by inhibiting the pro-anoikis pathway.  
 
1.3.5 MUC1 and its potential role in anoikis resistance and metastasis. 
MUC1 overexpression and abnormal glycosylation is a key feature of many 
metastasising epithelial tumour. Our previous work has shown that MUC1 
overexpression leads to the initial escape of the metastasising cell from the primary 
tumour and its interaction with its ligand, galaectin-3, leads to MUC1 cell surface 
polarization. This exposes the underlying adhesion molecules and leads to both 
tumour cells homotypic aggregation and heterotypic adhesion.  Homotypic 
aggregation leads to the formation of tumour emboli which prolongs the survival of 
metastasising tumour cells in circulation, enhances their physical trapping in the 
micro-vasculature and thus increases metastatic spread of cancer cells to remote 
sites. MUC1 interaction with its ligand galectin-3 therefore may represent an 
effective therapeutic approach for preventing tumour metastasis. 
 
1.4 Galectin-3 
MUC1 is a ligand for Galectin-3 and MUC1-galectin-3 interactions have been 
associated with tumour metastasis in several epithelial cancers. Galectin-3 belongs 
to galectin family of β-galactoside binding lectins that contain one or two highly 
conserved carbohydrate domains (CRD) that recognise galactose-terminated glycans 
(255). To date there are 15 known galectins categorised into three groups based on 
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their structural differences and the number of CRD (256).  Prototype galectins include 
galectins 1,2,5,7,10,11,13,14 and 15. They are classed as such based on the presence 
of a single CRD per subunit. Tandem repeat galectins, which includes galectins 4, 6, 
8, 9 and 12 contain two CRD joined by a linker peptide. Galectin-3 is the only known 
member of the chimera-type galectin and contains one CRD at its C terminal 
connected to an extended and flexible N-terminal. The N-terminal of galectin-3 is 
responsible for galectin-3 multimerization upon galectin-3 contact with a multivalent 
ligand.  
Of the known galectins, galectin-3 is perhaps the most studied. It was first 
characterized as a 32 kDa antigen on the surface of murine macrophages (257). As a 
multifunctional protein with varied expression in cancer and pre-cancerous 
conditions, varied presence at cellular locations (cell surface, nucleus, cytoplasm, 
mitochondria and endosomal compartments) (258) and direct involvement in 
tumorigenesis (259), cancer progression and metastasis (260); galectin-3 has 
generated significant interest in cancer research over the past decade.  
 
1.4.1 Galectin-3 structure 
The structure of galectin-3 is highly conserved (261) and typically comprises three 
structurally distinct domains: a highly conserved 12 amino acid long  short N-terminal 
domain (ND), a proline- and glycine-rich long  ND of 130 amino acid and a CRD domain 
of roughly 130 amino acids (262, 263) . The short ND may have a role in apoptosis 
and secretion as deletion of short ND blocks galectin-3 secretion (264) while 
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mutation of the highly conserved Ser6 affects galectin-3 anti-apoptotic signalling 
activity (265).  The long N-terminal domain of galectin-3 normally consists of 7-14 
repeats of a 9 amino acid sequence Pro-Gly-Ala-Tyr-Pro-Gly-X-X-X and due to its 
homology to collagen α1 (II) chain, is sometimes referred to as collagen like-ND (266). 
The long ND of galectin-3 is essential for galectin-3 multimerization and is sensitive 
to proteolysis by matrix metalloproteinases 2 and 9 (267, 268).  
The C-terminal domain of galectin-3 contains the CRD structure responsible for lectin 
activity. It typically forms a globular structure  with five- and six-stranded β-sheets 
arranged in a β-sandwich (269). NWGR is a particularly interesting amino acid 
sequence found within the CRD.  This motif is highly conserved within the BH1 
domain of the B-cell lymphoma 2 (Bcl2) family proteins and is responsible for  anti 
apoptotic properties in both Bcl-2 and galectin-3 (270), through its interaction with 
apoptosis regulator Bax (271) . 
 
Figure 1.4 The structure of galectin family members. The galectin family members 
are divided into three types: the prototype with one carbohydrate recognition 
domain (CRD), the tandem-repeat type with two CRDs connected by a non-
conserved linker, and the chimeric type with one CRD and a non-lectin N-terminal 
domain (ND). Some galectins can self-associate into dimers or oligomers.  
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1.4.2 Carbohydrate-binding properties and ligands of galectin-3 
Although all galectins bind to β-galactoside, they possess a different binding affinity 
to different galactose-containing structures. For example, galectins bind 5-10 more 
strongly to N-acetyllactosamine (Galβ1,4GlcNAc) than to lactose (272-275). 
Interestingly, a striking difference was observed between galectin binding towards 
TF-disaccharide. Preliminary data from our lab and others have shown that galectin-
3 has up to a 100 fold higher affinity to interact with TF antigen compared to galectin-
1 (276). This could potentially be due to the different tertiary structure of galectin-3 
following initial interaction with its carbohydrate ligand. Galectin-3 is present in 
cytosol and in ECM and has been shown to interact with a variety of proteins 
including laminin (277, 278), fibronectin (279), α1β1 integrin (279), Bcl-2 (280), and 
β-catenin(281, 282) via both protein-protein and protein-carbohydrate interactions. 
 
1.4.3 Galectin-3 role intracellularly and extracellularly  
Although much recent research has highlighted the link between overexpression of 
galectin-3 and tumorigenesis, galectin-3 also has a significant role physiologically. 
Galectin-3 regulates normal development through regulating cell proliferation, 
apoptosis, cell adhesion and angiogenesis (283-285). Physiological expression of 
galectin-3 has been linked to development and embryogenesis in both human (286) 
and mouse (287). In the initial stages of mouse embryogenesis galectin-3 first 
appears at 4th day of gestation followed by its expression in the notochord cells 
between 8.5 and 11.5 days of gestation (287). In later stages, galectin-3 expression is 
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tissue-specific and expressed primarily in cells undergoing rapid growth such as 
epidermis, endodermal lining of the bladder,  larynx and oesophagus (262). In 
humans , galectin-3 is mainly expressed in epithelial cells such as small intestine 
(288), colon (289), cornea (290), kidneys (291), lungs (292), thymus (293), breast 
(294) and prostate (295). The expression of galectin-3 is also detected in ductal cells 
such as salivary gland (296), pancreas (297), kidneys (298) and hepatocellular biliary 
ducts (299).  
Galectin-3 can shuttle between the cytoplasm and nucleus. Cytoplasmic galectin-3 
has the ability to bind to Bcl-2 protein family and inhibit apoptosis (270). The NWGR 
anti-death domain, mentioned previously, is crucial for this antiapoptotic property 
as it shows a strong homology with the groove BH1 motif interface of the Bcl-2 family 
proteins (300). Cytoplasmic galectin-3 can also interact with activated K-Ras and 
affect Ras-mediated Akt signalling. Nuclear galectin-3 has been shown to promote 
pre-mRNA splicing as well as regulating gene transcription by enhancing transcription 
factor association with gene promotor sequence (301, 302).  
Extracellularly, galectin-3 normally exists as a monomer (303) but it has been known 
to form homodimers by self-association through its CRDs in the absence of a ligand 
(304). In the presence of excess ligand however, galectin-3 can polymerise through 
interaction with its ND to form a pentameric structure (304, 305). Such 
multimerization cross-links its cell surface ligands and triggers the initiation of cell 
surface molecule-associated signalling (306, 307). Physiologically, galectin-3 is 
expressed in a wide variety of cells including immune, epithelial and sensory neuron 
cells (262, 308). Its absence, as experimented in galectin-3 knockout mice, has shown 
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a wide variety of phenotype including accelerated glomerular injury (309),  
attenuated inflammatory responses (310) and premature senescence without 
oncogenic stress (311); suggesting that galectin-3 has a much wider physiological 
function in body.   
 
1.4.4 Galectin-3 in cancer  
Galectin-3 overexpression is a common feature of several epithelial cancers including 
breast cancer (312), colon cancer (313) and melanoma (314, 315). There is also a 
general shift in location of galectin-3 with increased presence in cytoplasm (316, 317) 
and up to 30-fold increase in the circulation (318, 319). There is strong evidence that 
links increased expression and altered localization of galectin-3 to a broad range of 
cancer progression (320), including transformation, apoptosis resistance, adhesion, 
invasion, metastasis and angiogenesis at the secondary tumour site, some of which 
will be briefly covered here. 
 
1.4.4.1 Galectin-3 in tumour transformation 
Multiple research groups have shown that galectin-3 overexpression is linked to 
increased neoplastic transformation (306, 321-323). Suppression of galectin-3 in a 
highly malignant human breast carcinoma cells resulted in altered morphology and 
increased cell death via anoikis and supressed tumour progression in 
immunologically supressed mice (322). Similarly, galectin-3 knockdown in human 
thyroid papillary carcinoma led to inhibition of anoikis resistance (324). Furthermore, 
 
 
35 
 
transfection of galectin-3 cDNA into normal thyroid follicular cells led to increased 
anoikis resistance and serum-independent growth (324). These results suggest that 
increased expression of galectin-3 is highly associated with a tumorigenic phenotype 
in breast and thyroid cells. 
The molecular mechanism of the galectin-3-mediated tumorigenic phenotype is 
speculated to be due to a galectin-3 effect on oncogenic K-Ras (321). Galectin-3 has 
been shown to increase K-Ras availability at the plasma membrane, leading to 
continuous activation of Ras-dependent PI3K and Raf-1 activation (321). As well as 
this, the complex interaction of galectin-3 with BCL-2 has been linked to promotion 
of cell survival and tumour progression (325, 326). Lastly, galectin-3 interaction with 
β-catenin leading to enhanced expression of cyclin D and c-MYC (256, 281) has also 
been shown to promote cell cycle progression (262). 
1.4.4.2 Galectin-3 in apoptosis 
Galectin-3 has been shown to be both an apoptotic promotor and an apoptotic 
inhibitor. The overall fate of the cell depends on the precise location of galectin-3 
intracellularly. Cytoplasmic galectin-3 has been shown to interact with synexin (325). 
Galectin-3/synexin interaction leads to galectin-3 translocation to mitochondria, 
where its direct interaction with Bcl-2 stabilises mitochondrial membrane potential 
and blocks cytochrome C release(325, 326). Reduction of cytochrome C release 
protects the cells from apoptosis via intrinsic and indirect extrinsic apoptosis 
pathways. Nuclear galectin-3, on the other hand has been shown to promote 
apoptosis (327, 328). The precise mechanism of the nuclear action of galectin-3 is yet 
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to be decoded but it has been suggested that galectin-3 associates with the nuclear 
apoptosis-associated protein Nucling (329).  
 
1.4.4.3 Galectin-3 in tumour metastasis 
Tumour cell breaking from the primary tumour and into circulation, adherence to the 
endothelial cells and invasion through this endothelium to seed at the secondary 
tumour site are all an essential prerequisite to metastasis. Galectin-3 has been linked 
to all of these stages. Initially, overexpression of galectin-3 at the primary tumour site 
has been shown to enhance cell-ECM adhesion and facilitate tumour cells escaping 
the primary tumour site (307), attributed partly due to galectin-3 interaction with a 
range of ECM glycoproteins such as fibronectins, collagen IV, elastin, and laminin 
(262). Circulating galectin-3, via its interaction on cell surface glycans of tumour cells 
have been linked to promote tumour cell aggregation and formation of tumour 
emboli (25). Formation of tumour emboli further assists metastasising tumour cells 
to evade anoikis (330). Galectin-3 interaction with TF antigen on MUC1, discussed 
later, has been shown to lead to cancer cell adhesion to the endothelium. Finally, 
galectin-3 interaction with growth factor receptors such as epidermal growth factor 
receptor (EGFR) and transforming growth factor-β receptor (TGFβR) is believed to 
also contribute to the increased invasiveness of tumour cells. 
Neovascularisation is another essential requirement for tumour emboli to develop 
into a secondary tumour (306). Galectin-3 has been shown to have a key role in 
angiogenesis and neovascularization at the secondary tumour site (331) via its 
interaction with integrins and glycans (332), leading to eventual activation of focal 
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kinases. Activated focal kinases modulate vascular endothelial growth factor (VEGF)- 
and basic fibroblast growth factor (bFGF) leading to neovascularization and 
angiogenesis at the secondary tumor site (333). Recent research has also reported 
galectin-3 interaction with aminopeptidase N/CD13, which has been linked to early 
stages of angiogenesis (334). 
 
1.4.5 MUC1 and galectin-3 interactions in cancer 
The circulating galectin-3 level in patients with advanced metastasis has been found 
to be up to 30-fold higher than normal (335, 336). Work done in our lab has shown 
that galectin-3 binds to the oncofoetal Thomsen-Friedenreich (galactoseβ1,3 N-
acetylgalactosamineα, TF) antigen on the transmembrane mucin MUC1 expressed on 
tumour cells (79). The multimerization of galectin-3 together with its association with 
TF antigen on MUC leads to MUC1 cell surface polarization, thus revealing the 
previously covered underlying cell surface adhesion molecules (337). Exposure of 
underlying adhesion molecules leads to galectin-3 mediated tumour cell homo- and 
hetero- typic aggregation, leading to increased formation of tumour emboli and 
increased tumour-endothelium adhesion, respectively (25). Formation of tumour 
emboli suppresses anoikis by preventing anoikis initiation, whereas tumour-
endothelium adhesion leads to tumour invasion and eventual formation of 
secondary tumour. 
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As MUC1 is associated with EGFR in epithelial cancer cells (338, 339), the effect of 
galectin-3 binding to MUC1 on cancer cell-cell interactions led us to examine the 
impact of their interaction on EGFR activation in epithelial cancer cells.   
 
 
Figure 1.5: Galectin-3 MUC1 interaction. Galectin-3 concentration is greatly 
increased in the circulation of cancer patients.  interaction of circulating galectin-3 
with cancer-associated MUC1 causes MUC1 cell surface polarisation and 
consequently, exposure of small adhesion molecules including surface-associated 
galectin-3, which enhance cancer cell-endothelium adhesion, followed by migration 
through the endothelium. 
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1.5 EGFR 
A key cell surface protein associated with MUC1 is Epidermal growth factor receptor 
1 (EGFR/ERBb1). EGFR is a heavily studied cell surface protein which is known to 
overexpressed and/or abnormally activated in cancer cells. Abnormal (increased) 
activation of EGFR allows cancer cell to evade growth suppression signals and allows 
them to proliferate – hence allowing the tumour cells to acquire two of the major 
hallmarks of cancers, mentioned earlier. 
EGFR is a member of the ErbB family of receptor tyrosine kinases that includes EGFR/ 
ErbB1 (Her1), ErbB2 (Her2/c-Neu), ErbB3 (Her3) and ErbB4 (Her4) (340). EGFR 
receptors consist of a glycosylated extracellular domain, a hydrophobic 
transmembrane domain, a juxtamembrane domain adjacent to the inner leaflet of 
the plasma membrane, and a C-terminal kinase domain (341). The ErbB/Her receptor 
which includes the epidermal growth factor receptor, are among the most studied 
cell signalling families in biology (342). The receptor was first identified and 
characterised  by Stanley Cohen in the 1980s (343). Cohen et al found the 170 kDa 
polypeptide chain that contained both the EGF binding activity and protein kinase 
activity (344). 
The last two decades have seen significant research into EGFR-related signalling in 
cancer progression (219, 345-348). It is now generally accepted that increased EGFR 
activation and expression leads to a poor prognosis in cancer. Not surprising, EGFR is 
now a therapeutic target in the fight against cancer.   
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1.5.1 EGFR Structure 
The EGFR is synthesised as a 1210 residue precursor that is further cleaved at the N-
terminal to form the mature 1186 residue long transmembrane EGFR. (349) From N-
terminal to C-terminal, the EGFR consists of an extracellular ligand binding and a 
dimerization arm (exon 1-16) a hydrophobic transmembrane domain (exon 17) and 
the intracellular tyrosine kinase and c-terminal domain (exon 18-28) (341). 
The extracellular region of EGFR is composed of 621 amino acids and is subdivided 
into 4 domains 1-4. Domain 1 and 3 are leucine rich fragments that participate in 
ligand binding, whereas non-ligand interacting domains 2 and 4 are cysteine-rich. 
Domain 2 forms the homo- or hetero-dimer with the corresponding domain in other 
members of ErbB family. Domain 4 links the extracellular region of EGFR to the 
transmembrane domain and can also form a disulphide bond with domain 2.  
The transmembrane domain of EGFR is a 23-amino acid long hydrophobic single pass 
membrane structure, that anchors receptor to the membrane (350). The 
transmembrane domain of EGFR has been hypothesised to play a role in receptor 
dimerization (351), especially in heterodimerization with ErbB2, as mutation to 
transmembrane domain in ErbB2 has been shown to augment dimerization (352). 
The intracellular domain of EGFR is 542 amino acids long and consists of a 
juxtamembrane segment, a tyrosine kinase domain and a C-terminal tail (353). The 
tyrosine kinase domain can be further divided into an N-lobe consisting mainly of β 
sheet structures and C-lobe containing mainly α-helical structure, with an ATP 
binding site located between the two lobes (354). Transautophosphorylation relies 
on the interaction of N lobe from one receptor to C lobe of another (355). The C-
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terminal tail also includes various tyrosine residue, which when phosphorylated, 
allows anchoring of a variety of intracellular proteins to the activated receptor.  
                           
Figure 1.6: Basic structure of EGFR revealing relavent domain adapted from (356). 
(Permission under Creative Commons Attribution License) 
 
1.5.2 EGFR ligands and receptor dimerization 
Human EGF is a 6 kDa protein made up of 53 amino acid which was identified as the 
first ligand to bind and phosphorylate EGFR (357). Aside from EGF, six other ligands 
have been described to also bind to EGFR. These include transforming growth factor-
α (TGF-α), amphiregulin (AREG), epiregulin (EREG), betacellulin (BTC), heparin-
binding EGF-like growth factor (HB-EGF), and epigen (EPI). The ligand EGF, TGF-α, and 
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amphiregulin are specific for EGFR only (358), whereas BTC, HB-EGF, and EREG  have 
been shown to have a dual specificity for both EGFR and ERBB4 (219). Regardless of 
the ligand, the initial stages of receptor activation is the same, with ligand binding 
leading to receptor dimerization, receptor transautophosphorylation and 
recruitment of various signalling and adapter proteins. This is followed by EGFR 
receptor internalization and trafficking to the early endosome. Despite these 
similarities, the activation of EGFR by different ligand has been shown to cause 
distinct biological activity (359, 360). For example, Sweeney et al showed that 
although EGF and neuregulins (NRG) can both lead to downstream activation of 
ERK1/2, EGF mediated signalling normally leads to the formation of EGFR and ERBB2 
heterodimer and simulation of PKC, whereas NRG mediated simulation normally 
leads to ERBB2 and ERBB3 heterodimers and preferentially simulation of AKT (361). 
The exact mechanism as to how different ligands bring about different biological 
effects remain undiscovered.  
Ligand binding and EGFR dimerization are crucial to ensure EGFR activation. 
However, it was a matter of controversy as to which step occurs first. It is now 
generally accepted that ligand binding to EGFR precedes EGFR dimerization. Work 
done by Yarden and Schlessinger has shown that prior to ligand binding, domain II of 
EGFR is folded into domain IV via disulphide bond, in a confirmation that inhibits 
receptor dimerization (362, 363). Ligand binding to domain I and III of EGFR leads to 
domain rearrangement that exposes the dimerization arm in domain II, leading to a 
more stable confirmation (364, 365). Dimerization of domain II is followed 
rearrangement of transmembrane and juxtamembrane segment which promotes 
increased kinase activity. The EGFR dimer is an asymmetric dimer pair, so that the c-
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terminus of the activating kinase inserts into the active site of receiving kinase, 
resulting in transautophosphorylation (355). This is different from other receptor 
tyrosine kinases, where conformational changes following dimerization induces 
receptor monomers to activate itself.  
 
1.5.3 EGFR signalling 
Of the four family members, EGFR is known to signal the largest number of unique 
signalling pathways including the ERK/MAPK, PI3K-AKT, SRC, PLC-γ1-PKC, JNK, and 
JAK-STAT pathways. As these pathways are generally interlinked, the activation of 
EGFR simulates an entire signalling networks that are heavily involved in tumour 
growth, proliferation, differentiation, migration and inhibition of apoptosis. Many of 
the proteins involved in EGFR signalling transduction, as well as EGFR itself, is the 
subject of pharmaceutical targeting in malignancies. 
EGF binding to EGFR leads to receptor transphosphorylation of multiple tyrosine 
residue on the intracellular C-terminal tail. Tyrosine residue Y703, Y920, Y992, Y1045, 
Y1068, Y1086, Y1148, and Y1173 on intracellular C-terminal tail have all been 
identified to be phosphorylated following EGF addition to the cell. In addition to 
these, there are additional residues phosphorylated by other kinases which 
interestingly appear downstream in the EGFR activation cascade.  For example, Y845 
is phosphorylated by c-SRC (366), and T654 is phosphorylated by PKC (367). The 
newly phosphorylated tyrosine residues act as potential docking sites for proteins 
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harbouring phosphor-tyrosine-binding residues, such as those with Src Homology 2 
(SH2) and phosphotyrosine binding (PTB) domains (368). 
The receptor transphosphorylation and binding of key binding partners to 
phosphorylated tyrosine residues allows EGFR and the other ErbB family members 
to amplify the signal which eventually results in cells proliferation, survival, and 
migration. The main pathways activated in response to EGF ligand binding to EGFR 
includes the RAS-RAF-MEK-ERK-MAPK Pathway, PI3K-AKT-mTOR pathway and 
phospho-lipase C-γ (PLC-γ) pathway.  
 
1.5.3.1 RAS-RAF-MEK-ERK-MAPK Pathway 
Following receptor transphosphorylation, residues Y1068 and Y1086 play a key role 
in initiating RAS-ERK/MAPK pathways by binding to growth factor receptor binding 
protein 2 (GRB2) (369-371) and by recruiting Src homology and collagen (SRC) (372-
374). These two adaptor proteins act as a signal amplifier for ligand-activated EGFR 
to activate complex intracellular biological pathways. Upon binding to EGFR, SHC is 
phosphorylated and acts a phosphorylation site for GRB2 (373, 375). GRB2 then binds 
to son of sevenless 1 (SOS1) which subsequently activates RAS (376-379). RAS can 
then activate RAF1, which has been shown to directly activate MEK1/2 by 
phosphorylation at serine residue 217 and 221 (380-383). MEK (mitogen-activated 
protein kinase kinase-MAPKK) 1/2 forms a rare class of tyrosine and threonine/serine 
dual specificity kinases that activate ERK 1/2 (384). ERK 1/2 then phosphorylates 
multiple substrates to induce various biological responses.  Ras is also known to 
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activate the PI3K pathway (discussed below) in addition to the MEK/ERK pathway, 
demonstrating a role for signal crosstalk in cancer progression (385). 
 
1.5.3.2 PI3K-AKT-mTOR pathway  
PI3K is a major downstream activator of EGFR. Following activation by EGF simulation 
PI3K phosphorylates the 3-OH group of the membrane lipid phosphatidylinositol-4,5-
bisphosphate (PIP2) to generate phosphatidylinositol-3,4,5-triphosphate (PIP3) (386-
388). Although PI3K can binds directly and indirectly to members of ErbB family (389-
391), the major signal transduction with from PI3K is due to its ability to 
phosphorylate 3-OH group of the membrane lipid PIP2 to form PIP3. PIP3 is a potent 
second messenger and a predominant mediator of PI3K activity (392). The strong 
signalling potential of PIP3 is highlighted by the fact that the PI3K antagonist PTEN, 
which dephosphorylates and limits the activity PIP3, is frequently inactivated in 
cancer (393). PIP3 also leads to the recruitment and activation of AKT (also known as 
Protein Kinase B or PKB) that has an impact on cell survival, proliferation, 
metabolism, growth and migration. One of the most important AKT pathways is to 
signal mTOR (mammalian target of rapamycin) which is well known to regulate cell 
growth and autophagy. In terms of cell survival, AKT functions in an anti-apoptotic 
manner by directly interacting with components of cell death machinery. AKT directly 
phosphorylates BAD (394) and caspase-9 (395) which supresses their pro apoptotic 
action. Indirectly, AKT has also been shown to reduce the expression of pro-apoptotic 
protein BIM (396)  and downregulate P53 (397-399). 
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1.5.3.3 Phospho-lipase C-γ (PLC-γ) pathway 
PLC-γ1 (Phosphoinositide phospholipase C – isozyme γ1) directly binds to activated 
EGFR at Y992 and Y1173 in the cytoplasmic tail (400-403).  PLC-γ1 can also be 
recruited to the plasma membrane by binding to PIP3, formed in response to EGF 
stimulation (404, 405). Once translocated near the plasma membrane and activated, 
PLC-γ1 hydrolyses PIP2 into free intracellular 1,4,5-triphosphate (IP3) and 
diacylglycerol (DAG).  IP3 induces intracellular calcium release which converges with 
the DAG pathway to activate protein kinase C (PKC).  Activated PKC has a whole host 
of cellular substrate including EGFR, RAF-1, H-RAS, p21, BAD, and BCL-2 (406);  all of 
whom collectively promote proliferation and apoptosis resistance.  
Because the signalling cascade activated following EGFR activation is quite potent, 
physiologically, the signal is quickly quenched through receptor degradation. 
Following ligand receptor interaction, EGFR undergoes clathrin-mediated 
endocytosis (407, 408). These early endosomes can either be recycled back to the 
cell surface, or be degraded in lysosome. The fate of the EGFR receptor following 
endocytosis has important consequences for cell’s biological output, with the 
recycling pathway favouring cell proliferation whilst degradative and docking with 
lysosomes correlating with normal cellular homeostasis (409). Atypical trafficking 
pathways to the nucleus (410, 411) and mitochondria (412) have also been described 
and are proposed to favour survival, but the transport mechanisms are not well 
established. 
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1.5.4 EGFR in epithelial cancer 
EGFR is physiologically expressed with its expression and ligand availability tightly 
regulated to ensure that cell proliferation matches tissue requirements for 
homeostasis. In the tumour state however, EGFR activation is increased, either due 
to increased expression and mutation of the EGFR itself or due to increased 
availability of the EGFR ligand (413, 414). EGFR is an indicator of poor prognosis in 
gastric cancer (415) , head and neck squamous cell carcinoma (416) , colorectal 
cancer (417), breast cancer (418), renal cell carcinoma (419), medulloblastoma (420), 
non-small cell lung cancer (421), and prostate cancer (422) among others. 
 As EGFR is a powerful inducer of signals leading to phenotypes that are important in 
development, such as proliferation, survival, and motility, EGFR is often exploited in 
cancer. Mutation in the kinase and ligand binding domain of EGFR promoting 
continuous receptor activation has been noted in lung cancer and gliomas (340). In 
breast cancer, the EGFR is overexpressed and overactivated but it is not mutated 
(423). Aberrant expression of TGFα or nuclear localization of EGFR by tumours 
typically confers a more aggressive phenotype and is often an indicator of poor 
prognosis in several epithelial cancers (424). Not surprisingly, EGFR has emerged as 
a principal target for therapeutic intervention. 
 
1.5.5 Interaction between MUC1 and EGFR 
Recently several studies have pointed to a potential link between MUC1 and EGFR 
(338, 425). EGF is the primary ligand for EGFR during lactation (339, 426, 427), and 
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MUC1 is highly expressed during this period of mammary development (428). In 
addition, it has been shown that EGFR and MUC1 interact at the apical cell surface of 
lactating mammary gland (425). Furthermore, in the same study by Schroeder et al, 
Immunoprecipitation experiments revealed that full-length transgenic MUC1 
physically associates with all four erbB receptors, and co-localizes with erbB1 in the 
lactating gland (425).  
MUC1-C is also associated with other tyrosine kinase receptors such as ErbB2 to 4, 
fibroblast growth factor receptor-3, platelet-derived growth factor receptor b and 
MET, with resultant downstream signalling (429). Given the role of growth factor 
receptor in promoting pro-survival signal, it is possible that in cancer cells over-
expression of MUC1 coupled with increased expression and activation of growth 
factor receptors promotes pro survival signal, EMT, survival and anoikis resistance in 
suspension conditions.  
Activated EGFR have also been shown to associate with MUC1-CT directly and 
translocate to nucleus. In the nucleus, MUC1-CT and EGFR complex binds to cyclin 
D1 and v-myb myeloblastosis viral oncogene homolog-like 2 (MYBL2) promotors that 
enable G1/S phase gene expression (338). Activated EGFR has also been shown to 
drive high level MUC1 expression in multiple cell lines of uterine adenocarcinoma 
and pancreatic cancer origins (430). In some cells, addition of exogenous EGFR 
ligands (EGF or HB-EGF) elevates MUC1 levels while addition of the EGFR tyrosine 
kinase inhibitor, AG1478, reduces MUC1 levels (430). Recently a reciprocal action, 
with MUC1 presence simulating EGFR expression, has also been reported in 
endometrial cancer (339). 
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1.6 Potential for interaction between galectin-3, MUC1 
and EGFR 
 
It follows that there is a considerable potential for interactions between galectin-3, 
MUC1 and EGFR to underlie many of the changes that are essential to cancer 
progression and metastasis.  Previous work in our lab has identified complex 
interaction between MUC1 and galectin-3 leading to the formation of tumour 
homotypic aggregation and heterotypic adhesion (25). Recent work by various 
research groups has identified a potential interaction between MUC1 and EGFR 
suggesting a much broader role of MUC1 in tumour progression (338, 339).  
Exploration of these interactions is the principal aim of the work described in this 
thesis 
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1.7 Hypothesis  
MUC1 intracellular and extracellular domains may contribute differently to MUC1-
mediated resistance to anoikis of epithelial cancer cells 
 MUC1-galectin-3 interaction may influence EGFR activation of epithelial cells  
 
1.8 Aims 
To investigate the relative contributions of MUC1 extracellular domain and 
intracellular domain to MUC1-mediated epithelial cancer cell resistance to anoikis. 
To assess the influence of O-glycosylation of MUC1 extracellular domain on MUC1-
mediated cell resistance to anoikis. 
To investigate the impacts of expression of MUC1 and its interaction with galectin-3 
on EGFR activation and signalling in epithelial cancer cells 
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2 Materials and Methods 
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2.1 Materials 
Proteome profiler human apoptosis array kit (ARY 009), full- length recombinant 
galectin-3 (1154-GA/CF, carrier free), and anti-CD44 (BBA10), anti-integrinβ1 
(MAB17782), anti-E-cadherin (MAB1838), anti-Fas (AF2267) and anti-Fas ligand 
(AF126) antibodies were from R&D Systems (Abingdon, UK). The Caspase 3/7 Glo® 
kits and Caspase-8 Glo® kits were obtained from Promega (Southampton, UK).  
Recombinant Fas-L, anti-EGFR antibody (500-p306), and recombinant human EGF 
(AF-100-15) was from PeproTech (London, UK). FITC-Annexin-V/PI apoptosis 
detection kit was from Cambridge Biosciences (Cambridge, UK). Biotinylated peanut 
agglutinin (PNA) and biotinylated Vicia villosa agglutinin (VVA) were purchased from 
Vector Laboratories, (Peterborough, UK).  FITC-conjugated anti-mouse antibody 
(115-095-146) was purchased from Jackson Immunoresearch Labs, (West Grove, PA, 
USA). Metafectene was from Biontex Laboratories (München, Germany). B27.29 
anti-MUC1 antibody was kindly provided by Dr Mark Reddish (Biomira, Edmonton, 
Canada), anti-MUC1 antibody 214D was kindly provided by Dr John Hilkens 
(Netherlands Cancer Institute, Amsterdam, NL) and CT2 anti-MUC1 antibody was 
kindly provided by Prof Sandra Gendler (Mayo Clinic, AR, USA). shRNA plasmid DNA 
for Core 1 Gal-transferase (SHCLND-NM_020156-C1GALT, TRCN0000289384), 
control shRNA (SHC002v, non-target shRNA), non-enzymatic cell dissociation 
solution (NECDS) and Lapatinib were purchased from Sigma-Aldrich (Dorset, UK). 
Antibodies against p-EGFR (SC-23420), EGFR (SC-03), p-ERK1/2(SC-7383), ERK1/2 (SC-
94) and Protein A/G plus agarose beads were purchased from Santa Cruz 
Biotechnology (Heidelberg, Germany). Anti-EGFR antibody used in confocal 
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microscopy and for immunoprecipitation (DB81) was purchased from New England 
Bio-Labs (Hitchin, UK). Bis(sulfosuccinimidyl) substrate (BS3) cross-linker, Alexa Fluor 
643 conjugated anti-rabbit antibody, FITC conjugated avidin and chemiluminence 
detection kits were from Life Technologies (Paisley, UK). Anti-actin (M0851) and 
peroxidase-conjugated secondary antibodies were from Dako (Glostrup, Denmark).  
Mouse IgG1 monoclonal (ab81032) and rabbit IgG monoclonal antibodies were 
purchased from Abcam (Cambridge, UK). 
 
2.2 Medium 
All cell culture media were purchased from Sigma-Aldrich, unless specified. 
• A) Dulbecco’s Modified Eagle’s medium (DMEM) 
1. Complete culture medium contains 10% fetal calf serum (FCS), 
penicillin 100 U/ml, streptomycin 100 μg/ml and glutamine 2 mM. 
2. Serum-free DMEM contains 0.5% bovine serum albumin, penicillin 
100 U/ml, streptomycin 100 μg/ml and glutamine 2 mM. 
3. Antibiotics-free and serum-free DMEM contains glutamine 2 mM 
The cell lines HCA1.7+, HCA1.7-, HTD, ACA19+, ACA19-, ADT, SW620 and fibroblasts 
calls with variable numbers of tandem repeats were cultured in DMEM. 
• B) McCoy’s 5A 
1. Complete culture medium contains 10% (FCS), penicillin 100 U/ml, 
streptomycin 100 μg/ml and glutamine 2 mM. 
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2. Serum-free McCoy’s 5A contains 0.5% bovine serum albumin, 
penicillin 100 U/ml, streptomycin 100 μg/ml and glutamine 2 mM. 
3. Serum free and Antibiotics free McCoy’s 5A contains glutamine 2mM 
The cell lines HCT116 MUC1 full, HCT116 MUC1 neo, HCT116 MUC1 ∆ CT, HCT116 
MUC1 ∆ TR were cultured in McCoy’s 5A.  
• C) Endothelial growth media (EGM) supplemented with 3mg/mL bovine brain 
extract (BBE),  10 mg/mL hEGF, 1 mg/mL hydrocortisone, 2% FBS, 50 mg/mL 
gentamycin and 50  μg/mL amphotericin-B (EGM bullet kit, Cambrex Bio 
Science, UK) were used for the culture of human umbilical vein endothelial 
cells (HUVEC). 
 
2.3 Cell lines 
HUVECS:  Human umbilical vein endothelial cells (HUVECS) were obtained from 
Cambrex Bio Science Wokingham Ltd (Wokingham, UK). HUVECS were cultured in 
endothelial growth media (EGM Bullet Kit, Cambrex Bio Science, UK).  Less than 6 
passage cells were used in all the experiments. The culture medium was changed 
every 2 days. 
MUC1 transfection of HBL-100 human breast epithelial cells and human melanoma 
A375 cells with full-length cDNA encoding MUC1 and the subsequent selection of the 
MUC1-positive transfectant HCA1.7+ (from HBL-100) and ACA19+ (from A375), and 
the negative revertant HCA1.7− (from HBL-100) and ACA19− (from A375) was 
conducted as described previously (431). The cell lines were last authenticated by 
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DNA profiling (DNA Diagnostics Center, London, UK) in May 2014. MUC1 transfection 
of A375 cells with cDNA encoding only the MUC1 extracellular and transmembrane 
domains and subsequent selection of the MUC1-positive transfectant ATD and 
fibroblast cells transfected with zero (parental), eight, fifteen and thirty-six variable 
number of tandem repeats (VNTR) was kindly provided by Dr. John Hilkens 
(Netherlands Cancer Institute, Amsterdam, NL). 
 
The MUC1-negative human colon cancer HCT116 and MUC1-positive human colon 
cancer SW620 cells were obtained from European Collection of Cell Culture 
(Salisbury, UK) and were cultured in McCoy’s5A medium and DMEM, respectively. 
The cell lines were last authenticated by DNA profiling (DNA Diagnostics Centre, 
London, UK) in 2014. MUC1-expressing HCT116MUC1-F3 and MUC1-negative 
HCT116MUC1-neo cells were obtained by stable transfection of HCT116 cells with 
MUC1-expressing or control vectors by other lab members as described previously 
(431, 432). MUC1 expression vectors for full-length MUC1, the extracellular domain-
depleted MUC1 (MUC1ΔTR), the cytoplasmic domain-depleted MUC1 (MUC1ΔCT) 
and control vector were kindly provided by Prof Tony Hollingsworth (University of 
Nebraska Medical Centre, Omaha, USA). 
Table 2.1 Summary of cells used in this thesis 
Cell name Property  
HCA1.7+  Human breast epithelial HBL100 cells stably transfected 
with full length MUC1. (62)  
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HCA1.7- Human breast epithelial HBL100 cells stably transfected 
with control vector. (62) 
HTD Human breast epithelial HBL100 cells stably transfected 
with MUC1 with mutant MUC1 ∆ CT.. (62)  
ACA19+    Human melanoma cells A375 stably transfected with full 
length MUC1. (62) 
ACA19- Human melanoma cells A375 stably transfected with 
control vector. (62) 
ATD Human melanoma cells A375   stably transfected with 
mutant MUC1 ∆ CT. (62) 
HCT116 MUC1 full Human colon cancer HCT116 cells stably transfected with 
full length MUC1. (433) 
HCT116 MUC1 neo Human colon cancer HCT116 cells stably transfected with 
control vector. (433) 
HCT116 MUC1 ∆ CT Human colon cancer HCT116 cells stably transfected with 
MUC1 without MUC1 intracellular domain. (433) 
HCT116 MUC1 ∆TR Human colon cancer HCT116 cells stably transfected with 
MUC1 without MUC1 extracellular domain. (433) 
HCT116 MUC1 F3 Human colon cancer HCT116 cells stably transfected with 
full length MUC1. 
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F3 sh-con (F2) Human colon cancer HCT116 cells stably transfected with 
full length MUC1 subsequently transfected with control 
vector for C1GT, variant F2. 
F3 sh-con (C8) Human colon cancer HCT116 cells stably transfected with 
full length MUC1 subsequently transfected with control 
vector for C1GT , variant C8. 
F3 sh-C1GT (E7) Human colon cancer HCT116 cells stably transfected with 
full length MUC1 subsequently transfected with C1GT 
knockdown shRNA, variant E7 
F3 sh-C1GT (B7) Human colon cancer HCT116 cells stably transfected with 
full length MUC1 subsequently transfected with C1GT 
knockdown shRNA, variant B7 
Neo sh-con 1 Human colon cancer HCT116 cells stably transfected with 
control vector subsequently transfected with control 
vector for C1GT, variant con 1 
Neo sh-con 2 Human colon cancer HCT116 cells stably transfected with 
control vector subsequently transfected with control 
vector for C1GT, variant con 2 
Neo sh-C1GT 3 Human colon cancer HCT116 cells stably transfected with 
control vector subsequently transfected with C1GT 
knockdown shRNA , variant C1GT 3 
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Neo sh-C1GT 4 Human colon cancer HCT116 cells stably transfected with 
MUC1 negative control vector subsequently transfected 
with C1GT knockdown shRNA, variant C1GT 4 
SW620 Metastasizing colon cancer cells naturally overexpressing 
MUC1 
SW620 sh-con Metastasizing colon cancer cells naturally overexpressing 
MUC1 stably transfected with control vector for C1GT 
SW620 sh-C1GT Metastasizing colon cancer cells naturally overexpressing 
MUC1 stably transfected with shRNA for C1GT 
knockdown 
 
2.4 Detachment of cells with trypsin or non-enzymatic-cell dissociation 
solution.  
Enzymatic cell sub-culture was performed using 0.25% Trypsin-EDTA. Trypsin acts by 
cutting amino acids, specifically lysines or arginies, on their c-termini unless these 
amino acids are followed by proline. EDTA is frequently included in the trypsin 
solution for its function as divalent cations chelator. By removing calcium from a 
solution with cells, cadherins which hold cells to each other, are broken and cells 
separate from each other as well as from the surface of the tissue culture plastic. 
Non-enzymatic cell dissociation solution (NECDS) was used to detach cell for anoikis 
assays and to assess the accessibility to cell surface molecules. NECDS are 
 
 
59 
 
membrane-filtered, isotonic, and enzyme-free solution of salts, chelating agents, and 
cell-conditioning agents in calcium-free and magnesium-free phosphate-buffered 
saline (PBS). They ensure a gentle dissociation of mammalian cells without partly 
digesting cell surface molecules. 
Sub-confluent cells were washed with PBS before 1 ml of either 0.25% trypsin EDTA 
(for sub-culture) or NECDS (for flow cytometry and anoikis experiments) was added 
to detach the cells. The cells were briefly incubated at 370C for 5-10 minute until the 
cells became detached from the flask. After gentle tapping and pipetting cells up and 
down to ensure single cell suspension, 10 ml of pre-warmed complete culture 
medium was added to the cells to inhibit the effect of trypsin or NECDS.  FCS in 
complete media contains protease inhibitors, such as α1-antitrypsin and α2-
macroglobulin which inhibits trypsin activity. FBS also contains a high concentration 
of calcium which has a neutralizing effect on chelating agents found in NECDS and 
EDTA. 
 
2.5 Cell counting 
Cell numbers were counted using a haemacytometer.  
 
2.6 Electrophoresis and Immunoblotting 
Cell lysis: Up to 90% confluence cells in a T25 flask were washed with PBS 10 ml twice. 
One ml/T25 flask of sodium dodecyl sulphate (SDS) sample buffer was added and 
 
 
60 
 
incubated for 20 minutes at room temperature. The cell lysates were collected into 
1.5 ml tubes and kept at -800C until use. 
Table 2.2 SDS-sample buffer. 
     X 2 Concentration      X 4 concentration 
0.5% Tris-HCL      2.5ml      0ml 
glycerol      1.0ml (20%)      2ml 
Β-Mercaptoethanol       0.5ml (10%)      1ml 
20% SDS      1.0 ml       2ml 
1% Bromophenol blue      50 µl     0.1ml 
 
Table 2.3 Gel preparations separating gel 
 4% 7.5% 10% 15% 
Deionized Water 6ml 4.85ml 4.2ml 2.35ml 
1.5M Tris-HCL resolving gel buffer 2.5ml 2.5ml 2.5ml 2.5ml 
10% SDS 100 µl 100 µl 100 µl 100 µl 
30% acrylamide (acrylamide to bis 
acrylamide ratio 29:1) 
1.35ml 2.5ml 3.33ml 5ml 
TEMED 5µl 5µl 5µl 5µl 
10% ammonium persulfate 50µl 50µl 50µl 50µl 
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Table 2.4 Gel preparations stacking gel 
 3.75% 4% 
Deionized water 3.09 ml 3.05ml 
0.5M Tris-Hcl stacking gel buffer 1.25ml 1.25ml 
10% SDS 50µl 50µl 
30% acrylamide  
(acrylamide to bisacrylamide ratio 29:1) 
0.625ml 0.665ml 
TEMED 10µl 10µl 
10% ammonium persulfate 50µl 50µl 
 
After the glass plates and spacers (1.0 mm or 1.5 mm) thick were assembled, the 
running gel was poured to about 1cm below the wells of the comb ( ~4.8 ml or 9.6ml 
for 1.0 mm and 1. 5mm, respectively). Then 200µl water saturated butanol-1 was 
added on top of the gel. When the gel had set (~40 minute), the butanol was poured 
off and the gels were rinsed with about 2ml deionised water 3 times. Stacking gel 
was added and the 10 well or 15 well combs were inserted immediately. When the 
stacking gel had set, the glass plates were placed in a gel rig and immersed in running 
buffer. Prior to running the gel, the wells were flushed out thoroughly with running 
buffer. 
Table 2.5 Running buffer 
Tris-Base 30.67 grams 
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Glycine 64.04 grams 
SDS 2.2 grams 
Make up with dH2O 4L 
 
Running the gels 
The samples were heated at 1000C for 10 minutes before being loaded to the gels. 
The gels were run at 60 volts for 10 minutes before voltage was increased to 100 
volts for 90-120 minutes. The duration of gel run varied depending on gel percentage. 
The proteins separated on the gel were transferred to nitrocellulose membrane using 
a transfer buffer containing following ingredients 
Table 2.6 Transfer buffer 
Tris-Base 12.12 grams 
Glycine 57.65 grams 
Methanol 800 ml 
Make up with dH2O 4L 
 
The gel was sandwiched as negative pole (black) – sponge- filter paper- gel- 
nitrocellulose membrane-filter paper-sponge- positive pole (white) and transferred 
at 100 volts for 1 hour. 
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Immunoblotting 
The membrane was blocked in blocking buffer (1% BSA in PBS or TBS and 0.05% 
Tween-20) for 1 hour at room temperature or at 40C overnight.  Following blocking, 
the primary antibodies were mixed in blocking buffer at a concentration specified in 
the results section before being added to the membrane for one hour at room 
temperature. The blot was washed 3 times with 50 ml of 0.05% Tween 20 in PBS or 
TBS before being rolled on a rolling machine for 10 minutes between washes. After 
removal of the solution, secondary antibody was diluted in blocking buffer before 
being added at to the membrane for 1 hour at room temperature. After 3-5 washes 
with 0.05% Tween 20 in PBS 100ml each time, the binding was visualized using 
luminol-based enhanced chemiluminescence (ECL) HRP kit.  
 
2.7 Assessment of cell anoikis 
Anoikis conditions were created by triple coating 96 well and 6 well plates with 2-
hydroxyethyl methacrylate (poly-HEMA). Poly-HEMA is a polymer that forms a 
hydrogel in water and prevents cell adhesion, thereby creating anoikis conditions.  
Briefly, poly-Hema Crystals were dissolved in 95% ethanol to make a 10mM solution. 
200 μl or 1 ml of this solution as added to each well of a 96 well plate or a 6 well 
plate, respectively and the plates were allowed to incubate overnight in sterile 
environment. The coating process was repeated 3 times to ensure that poly-HEMA 
coated the bottom and the side of the wells used for anoikis assessment.  
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2.8 Caspase 3/7 activity assay 
The Caspase-Glo® Buffer was thawed and equilibrated prior to use. The Caspase-Glo® 
substrate was equilibrated to room temperature prior to use. All of the Caspase-Glo® 
Buffer was transferred into Caspase-Glo® substrate to reconstitute the lyophilized 
enzyme/substrate mixture. This formed the Caspase-Glo® Reagent.  
All the caspase 3/7 assays in this study were done at a 0 or 24-hour time-points, 
unless specified. The cells were plated at a concentration of 1 X 104 cells/ml in a flat 
white (block) transparent 96 well plate.  For 0-time point, assessment was done on 
cells under adhesion conditions and for 24-hour time points the cells were plated in 
a poly-HEMA coated plate. Prior to the addition to cells, Caspase-Glo® Reagent was 
mixed gently vortexing, swirling or by inverting the contents to obtain a homogenous 
solution. One hundred µl of this solution were added to cells in media in a 1:1 ratio. 
The control wells with medium only were used to obtain a value for background 
luminescence. Contents were mixed for 2 minutes on an orbital shaker to lyse the 
cells. The plate was allowed to incubate at room temperature for 30 minutes to 
equilibrate.  A luminescence reading was taken after 30 minutes using Tecan infinite 
200.  
Application:  Tecan i-control, 1.3.3.0 
Device:  infinite 200 
System:  MED17-86467C 
Plate:   Corning 96 flat bottom transparent polystyrol 
Mode:   Luminescence 
 
 
65 
 
Attenuation:  none 
Integration time: 500 ms 
Settle time:  0 ms 
 
2.9 Annexin V/ PI cell surface binding analysis 
The cells were released by NECDS and were cultured in either a 6 well cell culture 
plate (0 time point) or a 6 well poly-HEMA coated cell culture plate (24 hour time 
point). Approximately 2.5 x 105 cells were collected by centrifuging the cell at 330 x 
g for 5 minutes. The cells were then resuspended in 500 μl of 1X binding buffer (from 
Biovision) at a concentration of 5 X 105 cells/ml. Five μl of annexin V-FITC and 5 μl of 
propidium iodide (PI 50 μg/ml) were added into 0.5 ml cell solution incubated at 
room temperature for 5 minutes in the dark before analysis of annexin-V cell surface 
binding by flow cytometry (Ex= 488 nm, Em= 530 nm) using FITC signal detector 
(usally FL1) and PI staining by the phycoerythrin emission signal detector (usually 
FL2).  
Cells without staining and cells stained with either annexin V-FITC or propidium 
iodide (PI) were used as control to identify the position of non-staining live cells 
(bottom-left panel). Annexin-V FITC (bottom right panel) and PI (upper right panel) 
labelled cell population in the bivariate correlation plot. Annexin-V FITC positive and 
PI negative (early apoptotic, at the bottom right of the bivariate correlation plot) and 
annexin-V positive and PI positive (late apoptotic, at the top right in the bivariate 
correlation plot) cells are considered as apoptotic cells. 
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Figure 2.1: Annexin-V and PI analysis of F3 sh-C1GT (E7) at 0 hour. The analysis 
shows that at 0 time point 86.2% of cells are alive (bottom left quadrant), 10% of cells 
are undergoing late apoptosis (top right quadrant) and 1.87% of cells are undergoing 
early apoptosis (bottom right quadrant). 
 
2.10 Apoptosis array 
Proteome Profiler™ Human Apoptosis Array Kit (Ary009) was purchased from R&D 
systems.  HBl100 breast epithelial cells transfected with either the full length MUC1 
(HCA1.7+), no MUC1 (HCA1.7-) or MUC1 Δ CT (HDT) along with HCT116 cells 
transfected with either Full length/ neo/ Δ CT or Δ TR MUC1 were cultured at 1 × 
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105 cells/ml in serum-free DMEM for 24 h in poly-HEMA-coated plates at 37 °C. The 
suspended cells were collected, lysed and protein amount was measured using a 
bicinchoninic acid assay (BCA) protein assay kit.  The cells were collected and lysed 
with lysis buffer (provided by the Human Apoptosis Array Kit, R&D Systems) at 4 °C 
for 30 min. After centrifugation at 14 000 x g for 5 min, the supernatants were 
obtained and 500 μg proteins from each sample were applied to the Human 
Apoptosis Array as described by the array kit. Each array contains 35 apoptosis-
related proteins, each in duplicate (Bad, Bax, Bcl-2, Bcl-x, pro-caspase-3, cleaved 
caspase-3, catalase, cIAP-1, cIAP-2, claspin, clusterin, cytochrome c, TRAIL R1/DR4, 
TRAIL R2/DR5, FADD, Fas/TNFSF6, HIF-1α, HO-1/HMOX1/HSP32, HO-2/HMOX2, 
HSP27, HSP60, HSP70, HTRA2/Omi, livin, PON2, p21/CDNK1A, phosphor-p53(S15), 
phosphor-p53(S46), phosphor-p53(S392), phosphor-Rad17(S635), SMAC/Diablo, 
surviving, TNF R1/TNFRSF1A and XIAP). The density of each apoptosis-related protein 
in the array was quantified by ChmiDoc XRS Imager (Bio-Rad, Hertfordshire, UK). 
 
2.11 Flow-cytometry to access the cell surface expression of MUC1, E-
cadherin, Integrin β1, FAS and CD44 
Sub-confluent cells were released by 1 ml NECDS solution and were washed twice 
with 10 ml PBS. Following the removal of supernatant, the cell pellets were re-
suspended in 5 ml of 2% paraformaldehyde and cells were fixed at room temperature 
for 15 minute. After washing the cells twice with PBS and centrifugation at 1000 x g 
for 5 minute, the supernatants were removed and the cell pellets were incubated 
with 5% goat serum (106 cells/ml) for 30 minutes at room temperature on the roller 
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mixer. After removal of the supernatant following centrifugation at 1000 x g for 5 
minute, the cells were re-suspended into 106 cells/ml in 1% goat serum in PBS and 
divided 1ml/tube in 1.5ml eppendorf tubes. Biotin-PNA (2 μg/ml), biotin-VVA 
(2 μg/ml) or antibodies against MUC1 extracellular domain B27.29 (1 μg/ml), E-
cadherin (0.5 μg/ml), CD44 (0.5 μg/ml), integrinβ1 (0.5 μg/ml), Fas (0.5 μg/ml) or 
control mouse IgG were added to the cells and the solution was incubated at room 
temperature for 1 hour on a roller (or overnight at 40C). After washing twice with 
PBS, fluoroscein-conjugated secondary antibodies (1:400 in 1% goat serum in PBS) or 
fluoroscein-avidin (1:400 in 1% goat serum in PBS) were applied for 1 hour at room 
temperature. After three washes with PBS, the cells were re-suspended in PBS in 
0.5ml/tube. The cell surface expression of MUC1, E-cadherin, FAS, CD44 and 
integrinβ1 was analysed by flow cytometry (BD FACS Canto II). Flow cytometry data 
was analysed via either FlowJo (FlowJo LLC, Ashland, USA) version 10 or WinMdi 
version 2.9 (The Scripps Research Institute, La Jolla, USA) 
Table 2.7 Primary and secondary antibodies used in Flow cytometry analysis 
Primary antibody or lectin Secondary antibody 
B 27.29 FITC anti mouse antibody 
Biotinylated PNA FITC conjugated avidin 
Biotinylated VVA FITC conjugated avidin 
Mouse anti E-cadherin FITC anti mouse antibody 
Mouse anti Fas receptor FITC anti mouse antibody 
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Mouse anti CD44 FITC anti mouse antibody 
Mouse anti integrin beta 1 FITC anti mouse antibody 
 
2.12 Epithelial cell- endothelial adhesion 
HUVEC cells were released from the T25 flask using trypsin as above and suspended 
at 1x105 cells/ml with EGM culture medium. A 13-mm sterile coverslip was inserted 
in each well of 24-well plats. 200 µl of HUVEC cell at 1x 105 cell/ml was then added 
to each well of the 24 well plate and a HUVEC cell monolayer was grown on the glass 
coverslip (~ 3 days). The 24 well plate was incubated at 370 C at 5% CO2 for 24 hours. 
The cells were deemed suitable for adhesion assay at 100% confluence. 
ACA19+, ACA19-, ATD, HCA1.7+, HCA1.7- and HTD cells were maintained in DMEM 
containing fetal calf serum (FCS) before being detached from the T25 flask using 1 ml 
NECDS at 370 C for 5 minutes. Cells were washed twice with serum-free DMEM 
followed by centrifugation at 300 RCF for 5 minutes between washes, as mentioned 
above. The cells were then re-suspended in 1 ml serum-free DMEM and 5 µl/ml of 
fluorescent dye, Calcein-AM, was added and the cells followed by an incubation at 
370 C for 30 minutes. Once the ACA19+ cells were fluorescent labelled, they were re-
suspended at 1 x 105 cells/ml. 
The 24 well plates, containing glass coverslips with a monolayer of HUVEC cells were 
washed carefully with PBS and 0.5 µl/ml of fluorescent dye, 1,1'-Dioctadecyl-3,3,3',3'-
Tetramethylindocarbocyanine Perchlorate (DiL) was added for 30 minute at 370 C. 
HUVEC cells were again washed twice with PBS and 300 µl of the incubated ACA19+ 
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cells with galectin-3 (2 μg/ml), control (BSA 2 μg/ml) or 214 D (2 μg/ml) were added 
to corresponding well on the 24 well plate containing the glass coverslip with 
confluent HUVEC monolayer.  The 24 well plates were then incubated at 370 C for 2 
hours. 
To finish, the medium was removed from the 24 well plates and the plates were 
carefully washed with PBS. The cells were also fixed with 2% paraformaldehyde for 
10 minutes. The glass coverslip was carefully taken out from the wells and mounted 
with mounting medium for fluorescence (HI200 with DAPI from Vector labs). The 
cover slips were covered with a new 22mm cover slide. The slides were blinded with 
tape and fluorescence-labelled cells remaining on the endothelial monolayer were 
counted in 10 random fields of view under fluorescence microscopy (Olympus B51 
fluorescence microscope). 
 
2.13 Immunofluorescence 
Sterile 13 mm coverslips were inserted into each well of a 24 well plate before cells 
to be assessed were added at a concentration of 1 x 105 cells/ml. The cells were 
grown to about 60% confluence before media was changed to serum free media 16 
hours prior to treatment.  Following treatment (details of which are given in 
individual result chapters) the cells were washed with either PBS or TBS before being 
fixed with 4% paraformaldehyde for 10 minutes at room temperature. Following 
fixation, the cells were washed twice with either PBS or TBS before being blocked in 
5% goat serum for 30 minutes at room temperature. This was followed by addition 
of primary antibodies in 1% goat serum (details and concentration given in individual 
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result chapters) and the cells were incubated at room temperature for 2 hour. The 
cells were washed twice before an appropriate FITC or Alexa fluor conjugated 
secondary antibody was added and the cells were incubated in dark at room 
temperature for a further 60 minutes.  The cells were washed twice before mounting 
using DAPI containing fluorescent mounting media. The slides were analysed via 
either AQM 6 (Olympus B51 fluorescence microscope) or with 3i confocal microscope 
(Marianas SDC, 3i Imaging) and Slidebook 6 Reader version 6.0.4 (Intelligent-
imaging). 
 
2.14 Caspase 8 activity assay 
Like the caspase 3/7. The Caspase 8-Glo® Buffer was thawed and equilibrated prior 
to use. The Caspase-Glo® substrate was equilibrated to room temperature prior to 
use. All of the Caspase-Glo® Buffer was transferred into the amber bottle containing 
Caspase-Glo® substrate to reconstitute the lyophilized enzyme/substrate mixture.  
All the caspase 8 assays in this study was done at either 0 or 2-hour time-points. The 
cells were plated at a concentration of 2 X 105 cells/ml in a flat white (block) 
transparent 96 well plate.  For 0-time point, assessment was done on cells under 
adhesion condition and for 2-hour time points the cells were plated in a poly-HEMA 
coated plate. FAs ligand treatment included introduction of 100 ng/ml Fas-L for 0 and 
2 hr before measuring the cellular caspase-8 activity using caspase-8 Glo assay. 
Prior to the addition to cells, Caspase-Glo® Reagent was mixed gently vortexing, 
swirling or by inverting the contents to obtain a homogenous solution. One hundred 
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µl of this solution was added to cells in media in a 1:1 ratio. The control wells were 
added with medium only to obtain a value for background luminescence. Contents 
were mixed for 2 minutes on an orbital shaker to lyse the cells. The plate was allowed 
to incubate at room temperature for 30 minutes to equilibrate.  A luminescence 
reading was taken after 30 minutes using Tecan infinite 200.  
Application:  Tecan i-control, 1.3.3.0 
Device:  infinite 200 
System:  MED17-86467C 
Plate:   Corning 96 flat bottom transparent polystyrol 
Mode:   Luminescence 
Attenuation:  none 
Integration time: 500 ms 
Settle time:  0ms 
 
2.15 C1GT knockdown 
Plasmids containing shRNA for C1GT and Puromycin resistance (Vector-pLKO.1-Clone 
Number TRCN0000289384) or control vector (MISSION® TRC2 pLKO.5-puro Empty 
Vector Control Plasmid DNA SHC201) were purchased from Sigma-Aldrich. Prior to 
any stable transfection, a kill curve assay was performed.  
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2.15.1 Killing curve 
Cells to be transfected (SW620, HCT116 MUC1 full and HCT116 MUC1 neo) were 
plated in a 96 well plate at a concentration of 1x105 cells/ml. The cells were allowed 
to grow till 70-80% confluent before the media was changed to 200 μl/well complete 
media (10% FCS, 2mM glutamine, penicillin 100 U/ml, streptomycin 100 μg/ml) 
containing a range of different puromycin concentrations from 0 μg/ml to 15 μg/ml. 
The cells were observed at 6 hours interval for up to 3 days after which the minimum 
puromycin concentration required to kill all the cells of a particular cell type was 
recorded. This concentration was used later in the selection phase of the stable 
transfection 
2.15.2 shRNA transfection 
HCT116 MUC1 full, HCT116 MUC1 neo and SW620 cells were seeded in 
corresponding complete media ( McCoy’s 5A for HCT116 MUC1 full and HCT116 
MUC1 neo, DMEM for SW620) until the cells were 60-70% confluent. ShRNA for C1GT 
or control shRNA (100 ng) was pre-mixed in a 1:4 ratio with Metafectene transfection 
reagent in serum-free and antibiotic-free McCoy’s 5A media (100 µl) for 30 min 
before addition to the cells in antibiotic-free and serum-containing medium (100 µl) 
in a single 96-well plate. The cells were then cultured at 370C and 5% CO2 for 6 hours.  
After 6 hours culture the culture media was removed and replaced with complete 
media containing puromycin concentration pre-determined using the kill curve 
assays. The cells were incubated at 370C and 5% CO2 for a further 72 hours. The 
surviving cells were released by trypsin, were re-suspended in a very low cell density 
and seeded into new 96 well plates. Wells containing single cells were identified 
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under microscope and were allowed to proliferate before being selected and 
analysed for successful shRNA transfection. 
2.15.3 Transfection Validation 
C1GT is an essential transferase that encodes for Core 1 structure following 0-
glycosylation. Absence of C1GT leads to a reduction of core 1 structure as well as 
increased availability of sialyl-Tn and Tn cellular glycans. Using this justification, we 
tested for MUC1 expression (using B27.29 and CT2 to detect extracellular and 
intracellular domain of MUC1), Core 1 expression (Using PNA that binds to core 1 
structure on MUC1) and Tn expression (using VVA that recognises the Tn antigen) via 
both immunoblotting and flow cytometry analysis.  
shRNA transfection was considered successful for C1GT knockdown when Core 1 
expression (PNA binding) was reduced and Tn expression was increased. 
 
2.16 EGFR activation assays 
The cells to be assessed were seeded at a concentration of 1x105 cells/ml in a 24 well 
plate under complete media, till 50-60% confluent. At this point the medium was 
changed to serum-free for 16 hours. The cells were washed with sterile TBS before 
addition of different treatment (details of treatment and durations are explained in 
corresponding result chapter). The cells were then incubated at 370C and 5% CO2 for 
varying times after which they were washed again in ice cold TBS before being 
immediately lysed in 2x SDS-sample buffer on ice. The lysates were collected in 1.5 
ml eppendorfs and stored at -800C prior to immunoblot analysis. In immunoblots 
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detecting either pEGFR or pERK1/2, the wash buffer and blocking buffer were made 
in TBS to reduce non-specific interactions.  
 
2.17 EGFR crosslinking 
A detailed protocol for EGFR crosslinking using BS3 cross-linker is  published by Turk 
et al. (434). We followed the general principles of this protocol and adapted it for our 
assay as follows: 
The cells were seeded in a T25 flask at a concentration of 2x 105 cells/ml and were 
grown till 50-60% confluent, at which point the complete medium was removed and 
the cells were serum-starved overnight (16 hours). The following day the cells were 
washed twice with Ca2+ and MG2+ free PBS and were treated with serum-free media 
containing the treatments (details of treatments are given in corresponding 
chapters). Following treatment, the cells were incubated in 370C and 5% C02 for 10 
minutes after which they were washed with ice-cold Ca2+ and Mg2+ free PBS and 
incubated with 3mM BS3 cross-linker in Ca2+ and Mg2+ free PBS on ice for 20 minutes. 
Excess BS3 was quenched with 250 mM glycine in PBS for 5 minutes at 40 C , as per 
manufacturer’s instruction. The cells were washed three times with ice cold PBS, 
lysed in SDS-sample buffer and analysed by immunoblotting with antibodies against 
EGFR. 
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2.18 Immunoprecipitation 
Sub-confluent cells were incubated in serum-free medium containing 0.5mg/ml BSA 
overnight. The cells were with TBS and   incubated with EGF (20ng/ml), EGF (20ng/ml) 
and galectin-3 (2μg/ml), galectin-3 (2 μg/ml) or 20 ng/ml BSA (control) in serum free 
media for 10 min at 370 C. The cells were washed with ice cold PBS, scraped and 
collected in a 1 ml PBS containing 1% TritonX-100 and protease inhibitors 
(Calbiochem). The cells were lysed on ice for 30 min followed by centrifugation at 
10,000g at 4oC for 15 minutes. The supernatants were collected and pre-cleared by 
adding 20 μl of the protein A/G beads and incubating at 40C for 30 minutes with 
gentle agitation. One ml lysates (protein concentration 2mg/ml) were incubated with 
B27.29 (1 μg/ml), anti-EGFR (DB81) (2 μg/ml) or isotype-matched IgG (rat anti-mouse 
IgG1 for B27.29 and Armenian hamster anti rabbit for anti-EGFR, produced against a 
synthetic hapten) at 40C with continuous agitation for 16 hours. Thirty μl of protein 
A/G plus agarose beads were added for 4 hr and the beads were washed five times 
at 40C with ice cold PBS. Proteins were eluted from the beads by boiling in SDS-
sample buffer for 10 minutes before application to SDS-PAGE and subsequent 
immunoblotting.  
 
2.19 Statistics  
Data is presented as mean or percentage of control ± SEM or ±SD (stated in individual 
figures).  For the experiments repeated in at least triplicates, a one-way ANOVA with 
either Dunnett or Bonferroni post-hoc test was used to establish statistical 
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significance where appropriate. A Fisher exact test was used to assess statistical 
differences in MUC1 polarization when treated with MUC1 polarizing agents 
(antibody 214D and galectin-3) and control Bovine serum albumin (BSA). A two-way 
ANOVA with Sidak post-hoc test was used to assess statistical difference in EGFR 
activation when tested with ligand EGF, EGF in combination with galectin-3 or control 
(galectin-3). For all statistical analysis P<0.05 was considered significant. 
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3 Investigation into the 
impact of different 
domains of MUC1 on 
cellular resistance to 
anoikis 
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3.1 Hypothesis 
 
Different domains of MUC1 may contribute differently to MUC1-mediated 
resistance to anoikis. 
 
3.2 Aims 
To investigate the contributions of MUC1 extracellular and intracellular domains on 
MUC1-mediated resistance to anoikis. 
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3.3 Introduction 
Anoikis is apoptosis induced in cells following inadequate or inappropriate cell-cell, 
cell-matrix contact (126, 435). This fundamental process ensures tissue homeostasis 
and prevents displaced epithelial/endothelial cells from seeding to inappropriate 
sites. Absence or resistance to anoikis is one of the first steps in eventual tumour 
metastasis. Metastasising tumour cells are able to survive independently in 
suspension and are able to ‘seed’ at secondary tumour sites leading to tumour 
metastatic spread (436). 
Many cell surface and intracellular proteins are involved in regulating anoikis. It is 
generally accepted that following loss of contact with extra-cellular matrix, anoikis 
signalling starts from the cell surface through activation of cell surface anoikis-
initiating molecules such as integrins, cadherins and death receptors. Loss of the 
integrin-mediated cell-basement matrix contact (131),  loss of the E-cadherin-
mediated cell–cell contact (437, 438) or ligation of the cell surface death receptors 
with their ligands (131, 439) have been shown to induce conformational changes or 
oligomerization of these cell surface anoikis-initiating molecules. This triggers a series 
of events leading to activation of either the caspase-8-mediated extrinsic apoptotic 
signalling pathway or the mitochondrion-mediated intrinsic apoptotic signalling 
pathway leading to eventual accumulation of executioner caspases, caspase 3 and 7 
(135).  
MUC1 is a large transmembrane mucin protein that is physiologically expressed 
exclusively on the apical side of normal epithelial cells and some other cell types. 
MUC1 consists of a large extracellular domain, a transmembrane region and a short 
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cytoplasmic tail. The MUC1 extracellular domain contains a variable number of 
tandem repeats (VNTR) that are heavily glycosylated (up to 50% of the MUC1 
molecular weight) with complex O-linked mucin-type glycans (440) and flanked by a 
unique N-terminal domain and an SEA domain. The cytoplasmic tail of MUC1 contains 
72 amino acids and harbours several phosphorylation sites and is able to interact 
with various growth factor receptors and intracellular signalling proteins (32, 116, 
441). 
MUC1 is overexpressed by up to at least 10-fold in many epithelial cancer cells (442) 
and this overexpression of MUC1 is closely associated with high metastatic potential 
and poor prognosis in many cancer types (61, 443). In epithelial cancer cells, the 
overexpressed MUC1 loses its apical membrane polarization and becomes expressed 
over the entire cell surface (431).  Overexpression of MUC1 in epithelial cancer cells 
has been shown in our previous study to lead to increased resistance of the cells to 
anoikis (433). A model for this effect was proposed in which MUC1 forms a  
‘protective barrier’ on the cell surface that prevents activation of anoikis-initiating 
molecules in response to loss of cell-matrix contacts (25) 
This part of the study aims to determine the influence of MUC1 extracellular and 
intracellular domains on MUC1-associated cellular resistance to anoikis   
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3.4 Methods 
 
Immunoblotting 
The immunoblotting protocol has been described in detail previously. Here antibody 
B27.29 (1μg/ml) was used to detect MUC1 extracellular matrix, biotinylated PNA (2 
μg/ml) to detect TF antigen, anti-CT2 (2 μg/ml) to detect MUC1 intracellular domain, 
and actin (1 μg/ml) to ensure equal loading.  
 
Caspase-3-7 activity assay 
Ninety-six well plates were washed with sterile PBS and coated with 10 mg/ml poly-
HEMA. The cells were released by NECDS from culture flasks, washed with PBS and 
re-suspended to 5x104 cells/ml with serum-free DMEM containing 0.5 mg/ml BSA 
and seeded at 1 x 104 cells/well and cultured for 24 hours at 370C. Anoikis was 
assessed by using Caspase- Glo® 3/7 Assay kit according to manufacturer’s 
instructions.  
 
Apoptosis Array  
Proteome Profiler™ Human Apoptosis Array Kit (ARY009) was purchased from R&D 
systems.  HBl100 breast epithelial cells transfected with either the full length MUC1 
(HCA1.7+), no MUC1 (HCA1.7-) or MUC1 Δ CT (HDT), or HCT116 cells transfected with 
either full length MUC1 (HCT116 MUC1 F3), intracellular domain deleted MUC1 
(HCT116 MUC1 Δ CT, extracellular domain deleted MUC1 (HCT116 MUC1 ΔTR) or 
MUC1 negative control (HCT116 MUC1 neo) were grown in serum-free media while 
suspended in a poly-HEMA coated 6 well plate for 24 hours at 370C.  The suspended 
cells were collected, lysed and protein concentration was measured using BCA 
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protein assay kit. Four hundred µg/ml of lysate from each cell line was added to an 
apoptosis array and apoptosis proteins were analysed and quantified as per 
manufacturer’s instructions  
 
Adhesion assay 
HUVEC cells were cultured in 96-well plates at 1 X 105 cells/ml till a monolayer formed 
(~48 hours). Subconfluent ACA19+, ACA19-, ATD, HCA1.7+, HCA1.7- and HTD cells 
were labelled with Calcein-Am at a concentration of 5 µl Calcein-AM in 1 ml 
containing 1x106 cells for 30 min at 370 C. The cells were then washed twice with PBS 
and mixed with either BSA (2 µg/ml) , recombinant galectin-3 (2 µl/ml) or antibody 
214-D (50 µg/ml)  in serum-free media before being added to the 96-well plate 
containing HUVEC monolayer.  The plate was incubated at 370C with 5% CO2 for 1 
hour before being washed twice with PBS. A final fluorescence reading was taken 
using a TECAN plate reader. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
84 
 
3.5 Results 
3.5.1 Validation of MUC1 status and cell morphology in MUC1-transfected cells  
The cells used in this study were the A375 Melanoma cells, HBL100 human breast 
epithelial cells and HCT116 colon cancer cells that were stably transfected with either 
the full length, control MUC1 neo, MUC1 ΔCT or MUC1 ΔTR. Prior to any further 
investigation to assess the effect of these transfection, the cells were validated to 
confirm the correct MUC1 status.  
Expression of full length MUC1 can be validated by detection of both MUC 1 
extracellular domain with B27.29 anti-MUC1 antibody and intracellular domain by 
anti-MUC1 CT2 antibody in all HCT116 MUC1 full (figure 3.1 A), HCA 1.7+ (figure 3.1 
B) and ACA19+ cells (figure 3.1C).  No MUC1 expression was detected in Control 
MUC1 negative HCT116 MUC1 neo
 
HCA1.7- and ACA19- cells by either B27.29 or CT2 
antibodies in all three cell types. As expected, ΔCT cells could only be detected by 
B27.29 and not CT2 (HCT116 MUC1 ΔCT , HTD and ATD)  whereas ΔTR cells could only 
be detected by CT2 and not B27.29 antibodies (HCT116 MUC1 ΔTR ). 
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Figure 3.1: Immunoblot analysis of MUC1 transfected cells. HCT116 (panel B), HBL100 (panel C) and A375 (panel D) cells were stably transfected 
with either full length, ΔTR, ΔCT or control variant. A schematic diagram of transfection is shown (panel A). Cells transfected with full length 
MUC1 could be detected with both antibodies B27.29 and CT2, which targets the extracellular and the intracellular domains of MUC1 
respectively.  ΔCT cells could be detected by only B27.29 and not CT2, whereas ΔTR cells could be detected only by antibody CT2 and not B27.29. 
MUC1 neo cells were negative for both anti-MUC1 antibodies.
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The morphology of these cells was also checked (figure 3.2).  Although 
morphologically very similar, cells transfected with full length or only the 
extracellular domain of MUC1 tended to be more spindle shaped, whereas those 
transfected with control vector tended to be rounder. It was also observed that cells 
transfected with full length or either the intracellular or extracellular domain of 
MUC1 had slower rates of growth compared to control group, supporting the idea 
that MUC1 expression may have inhibit cell proliferation (64, 67). 
 
Figure 3.2: Morphology of MUC1-transfected melanoma and Breast epithelial cells 
Morphology of melanoma (A375) and human breast epithelial (HBL100) cells 
transfected with either full length MUC1 (ACA19+ and HCA1.7+ respectively), with 
extracellular domain of MUC1 only (ATD2 and HTD respectively) or control MUC1 
neo group (ACA19- and HCA 1.7- respectively) after 2-day culture at 370C. 
Representative images of 10 random field observations from 2 experiments (10 x 
magnification).  
  
Further validation of MUC1 expression was also done by flow cytometry. Figure 3.3 
is a flow cytometry analysis on MUC1 transfected HCT116 cells when tested with 
antibody B27.29 and appropriate FITC-conjugated secondary antibodies. As 
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expected, minimal signal is noted for MUC1 neo and MUC1 ΔTR cells with increased 
signal for MUC1 full and ΔCT variants, indicating the presence of MUC1 extracellular 
domain in these cells in the MUC1 full and ΔCT variants. MUC1-positive melanoma 
cell ACA19+, MUC1-negative melanoma cells ACA19-, MUC1 intracellular domain-
deleted melanoma cells ADT, MUC1-positive breast epithelial cell HCA1.7+, MUC1-
negative breast epithelial cells HCA1.7- and MUC1 intracellular domain-deleted 
melanoma cells HDT were also tested for TF expression on MUC1 extracellular 
domain by the TF-binding Peanut agglutinin (PNA). No PNA binding was noticed in 
MUC1 neo cells but MUC1 full and ΔCT variant all showed strong PNA binding 
suggesting the presence of TF region on MUC1 extracellular domain. (see figure 3.4) 
 
Figure 3.3: Analysis of MUC1 expression by Flow cytometry of the MUC1 
transfected HCT116 cells. HCT 116 cells transfected with either the full length (MUC1 
Full), intracellular (MUC1 Δ TR), extracellular (MUC1 Δ CT) or control group (MUC1 
Neo) were probed with primary antibody B27.29 (to detect MUC1 extracellular 
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domain) and FITC conjugated secondary antibody followed by analysis with flow 
cytometry. 
 
 
Figure 3.4: MUC1 full and MUC1 ΔCT cells show similar TF expression in Breast 
epithelial and melanoma cells. Stable Transfected Melanoma cells ACA19+, ACA19-, 
ADT and stable transfected breast epithelial cells HCA1.7+, HCA1.7-, HDT were 
immunoblotted using antibodies B27.29 and PNA.  PNA shows binding to both MUC1 
full and MUC1 ΔCT cells.  
 
3.5.2 MUC1 overexpression leads to resistance to anoikis 
Following 24 hours in suspension in poly-HEMA coated plates to mimic anoikis 
conditions; HCA1.7+ and ACA19+ cells transfected with full length MUC1 showed a 
marked reduction in caspase 3/7 activity compared to their control variants (Fig 3.5A 
and Fig 3.5B). These data further confirm our previous report that overexpression of 
MUC1 leads to resistance to anoikis.(433) 
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Figure 3.5: MUC1 transfection in human breast epithelial HBL-100 and Melanoma 
A375 cells inhibits anoikis.  Assessment of caspase-3/7 activity of HCA1.7+/- 
(Figure3.5 A) and ACA19+/- (Figure 3.5 B) cells in response to 24-hour culture in 
suspension condition shows that MUC1 transfected cells are more resistant to 
anoikis compared to the MUC1 negative controls. The data are presented as mean 
+/- SD of triplicate determinations from 2 experiments. N=2, n=3 
 
3.5.3 Both intracellular and extracellular domains of MUC1 contribute to MUC1-
mediated anoikis resistance  
Having shown that expression of MUC1 leads to resistance to anoikis, we then 
compared the effect on anoikis of MUC1-mutant cells which express different 
domains of MUC1. 3 different cell lines transfected with either MUC1 full (ACA19+, 
HCA1.7+ and HCT116 MUC1 Full), MUC1 ΔCT (ADT, HTD and HCT116 MUC1 ΔCT) and 
control MUC1 neo cells (ACA19-, HCA1.7- and HCT116 MUC1-neo) were used. For 
HCT116 cells we also had MUC1 ΔTR variant. Using poly-HEMA coated plates to 
simulate anoikis conditions, we compared Caspase 3/7 activity in these cells in 
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response to 24-hour cell suspension culture. Cells expressing the full length MUC1 
(HCA1.7+, ACA19+ and HCT116 MUC1 full) were shown more resistant to anoikis 
compared to MUC1-negative transfects (HCA1.7-, ACA19- and HCT116 neo). This is 
in accordance with the earlier results (Figure 3.5 and (433)). MUC 1 transfectants 
without the MUC1 cytoplasmic domain (ATD, HTD and HCT116 Δ CT) showed higher 
levels of anoikis (~50%) compared to full length MUC1 transfectants (HCA 1.7+ and 
ACA19+) but significantly less (p<0.001) than the MUC1 negative transfect (HCA 1.7- 
and ACA19- HCT116 MUC1 Neo) (Figure 3.6). When comparing HCT116 Δ TR with 
HCT116 MUC1 Full and HCT116 MUC1neo, a similar pattern was observed, whereby 
HCT116 Δ TR had a higher level of anoikis compared to HCT116 MUC1 full but 
significantly less than HCT116 MUC1neo.  Together, these results suggest that both 
the intracellular and the extracellular domains of MUC1 contribute to the effect of 
MUC1 on anoikis.  
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Figure 3.6:  Depletion of either MUC1 intracellular (ΔCT) or extracellular (ΔTR) domain leads to a reduction in MUC1 mediated resistance to 
anoikis. ACA19 MUC1 neo/full/ ΔCT (figure 3.6 A) HBL100 MUC1 neo/full/ ΔCT (figure 3.6 B) and HCT116 MUC1 Neo/Full/ ΔCT and Δ TR (figure 
3.6 C) were assed for anoikis resistance. The absence of either of MUC1 extracellular or cytoplasmic domain reduces full MUC1-mediated cell 
resistance to anoikis when cellular caspase-3/7 activity was assessed. The data are presented as mean +/- SE of triplicate determinations of 
three experiments. N=3, n=3, one-way ANOVA with Bonferroni, ***p<0.001.
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3.5.4 The length of the MUC1 extracellular domain influences the effect of MUC1 
on resistance to anoikis 
To test whether the length of the MUC1 extracellular domain influences MUC1-
mediated resistance to anoikis, we tested anoikis resistance in fibroblasts transfected 
with MUC1 shRNA consisting of either 0 (parental), 8 15 or 36 variable number of 
tandem repeat. (Figure 3.7 A) By changing the length of VNTR, the size of extracellular 
domain of MUC1 can be controlled, with higher numbers of VNTR leading to a longer 
extracellular domain and increased MUC1 size.  
 
Figure 3.7: Increase in variable number of tandem repeats (VNTR) reduces anoikis 
in fibroblast cells.  A) Human fibroblast cells stably transfected with either 0 
(parental), 8, 15 or 36 tandem repeats in MUC1 extracellular domains were assessed 
for anoikis. b) Immunoblot with antibodies against the MUC1 extracellular domain 
(b27.29), intracellular domain (CT2) and actin. N=3, n=3, one-way ANOVA with 
Bonferroni * *p<0.01, ***p<0.001. 
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Although an increase was noted between parental and 8 or 15 tandem repeats, a 
marked reduction in anoikis was noted for the cells transfected with 36 tandem 
repeats in comparison to MUC1 without tandem repeats (0) cells. The effect of the 
36-tandem repeat in contrast to 8 and 15 tandem repeats suggests that a large 
number of VNTR are needed to ensure anoikis resistance in fibroblasts. Further 
immunoblot analysis of these fibroblasts shows that cells transfected with 36 VNTR 
MUC1 also had a higher expression of MUC1 compared to 8 and 15 VNTR group 
(figure 3.7 B), suggesting that the effect on anoikis resistance in 36 VNTR group could 
be related to the combined effect of increased length as well as increased expression 
of MUC1 extracellular domain.  
 
3.5.5 Expressions of several apoptotic proteins are altered in MUC1-expressing cells 
in response to anoikis 
Having established that both extracellular and intracellular domains of MUC1 are 
involved in MUC1-mediated resistance to anoikis, we compared the effects of the 
presence of different MUC1 domains on expression of key apoptosis proteins in 
response to anoikis culture using the Proteome Profiler™ Human Apoptosis Array Kit 
(Ary009) R&D systems) which tests for 35 key apoptosis proteins. 
 
We first tested HBL100 cells transfected with full length MUC1 (HCA1.7+) and 
compared them with HBL100 neo cells (HCA1.7-). It was noted that expression of 
several key apoptosis proteins was increased in HCA1.7+ cells compared to HCA 1.7- 
with several hundred-fold increase noted in pro caspase 3, Cytochrome c and p53 
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(figure 3.8). Interestingly, a similar pattern as HCA1.7+ was observed in HDT cells. All 
the key apoptosis proteins noted to have a higher expression in HCA1.7+ also had a 
higher expression in HTD cells, and in some cases this level of increased expression 
was almost similar.  For example, pro caspase 3 levels were noted to be almost 50-
fold and 46-fold higher in HCA 1.7+ and HTD cells, respectively, compared to HCA1.7-
. Similarly, P53(s392) level were 148 and 154 folds higher in HCA 1.7+ and HTD cells, 
respectively, compared to HCA1.7-. However, a few key apoptosis proteins did show 
a degree of variation.  For example, Bcl-X expression level was increased by 503% and 
332% in HCA1.7+ and HTD cells, respectively, when compared to HCA1.7- . Similarly, 
P21 level was increased by 8.7-fold and 3.2-fold in HCA1.7+ and HTD cells, 
respectively, when compared to HCA1.7- .  
 
Apoptosis array analysis was also performed in MUC1-transfected HCT116 cells 
(figure 3.9). In these cells the pattern of expression of key apoptosis proteins was 
surprisingly different from that seen in MUC1-transfected HBL100 cells. The several-
fold increase in key apoptosis proteins as noted in HCA1.7+ and HTD cells when 
compared with HCA1.7- cells was not noted in HCT116 mutant cells. Instead, the 
changes in expression level of key apoptosis proteins between these cells were rather 
modest. The table in figure 3.9 shows several key apoptosis proteins that were noted 
to be either increased or decreased by 50% in MUC1F3, MUC1 ΔCT or MUC1 ΔTR cells 
when compared to HCT116 MUC1 Neo. For example, cleaved caspase- 3 levels were 
decreased by 83.4% in HCT116 MUC1 full (F3) cells, decreased by 67% in HCT116 
MUC1 ΔTR but increased by 15.5% in HCT116 MUC1 ΔCT, when compared to HCT116 
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MUC1 neo. Similarly, P21 level were decreased by 46.5% in F3, increased by 131.8% 
in ΔTR and decreased by 60.2% in ΔCT cells compared to HCT116 MUC1 neo cells. 
Thus, expression of MUC1 and MUC1 mutants has a complex effect on expression of 
several key apoptotic proteins. 
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Figure 3.8: Apoptosis array on MUC1 transfected HBL100 cells. HBL 100 cells transfected with either no, full length or ΔCT domains of MUC1 
were cultured in suspension condition for 24 hours followed by apoptosis array. The apoptosis array and apoptosis proteins were analysed and 
quantified as per manufacturer’s instructions. The table in figure B shows some of the key apoptosis proteins that were noted to be either 
increased or decreased by 50% or more in HCA1.7+ or HDT cells when compared to HCA1.7-.  Representative images from two arrays, N=2.  
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Figure 3.9: Apoptosis array on MUC1 transfected HCT116 cells. HCT116 cells transfected with either no, full length, ΔCT or ΔTR domains of 
MUC1 were cultured in suspension condition for 24 hours followed by apoptosis array. The apoptosis array and apoptosis proteins were 
analysed and quantified as per manufacturer’s instructions. The table on the right-hand side shows some of the key apoptosis proteins that 
were noted to be either increased or decreased by more than 50% in MUC1 full, MUC1 ΔCT or MUC1 ΔTR cells when compared to HCT116 
MUC1 Neo. Representative images from two arrays, N=2.
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3.5.6 Effect of MUC1 polarization on MUC1 cell surface localization and on cancer 
cell adhesion to endothelial cells.  
 
The large and abnormally glycosylated MUC1 proteins surround the entire cell 
surface and acts as a protective barrier against the underlying cell surface molecules. 
Our previous work has shown that the expression of MUC1 reduces the accessibility 
to several key anoikis initiating molecules, including integrins, cadherin and FAS 
(433). Polarization of MUC1, reduces the ‘barrier’ nature of MUC1 and exposes the 
underlying anoikis initiating and adhesion molecules.   
Galectin-3 is a multi-functional galactoside-binding lectin that is physiologically 
expressed by many types of human cells. It is found intracellularly, in the circulation 
and on the cell surface.  Intracellular galectin-3 is an apoptosis inhibitor (270) and 
mRNA splicing promoter (444) whilst cell surface-associated extracellular galectin-3 
acts as an adhesion molecule in cell-cell interactions (445, 446) and promotes cancer 
progression and metastasis (306, 447). The concentration of free circulating galectin-
3 is markedly increased in the sera of patients with breast, colorectal, lung (448), 
head and neck cancers (319) and melanoma.(449) Patients with metastatic disease 
are seen to have higher concentrations of circulating galectin-3 than those with 
localized tumours. Recently, we have shown that the transmembrane mucin protein 
MUC1 is an endogenous ligand of galectin-3 in human colon cancer cells and that the 
interaction between MUC1 and galectin-3 occurs via binding of galectin-3 to the 
oncofetal Thomsen-Friedenreich carbohydrate (Galβ1,3GalNAcα-, T or TF) antigen on 
MUC1.(79) Interaction between cell surface MUC1 and galectin-3 at concentrations 
similar to those found in the sera of cancer patients increases cancer cell heterotypic 
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adhesion to endothelium as a result of MUC1 cell surface polarization which leads to 
exposure of heterotypic cell-cell adhesion molecules that are otherwise concealed 
by elongated structure of MUC1.(79) 
214D is an anti MUC1 antibody that binds to the VNTR region of MUC1 extracellular 
domain. Given the role of galectin-3 in tumour progression and metastasis, we 
wanted to assess whether 214D anti-MUC1 antibody, which is known to induce 
MUC1 cell surface polarization, has a similar effect as galectin-3; as galectin-3 
induced MUC1 polarization is associated with cell adhesion. 
When binding of the HCT116 MUC1 transfected cells to endothelial cells was tested, 
the MUC1 neo cells bound to endothelial cells most strongly, when compared to 
HCT116 MUC1 full and HCT116 ΔCT cells (figure 3.10). This adhesion of MUC1 neo 
cells to the endothelium was not affected by addition of either galectin-3 or 214D 
anti-MUC1 antibody. HCT116 MUC1 full and HCT116 ΔCT cells had a lower adhesion 
to endothelial cells compared to MUC1 neo variant, but the level of adhesion was 
significantly increased in the presence of either galectin-3 or 214D, suggesting that 
MUC1 polarisation by galectin-3 or 214D anti-MUC1 antibody increases heterotypic 
adhesion of MUC1full and MUC1 ΔCT cells (figure 3.10, 3.12). Immunofluorescence 
analysis of these cells (figure 3.11) showed that presence of galectin-3, but not the 
truncated galectin-3C, or antibody 214D induced MUC1 cell surface polarization of 
both MUC1 full and MUC1 ΔCT cells and this effect is independent of the 
expression/presence of MUC1 intracellular domain. 
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Figure 3.10: exogenous addition of galectin-3 or 214D anti-MUC1 antibody 
increased adhesion to endothelial cells of both MUC1 full and MUC1 ΔCT cells. 
ACA19+/ACA19-/ADT (figure 11 A) and HCA1.7+/HCA1.7-/HDT were treated with 
either control (BSA 2 μg/ml), galectin-3 (2 μg/ml) or 214d (50 μg/ml) before being 
added to a HUVEC monolayer. Results are shown as percentage to control (BSA 
binding). Addition of galectin-3 or antibody 214D substantially increased cell 
adhesion of HCA1.7+, HTD, ACA19+ and ATD cells to the endothelial monolayer. 
N=3, n=3, ANOVA (Bonferroni), ** = p<0.01, ***= p<0.001. 
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Figure 3.11: Addition of Galectin-3 or antibody 214D induces MUC1 cell surface 
polarization of MUC1full and MUC1 ΔCT cells. HCA1.7+ and HDT cells were mixed 
with either control (BSA 2 μg/ml), galectin-3 (2 μg/ml), truncated form of galectin-3 
(galectin-3C 2 μg/ml) or 214D (50 μg/ml) before being immunofluorescent labelled 
by antibody B27.9 and FITC conjugated secondary antibody. Galectin-3, but not 
galectin-3C, and antibody 214D induces MUC1 cell surface polarisation (as illustrated 
by discontinuous MUC1 localization on the cell surface) of HCA1.7+ and HTD cells. 
Representative images of 20 random field observations from 3 experiments (40 x 
magnification). 
 
Figure 3.12 summarises MUC1 cell surface polarization of the cells in response to 
galectin-3 or 214D treatment. Following addition of galectin-3, 54% of HCA1.7+ cells 
and 65.2% of HTD cells showed MUC1 polarisation. Following treatment with anti 
MUC1 antibody 214D 82% of HCA1.7+ cells and 87% of HTD cells showed MUC1 
polarisation.  
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Figure 3.12: Galectin-3 and antibody 214D induces MUC1 cell surface polarization 
in HCA1.7+ and HTD cells. Following treatment of HCA1.7+ or HTD cells with either 
control (BSA 2 μg/ml), 2 μg/ml of truncated form of galectin-3 (Gal-3C), 2 μg/ml of 
commercial galectin-3 (Gal-3F commercial) from R&D systems (1154-GA/CF), 2 
μg/ml of galectin-3 produced in our lab (Gal-3 F) or antibody 214D (10 μg/ml) 200 
cells in each group shown in the immunofluorescent experiment (figure 3.11) were 
randomly selected and were quantified for MUC1 cell surface polarization as 
determined by loss of continuous MUC1 ring on cell surface. Galectin-3 and 214D 
treated cells showed significant increase in MUC1 polarization when compared to 
control BSA group. This effect was not seen when cells were treated with Gal-3 C. 
Fisher exact test, ***= P-value <0.001 vs control (BSA) for the same cells.  
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3.6 Summary of results  
1. Expression of MUC1 by transfection in Human breast epithelial (HBL100), 
Melanoma (A375) and colon cancer (HCT116) cells is associated with 
resistance of the cells to anoikis. 
2. Both the MUC1 intracellular and extracellular domains are shown to 
contribute to MUC1 mediated cell resistance to anoikis 
3. MUC1 transfected cells showed alteration of several apoptosis-related 
proteins in response to anoikis culture in comparison to control cells. 
4. Exogenous addition of either galectin-3 or 214D anti-MUC1 antibody 
induces MUC1 cell surface polarization and increases cell adhesion to 
endothelial cells.  
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3.7 Discussion  
 
This part of the study shows that expression of MUC1 by transfection in three 
different types of epithelial cancer cells is associated with increased resistance of the 
cells to anoikis. This further confirms our earlier work which identified a role of MUC1 
expression in anoikis (433). It was found in this study that both the MUC1 
extracellular and intracellular domains contribute to MUC1-mediated cell resistance 
to anoikis, to some degree, independently cell anoikis was reduced in intra- or extra-
cellular MUC1 domain depleted cells compared to MUC1 full cells but still 
significantly lower than the MUC1 neo cells.  
 
The role of MUC1 in tumour progression is well documented (23, 37, 450, 451). It has 
been shown that the MUC1 intracellular domain, with a potential 22 phosphorylation 
sites, has an ability to facilitate the phosphorylation of key downward signalling 
proteins, such as ERK,(452) AKT(453) and PI3K(81). A study published by Kumar et al 
(454) shows that MUC1 extracellular domains are found in nuclear speckles and 
associate with spliceosomes. It was found in this study, that depletion of the MUC1 
extracellular domain abolishes ~61% of the MUC1-mediated cell resistance to anoikis 
(Figure 3.6), suggesting a predominant role of the MUC1 extracellular domain in 
MUC1-mediated cell resistance to anoikis. It was also found that MUC1 transfection 
without the extracellular domain still causes anoikis inhibition of the cells, albeit 
much less efficiently. This indicates that the MUC1 cytoplasmic domain also makes 
significant contribution to the MUC1-mediated cell resistance to anoikis through 
different mechanisms.  
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The role of the MUC1 extracellular domain in MUC1-mediated anoikis became more 
evident when we assessed anoikis in fibroblasts stably transfected with different 
numbers of MUC1 VNTR. (Figure 3.7) A significant increase in anoikis resistance was 
noted between transfects with lower numbers of VNTR than with cells with 36 VNTR. 
It is found that the cells transfected with 8 and 15 MUC1 VNTR did not add any ability 
to the cells to resist anoikis (albeit even slightly higher anoikis) in comparison to 
MUC1 neo cells. However, transfection of the cells with higher (n=36) MUC1 VNTR 
showed significantly increased resistance to anoikis. It is noted the expression of 
MUC1 in the 8 and 15 VNTR transfected cells is much lower than the 36 VNTR 
transfected cells.  It is possible therefore that the lack of effect of the 8 and 15 VNTR 
transfected cells on anoikis as compared to 36 VNTR transfected cells is due to 
insufficient expression of MUC1 by these cells. It is also possible that 36 MUC1 VNTR 
reflects a threshold in fibroblast cells, of the MUC1 extracellular domain required for 
its effect on anoikis. It is also possible that fibroblast cells behave differently from 
epithelial cells where MUC1 is usually expressed. Further investigation in this area 
will be needed.  
 
Initiation of anoikis starts from the cell surface with various triggers followed by 
common downstream apoptosis signalling. Cell surface proteins such as integrins and 
cadherins detect cell-matrix and cell-cell contact respectively. Disruption in these 
contacts leads to integrin- and cadherin- mediated activation of apoptotic activators 
Bid and Bim.  Bid and Bim promote the assembly of oligomers within the outer 
mitochondrial membrane (OMM) Bim also interacts with Bcl-XL, neutralizing its pro 
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survival effect. Formation of oligomers in OMM leads to the release of cytochrome C 
from mitochondria. Cytochrome C binds to apoptotic protease activating factor 
(APAF1) leading to eventual cleavage of pro-caspase 9 into activated caspase 9.  
Activated caspase 9 then activates the caspase pathway leading to eventual cleavage 
of executioner caspase-3 and cellular proteolysis.  Fas receptor, also found on the cell 
surface, once activated by its ligand leads to formation of Fas-associated death 
domain and eventual cleavage of caspase 3 via extrinsic apoptotic pathway, as 
detailed previously. 
 
We had previously reported that expression of MUC1 leads to a reduced accessibility 
to underlying anoikis initiating molecules including FAS, integrins and cadherins 
(433). We have also shown that MUC1 expression reduces the activation of the 
extrinsic pathway following addition of recombinant FAS-ligand. The apoptosis array 
in this study paints a complex picture of expression of key apoptotic proteins in MUC1 
transfected cells. Following 24 hours in anoikis conditions, the ratio of pro-caspase-3 
to cleaved caspase 3 is increased in cells transfected with full length MUC1 compared 
to MUC1 neo transfected cells. Also, the level of survivin is increased in cells with 
transfected with full length MUC1 compared to their MUC1 neo counterparts.  
However, further work is needed to understand signalling transduction of MUC1-
mediated cell resistance to anoikis. This will enhance our understanding of anoikis 
and may also help development of new therapeutic agents for cancer treatment. 
 
Previous studies have shown that exogenous introduction of galectin-3 induces 
MUC1 cell surface polarization in epithelial cancer cells (25, 337, 455).  MUC1 
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polarisation induced by galectin-3 leads to MUC1 cell surface polarization and 
exposure of underlying cell surface adhesion molecules. This subsequently leads to 
an increase of tumour cell homotypic aggregation and heterotypic adhesion in 
tumour cell metastatic spread. 214D anti-MUC1 antibody was generated against 
VNTR region of MUC1 and has been reported to induce MUC1 polarization. It is found 
in this study that indeed introduction of the 214D anti-MUC1 antibody induces MUC1 
cell surface polarization of MUC1-full and MUC1ΔCT cells. This effect of 214D is 
found, like galectin-3, to also increase cancer cell adhesion to endothelial cells. This 
discovery further supports a role of MUC1 cell surface localization in cell-cell 
interaction in cancer progression.  
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4 Investigating the effect 
of MUC1 O-glycosylation 
on MUC1-mediated 
resistance to anoikis 
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4.1 Hypothesis  
The heavy O-glycosylation of MUC1 on its extracellular domain may contribute to 
MUC1-mediated cell resistance to anoikis. 
4.2 Aims 
To assess the influence of O-glycosylation of the MUC1 extracellular domain on 
MUC1-mediated resistance to anoikis 
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4.3 Introduction 
The presence of a variable number of tandem repeat regions (VNTR) is a defining 
feature of all mucins and the MUC1 external domain is no exception (33).  The 
number of these tandem repeats and their amino acid sequences varies, but they are 
generally rich in serine, threonine and proline amino acids which act as a building 
block for initiating O-linked glycosylation (456, 457).  The length and size of MUC1 
extracellular domain, determined by the number of VNTR and the amount of 0-
glycosylation on the VNTR region, ensures that MUC1 extracellular domain extends 
far outward from cell surface and is heavily glycosylated. The MUC1 0-glycosylation 
is critical for its function, as it confers specific molecular feature that modulates 
ligand-receptor interactions and cell-extracellular matrix (ECM) interactions (458, 
459). As the number and sequence of the tandem repeats is highly variable, mucins 
present a wide array of potential glycosylation patterns. 
The process by which mucin type O-linked glycosylation occurs is well characterized, 
though we know relatively little about its regulation (43-46). The initiating step 
involves the addition of N-acetylgalactosamine (GalNAc) to serine or threonine 
residues present in the mucin backbone to form the Tn-epitope, a step that is 
catalysed by a large family of polypeptide GalNAc-transferases (GalNAc-Ts).(43, 47) 
These structures can then be further extended to form Core 1, 2, 3, or 4 structures 
based on the identity of the carbohydrate and linkage (460). Core 1 structures are 
formed by addition of galactose (Gal) in a β1-3 linkage to GalNAc, which is catalyzed 
by a single enzyme, Core 1 Gal-transferase (C1GT) (48). Core 1 structures can then be 
extended for Core 2 structures by addition of N-acetylglucosamine (GlcNAc) in a β1-
6 linkage to the existing GalNAc of the Core 1 structure by Core 2 GlcNAc transferases 
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(C2GnTs) (49-51). As an alternative to Core 1, Core 3 structures can be generated 
through addition of GlcNAc in a β1-3 linkage to the Tn epitope (52).  Like Core 1 
structures, Core 3 structures may be extended or act as the scaffold for Core 4 
structure generation through addition of another GlcNAc in a β1-6 linkage (51). While 
other core structures do exist, Core 1, 2, 3, and 4 structures comprise the primary 
glycan structures observed in humans.  
Table 4.1 Structure of O-glycan cores 
O-Glycans Structure 
Core 
 Tn antigen GalNAcαSer/Thr 
 Sialyl-Tn antigen Siaα2-6GalNAcαSer/Thr 
 Core 1 or T antigen Galβ1-3GalNAcαSer/Thr 
 Core 2 GlcNAcβ1-6(Galβ1-3)GalNAcαSer/Thr 
 Core 3 GlcNAcβ1-3GalNAcαSer/Thr 
 Core 4 GlcNAcβ1-6(GlcNAcβ1-3)GalNAcαSer/Thr  
 Core 5 GalNAcα1-3GalNAcαSer/Thr 
 Core 6 GlcNAcβ1-6GalNAcαSer/Thr 
 Core 7 GalNAcα1-6GalNAcαSer/Thr 
 Core 8 Galα1-3GalNAcαSer/Thr 
 
Many tumours exhibit aberrant O-glycans. Alterations in the glycobiology of tumours 
occur principally through two mechanisms: neo-synthesis and incomplete synthesis 
(85). The expression of truncated Core 1 based structures, such as T, Tn, or sialyl-Tn 
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(STn), are observed in a majority of human carcinomas. These structures are typically 
absent in healthy tissues (86-88). In many instances, expression of these truncated 
structures is driven by alterations to the expression of enzymes involved in the 
glycosylation process. Recent studies have also found that the localization of GalNAc-
Ts is a critical factor in the generation of O-glycan structures (461, 462). Relocation 
of GalNAc-Ts from the Golgi to the endoplasmic reticulum (ER) results in changes to 
the compartmentalization of the initiation machinery and the normal O-glycosylation 
process. 
Phenotypically, altered expression of mucin-type glycoproteins bearing aberrant O-
glycans is associated with increased aggressiveness and metastatic behaviour in a 
variety of cancers (87, 92, 98). These effects result in part from changes to binding 
properties of secreted and cell surface proteins that modulate interactions between 
tumour cells and binding partners in the extracellular environment (e.g., selectins 
and integrins) (98) and from effects on other ligand-receptor interactions that alter 
signal transduction in affected cells. Re-expression of enzymes involved in the 
extension of the carbohydrate chain, such as Cosmc or Core 3 synthase, results in a 
decrease in these aggressive properties in pancreatic cancer cells by influencing 
these interactions. (99) 
Recent work done in our lab (433) and others (463) has revealed that overexpression 
of MUC1 on the cell surface protects the cell from anoikis. The effect was noted in 
breast epithelial cells, melanoma cells and colon cancer cells transfected with full 
length MUC1.  A substantial amount of evidence exists that MUC1 intracellular 
domain, with its 22 potential phosphorylation sites, are able to relay signals to key 
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anoikis resistance proteins, by increasing the activation of AKT (81, 453), PI3K (81) 
and ERK (452). Our recent work (433), part of which is presented in chapter 3, 
demonstrated that both the intracellular as well as extracellular domain of MUC1 
have a role in MUC1 mediated resistance to anoikis; with a bigger influence coming 
from the MUC1 extracellular domain. This has led us to hypothesize that 
overexpression of MUC1, as seen in the majority of metastasising epithelial cancers, 
leads to the formation of a MUC1 ‘protective shield’ around the cell which reduces 
the access/activation of anoikis-initiating molecules found on the cell surface. 
Indeed, our previous work, comparing the MUC1-transfected breast epithelial 
HBL100 cell with its control variant showed that over-expression of MUC1 on the cell 
surface leads to reduced access/activation of integrin β, CD44, E-cadherin and Fas-
receptor (433).  
The discovery of the impact of MUC1 extracellular domain on anoikis and the nature 
of MUC1 extracellular domain heavy O-glycosylation led us to speculate that the 
glycosylation and length (size) of the MUC1 extracellular domain may have an 
influence on MUC1-mediated cell resistance to anoikis.  
 
4.4 Methods 
Generation of core-1 galactosyl transferase knockdown MUC1 mutants and control 
variants  
ShRNA plasmid against C1GT (SHCLND-NM_020156-C1GALT1) or control vector were 
purchased from Sigma Aldrich (Gillingham, UK). 0.2 μg of the plasmid in antibiotics 
and serum-free media was premixed with to 0.6 or 0.8 μg of Metafectene 
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transfection reagent and added to approximately 60% confluent HCT116 MUC1 full 
(HCT116 MUC1-F3) or HCT116 MUC1-neo cells in 100 μl antibiotics-free and serum-
containing media in a 96-well plate for 6 hours at 370C with 5% CO2. The culture 
medium was replaced with serum-containing medium for 24 h before the cells were 
cultured in normal growth medium containing 1 μg/ml puromycin for 3 days at 37 °C. 
Surviving cells following the puromycin treatment were proliferated in serum-
containing media with 0.5 μg/ml puromycin. The cells were released, heavily diluted 
in media containing puromycin and plated in 96-well plates to ensure single cell 
clones.  At this point the cells were named based on the transfection they had and 
the well number from a 96 well plates where a single cell colony was confirmed, for 
example F3 sh-C1GT (B7) corresponds to single cell colony originating in well number 
B7 in a 96 well plate following ΔC1GT transfection of HCT116 MUC1 positive cells.  
Single-cell clones were then proliferated and analysed for C1GT knockdown. Selected 
C1GT colonies were initially analysed via slot blot based on a reduction of PNA 
binding and an increase in VVA binding. Selected colonies were then further analysed 
by immunoblotting and flow-cytometry. C1GT knockdown was confirmed based on 
reduced side of MUC1 extracellular domain (tested with antibody B27.27), reduced 
PNA binding and increased VVA binding compared to control vectors. Control 
colonies were selected based on similar PNA and VVA binding to non-transfected 
HCT116 MUC1 full cells. A schematic diagram of stable transfection knockdown and 
colony selection is illustrated in figure 4.1. 
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Figure 4.1: General plan for shRNA transfection and validation of C1GT 
knockdown in HCT116 MUC1 full and HCT116 MUC1 neo cells. 200 ng of plasmid 
was incubated with transfection reagent Metafectene in 1:4 ratios before being 
added to sub-confluent HCT116 MUC1 full cells for 6 hours. Following incubation, 
the cells were subjected to antibiotic selection using 0.5 μg/ml of puromycin in 
McCoy’s 5A complete medium. Surviving cells were highly diluted to clones 
originating from a single cell. Single clones were selected, proliferated and shRNA 
knockdown was validated using immunoblot and flow cytometry analyses Following 
transfection, successful C1GT knockdown colonies were initially identified via slot 
blot and were further validated via immunoblotting and flow cytometry. 
 
 
Assessment of cell anoikis  
The condition required to promote anoikis was created by culturing the cells in 
suspension as described previously. Cells undergoing apoptosis (anoikis) were 
assessed by both Caspase- Glo® 3/7 assay and using an Annexin-V/PI apoptosis 
detection kit followed by flow cytometry. 
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Analysis of the expression of cell surface adhesion molecules 
The cells in this analysis were released from culture flasks with NECDS and fixed 
immediately 2% paraformaldehyde for 15 min at room temperature. After washing 
with PBS, the cells were incubated with 5% goat serum in PBS for 30 min.  The cells 
were re-suspended to 5 × 105 cells/ml with 1% goat serum in PBS and incubated 
with antibodies (1 μg/ml) against, E-cadherin, CD44, integrinβ1, Fas-L or control IgG 
and lectins (1 μg/ml) against peanut agglutinin (PNA), Vicia Villosa Lectin (VVA) and 
Griffonia Simplicifolia Lectin II (GSL-II) for 1 h at room temperature. After three 
washes with PBS, FITC-conjugated secondary antibody (1 : 500 in 1% goat serum in 
PBS) was applied for 1 h. The cells were washed three times with PBS before flow 
cytometry analysis. 
 
Effect of exogenous Fas-L on caspase-8 activation under anoikis conditions 
HCT116 MUC1 full and null cells with validated C1GT knockdown and corresponding 
control were released with NECDS and were diluted to 2 × 105/ml in serum-free 
McCoy’s 5A. One hundred μl/well of these cells was transferred to a 96 well plates 
triple-coated with 10 mg/ml poly-HEMA with or without introduction of 100 ng/ml 
Fas-L for 0 and 2 h followed by assessments of the cellular caspase-8 activity using a 
Caspase- Glo® 8 Assay kit. 
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4.5 Results 
4.5.1 C1GT knockdown leads to reduced TF expression and increased Tn expression 
Suppression of C1GT knockdown using siRNA has previously been shown to lead to a 
reduction of TF and reciprocal increase of Tn, sialyl-Tn and core 3 glycans in human 
colon cancer cells (54). In this study we used a reduction in TF binding as an initial 
confirmation of successful C1GT knockdown. Further confirmation of C1GT 
knockdown was validated by monitoring the size of MUC1 molecular weight in SDS-
PAGE and expressions of Tn and core 3 structures by slot-blotting and flow 
cytometry.  
The control (empty vector) and C1GT shRNA vectors used in this study contains 
resistance to the antibiotic puromycin. Following C1GT shRNA transfection of the 
MUC1+ (HCT116 MUC1-F3) and MUC1 – (HCT116 MUC1-neo) transfected HCT116 
cells, single cell colonies were selected, proliferated and tested for the expressions 
of TF (via PNA), Tn (via VVA) and core 3 structures (GSL-II) via slot blot (figure 4.2).   A 
number of colonies (e.g. B7,D5,E7, C6 and F11) showed successful C1GT knockdown. 
Control transfected colonies (e.g. F2 and C2) showed a similar TF and Tn expression 
to non-transfected cells  
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Figure 4.2: Slot blot analysis for C1GT and control shRNA transfected HCT116 
MUC1 full cells.  4 selected colonies from control ShRNA transection and 13 
colonies from C1GT transfected cells, along with non-transfected HCT116 MUC1 full 
(F3) were tested for binding to PNA, VVA, and GSL-II. Actin was used as a measure 
of control of equal loading. C1GT knockdown colonies B7, D5, E7, C6 and F11 were 
selected on the basis of reduced expression of TF (detected by low PNA binding) 
and higher expression of TN (detected by VVA) and equally higher expression of 
core 3 structure (Detected by GSL-II) compared to F3 cells.  Based on these criteria 
two potential transfection control colonies (F2 and C8) were selected along with 5 
potential C1GT knockdown colonies (B7, D5, E7, C6 and F11) for further evaluation. 
These selected colonies were then analysed by immuno/lectin blotting with 
antibodies against MUC1 (B27.29 and CT2) or TF-binding peanut agglutinin. Figure 
4.3 shows that all the selected shRNA C1GT transfected cells showed on average ~ 
30% reduction in size of the MUC1 extracellular domain, compared to control 
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transfectants and non-transfected cells (as detected by B27.29 antibody against the 
MUC1 extracellular domain), suggesting reduction of MUC1 glycosylation following 
C1GT knockdown. Confirmation of successful C1GT knockdown was further validated 
by a reduction in PNA binding in these cells compared to both the control transfect 
and the non-transfected cells. When adjusted for actin, expression and movement of 
MUC1 intracellular domain in SDS-PAGE (as shown by anti-cytoplasmic tail MUC1 
antibody CT2) were not expected to be altered in response to the shRNA C1GT, as 
the MUC-1 O-Glycosylation occurs in the extracellular VNTR region. However, in 
some selected Δ C1GT colonies, when adjusted for actin, a reduction in CT2 
expression is noted in F3-C1GT (C6) and F3-C1GT (F11), indicating that the 
transfection process might have influenced overall MUC1 expression by these cells. 
Based on the data from these immunoblots, F3-sh-con (C8) and F3-sh-con (F2) were 
chosen as control colonies due to similar expression of MUC1 extracellular domain, 
PNA binding and MUC1 intracellular domain as non-transfected HCT116 MUC1 full 
cells. F3-sh-C1GT (B7) and F3-sh-C1GT (E7) were chosen as ideal C1GT knockdown 
colonies. 
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Figure 4.3: Immunoblot analysis for C1GT and control shRNA transfected HCT116 
MUC1 full cells. two transfected colonies from control F3 sh-con (C8) and F3 sh-Con 
(F2) and 5 transfected colonies from C1GT knockdown F3 sh-C1GT (B7) F3 sh-C1GT 
(D5), F3 sh-C1GT (E7), F3 sh-C1GT (C6) and F3 sh-C1GT (F11) were immunoblotted 
and probed for MUC1 extracellular domain expression (B27.29), MUC1 intracellular 
domain (via CT2) and Actin and lectin blotted for core 1 structure (PNA binding),.  
 
HCT116 MUC1-negative cells were also transfected with shRNA for stable C1GT 
knockdown and with control vector. (figure 4.4) Figure 4 A shows that when adjusted 
for actin, there is a reduction in PNA binding in C1GT transfects compared to control 
or non-transfected HCT116 MUC1-negative cells. When immunoblotted for PNA on 
a 10% polyacrylamide gel, multiple sites are identified in C1GT knockdown colonies 
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(highlighted by black arrows on figure 4.4B) where there is reduction in PNA binding 
compared to control and non-transfected cells.  
                                      
Figure 4.4: Immunoblot analysis for C1GT and control shRNA transfected HCT116 
MUC1 neo cells. HCT116 MUC1 neo cells were transfected with control shRNA and 
ShRNA for C1GT knockdown. The colonies were initially assessed for PNA binding 
on slot blot. When adjusted for actin the colonies transfected with C1GT 
knockdown showed a reduction in PNA binding compared to control and non-
transfected variant. A lectin blot for PNA binding in these cells was assessed using 
10% polyacrylamide gels. Although there are some non-specific bands there are 
multiple areas (highlighted by the arrow) which shows a reduction of TF expression 
compared to control variant. The percentage knockdown level was calculated by 
doing a densitometry analysis on the entire lane and normalizing it to actin. Based 
on these analysis Neo sh-Con 1 and Neo sh-Con 2 were selected as control 
transfectants along with Neo sh-C1GT 3 and Neo sh-C1GT 4 as C1GT knockdown 
colonies for further analysis. 
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Metastasising colon cancer cells, SW620, were also transfected with shRNA for stable 
C1GT knockdown and control shRNA vector (figure 4.5). Following immunoblotting 
with B27.29and CT2 and lectin blotting with PNA and VVA, colonies SW620 sh-con 
was selected as control colony and SW620 sh-C1GT was selected as being C1GT 
knockdown cells. 
                                                
Figure 4.5: Immunoblot analysis for Δ C1GT and control shRNA transfected SW620 
cells MUC1 expressing SW620 cells were transfected with either the control or 
ΔC1GT shRNA. Colonies were selected and immunoblotted for B27.29 and CT2 to 
detect MUC1 extracellular and intracellular domain respectively. PNA was used to 
detect Core 1 structure. Control transfected SW620 sh-con showed a similar level of 
PNA as non-transfected SW620 non-trans, whereas ΔC1GT transfected SW620 sh-
C1GT showed a marked reduction in PNA binding. 
 
Flow cytometry analysis for PNA and VVA binding in HCT116 MUC1 + C1GT 
knockdown and control variants shows that there is significant reduction in PNA 
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binding in both C1GT knockdown F3-sh-C1GT (B7) and F3-sh-C1GT (E7) cells compared 
to control F3-sh-con (C8) and F3-sh-con (F2) (p <0.001 following a one-way ANOVA with 
Dunnett’s test) (figure 4.6). Such a reduction was not noted between HCT116 MUC1 
neo C1GT knockdown (Neo sh-C1GT 3 and neo sh-C1GT 4) and control variants (Neo 
sh-Con 1 and Neo-sh Con 2) suggesting that C1GT knockdown in MUC1+ cells leads 
to reduction in core1 structure (figure 4.7). MUC1 expressing SW620 cells also 
showed a similar reduction in PNA binding in SW620 sh-C1GT when compared to the 
control transfected SW620 sh-Con (figure 4.8) 
Tn expression, as detected by VVA, was noted to be increased in C1GT knockdown 
transfectants compared to control transfectants in both HCT116 MUC1+ and SW620 
cells (p<0.001, one-way ANOVA with Dunnett’s test). This effect was not noted in 
HCT116 MUC1 neo transfected cells suggesting that C1GT knockdown in MUC1+ cells 
leads to a reduction in core 1 structure (TF) and a corresponding increase in Tn 
structure.  
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Figure 4.6: C1GT knockdown leads to a reduction in PNA binding and an increase in 
VVA binding in HCT116 MUC1 full cells. Control shRNA transfected cells F3 sh-Con 
(F2) and F3 sh-Con (C8) were assessed for PNA and VVA binding along with C1GT 
knockdown coloniesF3 sh-C1GT (B7) and F3 sh-C1GT (E7). F3 sh-C1GT (B7) and F3 sh-
C1GT (E7) showed a statistically significant reduction in PNA binding (p value <0.001) 
when compared with control variant F3 sh-Con (F2) and F3 sh-Con (C8). VVA binding 
on the other hand was significantly increased in C1GT knockdown cells compared to 
control suggesting that C1GT knockdown leads to a reduction in TF and a subsequent 
increase in Tn N=2, n=2, ANOVA with Dunnett’s test, ***= P<0.001 
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Figure 4.7: C1GT knockdown leads to no significant difference in PNA and VVA 
binding in HCT116 MUC1 neo cells. HCT116 MUC1 neo cells transfected with C1GT 
knockdown showed a slightly reduced PNA binding compared to control variants and 
this effect was statistically significant in Neo sh-C1GT4.when compared to control 
transfected Neo sh-Con 1 and Neo sh-Con 2 when mean fluorescence intensity was 
analysed. No difference was noted in VVA binding between C1GT knockdown cells 
and control. N=2, n=2, ANOVA with Dunnett’s test, *= P<0.05 
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Figure 4.8: C1GT knockdown in MUC1 expressing SW620 leads reduced PNA 
binding.  SW620 cells, which normally overexpress MUC1, were transfected with 
control and C1GT knockdown ShRNA and were assessed for PNA and VVA binding. 
C1GT knockdown cells SW620 sh-C1GT showed a significant reduction of for PNA 
binding. VVA expression for C1GT knockdown cells was higher compared to control 
SW620 sh-Con, N=2, n=2, ANOVA with Dunnett’s test, *=p<0.05 
 
4.5.2 Reduction in O-glycosylation by C1GT knockdown makes cells more 
susceptible to anoikis  
HCT116 MUC1 full cells transfected with/without C1GT shRNA were cultured in 
suspension in a poly-HEMA coated plate and were tested for anoikis using caspase 
3/7 Glo®assay. Readings were taken at 0 and 24 hours and percentage change in the 
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recorded luminescence level from 0 hour was analysed. HCT116 MUC1 neo cells and 
HCT116 MUC1 full cells were also tested and analysed as a means of internal control 
within the assay (figure 4.9).  
                        
Figure 4.9: C1GT knockdown leads to increased anoikis in HCT116 MUC1 full cells. 
HCT116 MUC1 full, HCT116 MUC1 neo, HCT116 MUC1 control transfected cells (F3 
sh-Con (F2) and F3 sh-Con (C8)) and HCT116 MUC1 full Δ C1GT cells ( F3 sh-C1GT (E7) 
and F3 sh-C1GT (B7)) were cultured in suspension condition. A caspase 3/7 glo assay 
was conducted at 0 hour and 24 hours. When percentage change in luminescence 
from 0 hour is analysed, HCT116 MUC1 neo cells show a roughly 3-fold increase in 
anoikis compared to HCT116 MUC 1 full cells (P<0.001 ANOVA with Dunnett’s test). 
Control transfected F3 sh-Con (F2) and F3 sh-Con (C8) cells show a similar level of 
luminescence as non-transfected HCT116 MUC1 full cells. C1GT knockdown cells F3 
sh-C1GT (E7) and F3 sh-C1GT (B7) show a roughly 2-fold increase in anoikis compared 
to control transfectant (F3 sh-Con (F2) and F3 sh-Con (C8)) and non-transfected 
HCT116 MUC1 full cells (***= p<0.001 ANOVA with Dunnett correction) (N=3, n=3) 
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HCT116 MUC1 full cells showed a marked reduction in anoikis compared to HCT116 
MUC1 neo cells as noted previously (chapter 3). HCT116 MUC1 full cells transfected 
with control shRNA showed a similar level of anoikis at 24 hours as non-transfected 
HCT116 MUC1 cells, suggesting that the transfection process does not have much 
effect on anoikis. HCT116 MUC1 full cells transfected with C1GT shRNA showed a 
marked increase in anoikis compared with both the control transfectant and non-
transfected HCT116 MUC1 full (P <0.001, ANOVA with Bonferroni correction) but still 
lower than that in HCT116 MUC1 neo cells (Fig 4.9). This reduction in anoikis in C1GT 
knockdown transfectant could be due to the anoikis prevention properties of MUC1 
intracellular region as noted previously (chapter 3, Figure 3.6). HCT116 MUC1 full Δ 
C1GT cells showed a similar level of anoikis as HCT 116 Δ TR (chapter 3, Fig 3.6 C), 
suggesting that O-glycosylation of the MUC1 extracellular domain is involved in 
MUC1-mediated resistance to anoikis.  
HCT116 MUC1 neo cells stably transfected with control shRNA or C1GT shRNA 
showed a different pattern of anoikis (figure 4.10). Although a slight increase in 
caspase 3/7 activity was noted in C1GT knockdown transfected cells compared to 
control variant following suspended culture, it was not statistically significant. This 
suggests that expression of MUC1 plays a significant role in resistance to anoikis and 
controlling the size and glycosylation properties of the MUC1 extracellular domain 
makes a significant difference in the ability to resist anoikis.  
MUC1+ SW620 cells transfected ShRNA for C1GT knockdown and control variant 
showed a similar pattern of anoikis following 24 hours suspension culture as that 
noted for HCT116 MUC1 full cells but to a lesser extent (figure 4.11) 
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Figure 4.10:  C1GT Knockdown in HCT116 MUC1 neo has no significant effect on 
resistance to anoikis. HCT116 MUC1 neo cells transfected with C1GT knockdown 
(Neo sh-C1GT 3 and Neo sh-CC1GT 4) had a slightly higher percentage change 
compared to control transfects (Neo sh-con 1 and Neo sh-con 2) but the difference 
was not statistically significant. Non-transfected HCT116 MUC1 full and HCT116 
MUC1 neo were compared to test the validity of the assay and as per previous results 
(Figure 4.9), showed statistically significant difference. (N= 3, n=3) ANOVA with 
Dunnett’s test, ***= P<0.001. 
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Figure 4.11: C1GT knockdown in MUC1 expressing SW620 cells leads to an increase 
in anoikis. MUC1 expressing SW620 cells were transfected with control shRNA 
(SW620 sh-con) showed a similar level anoikis at 24 hours as non-transfected SW620 
cells (SW620 non tran). CIGT knockdown SW620 cell (SW620 sh-C1GT) showed a 
statistically significant increase in anoikis at 24 hours when compared to control 
SW620 non tran.  N=3, n=3, ANOVA with Dunnett correction, *= P<0.05 
 
We also tested the level of anoikis in C1GT knockdown transfectant cell lines and 
control variant using the annexin V assay with PI.  Annexins are a family of calcium-
dependent phospholipid-binding proteins that preferentially bind 
phosphatidylserine (PS). Under physiological conditions, PS is predominantly located 
in the inner leaflet of the plasma membrane. Following initiation of apoptosis, PS 
loses its asymmetric distribution across the phospholipid bilayer and is translocated 
to the extracellular membrane leaflet, marking cells as targets of phagocytosis. Once 
on the outer surface of the membrane, PS can be detected by fluorescently labelled 
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Annexin V in a calcium-dependent manner. Propidium iodide (PI), a ready-to-use and 
red-fluorescence dye which binds to DNA. PI cannot cross the membrane of live cells, 
making it useful to differentiate necrotic, apoptotic and healthy cells. Combined 
together an annexin V/PI assay detects live cells at the bottom left (annexin V 
negative, PI negative), early apoptotic cells at the bottom right (Annexin-V-positive 
and PI-negative) and late apoptotic cells at the top right (Annexin-V-positive and PI-
positive). 
When comparing early and late apoptosis at 24 hour from 0 hour, there was 37.9% 
increase in HCT116 MUC1 neo cells compared to 8.6% increase noted in HCT116 
MUC1 full cells (figure 4.12). Our previous data using HBL100 MUC1 Full (HCA1.7+) 
and HBL100 MUC1 neo had shown a similar level of increase of early and late 
apoptosis in MUC1 neo cells compared to MUC1 positive cells (433). 
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Figure 4.12: Expression of MUC1 reduces anoikis in HCT116 cells. HCT116 cells 
transfected with MUC1 (HCT116 MUC1 full) and control variant (HCT116 MUC1 neo) 
were assessed for Annexin V binding at 0 and 24 hour following suspension in poly-
HEMA coated plates. At 24 hours MUC1 neo cells showed a higher level of early and 
late apoptosis than MUC1 full cells.  
 
When we compared HCT116 MUC1 full ΔC1GT cells and control variant using the 
annexing V assay, we found that control variant C8 had a slightly higher level of early 
and late apoptosis following 24 hours in suspension culture (42.1%) compared to 
non-transfected HCT116 MUC1 full cells (37.1%) (figure 4.13). The two selected 
HCT116 MUC1 Full cells with C1GT knockdown, F3 sh-C1GT (B7), showed a much 
higher level of early and late apoptosis following 24 hours under suspension 
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condition (53.9%) compared to the control variant F3 sh-con (C8) (42.1%). When we 
compared the percentage change in early and late apoptosis from 0 hour, we found 
that there was a 42.0% increase in early and late apoptosis for F3 sh-C1GT (B7), 
compared to a 25.3 % increase noted in control variant F3 sh-con (C8).  
We then compared selected HCT116 MUC1 neo Δ C1GT cells and its control variant 
(figure 4.14). Annexin V/PI analysis looking at early and late apoptosis between 
HCT116 MUC1 neo, Neo sh-con 1 and Neo sh-C1GT cells were very similar. Early and 
late apoptosis noted at 24hr following suspended culture were 62.3% for control 
transfected Neo sh-con 1, compared to 62.2 % for non-transfected HCT116 MUC1 
neo cells. When compared with C1GT transfected cells, early and late apoptosis at 24 
following suspended culture were 64.9% for neo sh-C1GT 3.  
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Figure 4.13: C1GT knockdown in HCT116 MUC1 full cells makes cells more 
susceptible to anoikis. HCT116 MUC1 full cells transfected with control shRNA (F3 
sh-con (C8)) and C1GT knockdown (F3 sh-C1GT (B7) were assessed for Annexin V 
binding at 0 and 24 hour following suspension in poly-HEMA coated plates. F3 sh-con 
(C8) had a similar level of late (32%) and early apoptosis (9.73%) at 24 hours as the 
non-transfected HCT116 MUC1 noted earlier. C1GT knockdown variant F3 sh-C1GT 
(B7) showed a higher level of early (noted in Q3) and late apoptosis (noted in Q2) 
compared to both the control F3 sh-con (C8) and non-transfected HCT116 MUC1 full 
noted earlier, However the level of anoikis noted at 24 hours in F3 sh-C1GT (B7) was 
still lower than that noted for HCT116 MUC1 neo cells (figure 4.12). 
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Figure 4.14: C1GT knockdown in HCT116 MUC1 neo cells has no significant effect 
on anoikis. HCT116 MUC1 neo cells transfected with control shRNA (Neo sh-con 1) 
and C1GT knockdown (Neo sh-C1GT 3) were assessed for Annexin V binding at 0 
and 24 hour following suspension in poly-HEMA coated plates. Like the effect noted 
in HCT116 MUC1 full cells, the early(Q3) and late apoptosis (Q4) levels were similar 
to no transfected HCT116 MUC1 neo cells (figure 4.12). Unlike the effect noted in 
HCT116 MUC1 full cells, however, the C1GT knockdown cells (Neo sh-C1GT 3) did 
not show much change in anoikis level compared to control transfectant or the 
non-transfected HCT116 MUC1 neo cells
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MUC1+ SW620 cells transfected ShRNA for C1GT knockdown and control variant 
showed a similar pattern of anoikis following 24 hours suspended culture as that of 
HCT116 MUC1 full cells but to a lesser extent (figure 4.15).  Like the effect for HCT116 
cells, the control transfectant SW620 sh-con cells showed a similar level of early and 
late apoptosis at 24 hours following suspension as the non-transfected SW620 cells 
(10.8% and 9.6%, respectively). This compares to an early and late apoptosis level of 
14.2% as noted in C1GT knockdown cells SW620 sh-C1GT, 12.7% of which was late 
apoptotic cells. The lower Annexin V level in SW620 transfectants compared to 
HCT116 MUC1 cells could be due to the fact that SW620 cells are more robust 
compared to HCT116 cells (as they have a higher tolerance to puromycin compared 
to HCT116 MUC1-F3 cells, 8 μg/ml compared to 0.5 μg/ml), have a different level of 
MUC1 expression and potentially different glycosylation state following C1GT 
knockdown.  
Collectively, these data show that the size of the MUC1 extracellular domain and its 
glycosylation state have a role in MUC1-mediated cell resistance to anoikis.  
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Figure 4.15: C1GT knockdown in MUC1 expressing SW620 cells leads to increase of anoikis. MUC1 expressing SW620 cells were transfected with control 
and C1GT Knockdown shRNA and were tested for annexin v with PI analysis at 0 and 24 hours along with non-transfected Sw620 cells. Control transfected 
SW620 cells SW620 sh-con, showed a similar level of early and late apoptosis as non transfected SW620 ells. C1GT transfected SW620, SW620 sh-C1GT 
however showed a higher level of apoptosis with particular increase noted in late apoptosis at 24 hours (Q2), 12.7 % compared to 6.5 % noted in control 
transfected  SW620  sh-con.
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4.5.3 C1GT Knockdown leads to increased caspase 8 activity following activation 
with Fas-L ligand (Fas-L)  
We had previously reported that HBL100 breast epithelial cells transfected with full 
length MUC1 show a reduced response of caspase 8 activation in response to Fas-L 
when compared to MUC1 neo transfectant (433). In this study, we found a similar 
pattern when we compared HCT116 MUC1 full with HCT116 MUC1 neo cells. (figure 
4.16). 
 
Figure 4.16: C1GT knockdown in HCT116 MUC1 full cells leads to an increase in fas-
L induced caspase 8 activation. HCT116 MUC1 full (HCT116 MUC1 F3) and HCT116 
MUC1 neo along with HCT116 MUC1 full cells transfected with either control or 
ΔC1GT shRNA were tested for caspase 8 activation following simulation with either 
the fas-L or control (PBS). HCT116 MUC1 neo cells showed an 80% increase in caspase 
8 activity following simulation by fas-L, whereas no statistically significant difference 
was noted in HCT116 MUC1 full and control shRNA transfected F3 sh-con (F2) and F3 
sh-con (C8). ΔC1GT transfected F3 sh-C1GT (E7) and F3 sh-C1GT (B7) showed a 60% 
and 65% increase, respectively, in caspase 8 activity following simulation with fas-L. 
N=3, n=3, ANOVA with Dunnett’s test, ***= P<0.001. 
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HCT116 MUC1 neo cells had on average 80% greater caspase 8 activity following 2-
hour simulation with Fas-L compared to control variants which were not simulated. 
In comparison, there was a slight reduction in caspase 8 activity in HCT116 MUC1 full 
cells simulated with Fas-L when compared to control. This suggests that expression 
of MUC1 expression is associated with reduced activity of Fas-L on induction of 
caspase-8 activation in anoikis. 
When we assessed HCT116 MUC1 full cells transfected with control shRNA, both F3-
sh-con (F2) and F3 sh-con (C8) (figure 4.16) showed a similar pattern of caspase 8 
activation as non-transfected HCT116 MUC1 full cells. Interestingly the C1GT 
knockdown variants, F3- sh-C1GT (E7) and F3 sh-C1GT (B7), both had a much higher 
caspase 8 activation when simulated with Fas-L compared to non-simulated control.  
A similar pattern of expression is also noted in SW620 cells (figure 4.17), with control 
transfectant SW620 sh-con showing a similar and non-significant caspase 8 activation 
when simulated with fas-L or control. SW620 Cells transfected with shRNA for C1GT 
knockdown however shows a marked increase in cell caspase 8 activity when treated 
with Fas-L compared to control.  
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Figure 4.17: C1GT knockdown in MUC1 expressing SW620 cells leads to an increase 
in Fas-L mediated caspase 8 activation. MUC1 expressing SW620 cells transfected 
with either control or Δ C1GT shRNA were tested for caspase 8 activation following 
simulation with either the Fas-L or control (PBS). A caspase 8-Glo® assay was 
performed at 0 hours and 2 hours following cells suspension culture. The percentage 
change in cellular caspase 8 activity compared to non-treated control was analysed. 
Non-transfected SW620 were also used as an internal control. Like the effect noted 
for HCT116 cells, no significant difference in caspase-8 activation was noted for non-
transfected or control transfected, SW620 sh-con cells when simulated with either 
the Fas-ligand or control. SW620 sh-C1GT however, showed a 56% increase in 
caspase 8 activity following simulation with Fas-ligand. 
 
Collectively these data suggest that MUC1 expression and its glycosylation state has 
an effect on anoikis initiated by Fas-L. 
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4.5.4 C1GT knockdown leads to increased accessibility to cell surface anoikis-
initiating molecules  
Our previous work has shown that expression of MUC1 reduces the accessibility of 
antibodies to key cell surface anoikis initiating molecules integrin beta 1, CD44, E-
cadherin and Fas (433). We therefore assessed whether reduction of MUC1 O- 
glycosylation affected antibody accessibility to these cell surface anoikis initiating 
molecules.  
Using HCT116 cells transfected with C1GT knockdown, F3 sh-C1GT (E7) and F3 sh-
C1GT (B7), and comparing them with control shRNA transfectant F3 sh-Con (F2) and 
F3 sh-Con (C8) we found that C1GT knockdown cells had an increased accessibility of 
antibodies to integrin beta 1 (p <0.001), E-cadherin (p <0.001) and also Fas-L cell 
surface binding (p<0.001) when compared with control variant. (figure 4.18, 4.19) 
Although there seemed a slight increase in accessibility of antibodies to CD44 in 
ΔC1GT cells, it was not statistically significant. SW620 cells transfected with C1GT 
knockdown, SW620 sh-C1GT and control transfectant SW620 sh-con also showed a 
similar pattern of cell surface anoikis-initiating molecule antibody accessibility as 
noted for HCT116 cells above. (figure 4.20, 4.21). SW620 sh-C1GT cells showed a 
marked increase of antibody accessibility to cell surface integrin beta (p <0.001), e-
cadherin (p<0.001) and Fas-L binding (p<0.001) when compared to control (SW620 
sh-con) non-significant rise in cell surface accessibility to CD44. 
Collectively, these results show that reduction of MUC1 glycosylation leads to an 
increase of the accessibility of antibodies against cell surface adhesion molecules. 
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Figure 4.18: C1GT knockdown in HCT116 MUC1 full cells leads to an increase of anti-integrin beta antibody accessibility. HCT116 MUC1 full 
cells transfected with either the control or Δ C1GT shRNA were tested for cell surface accessibility of antibodies to Integrin β1 and CD44. The 
cells were released with NECDS and were targeted with either anti integrin β1 or anti CD44 followed by appropriate fluorescently labelled 
secondary antibody before being analysed by flow-cytometry. Both ΔC1GT transfected F3 sh-C1GT (B7) and F3 sh-C1GT (E7) showed a statistically 
significant increase in integrin β1 antibody accessibility compared to control shRNA transfected F3 sh-con (F2) and F3 sh-con (C8). Anti-CD44 
antibody accessibility between these cells was found to be non-significant. The expression level of integrin β1 and CD44/antibody binding were 
also compared between transfectants and were found to be similar. N=2, n=2, ANOVA with Dunnett’s test, ***= P<0.001 
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Figure 4.19: C1GT knockdown in HCT116 MUC1 full cells leads to increased accessibility of antibodies to E-cadherin and Fas. HCT116 MUC1 
full cells transfected with either the control or Δ C1GT shRNA were tested for cell surface accessibility anti e-cadherin antibody and fas-L binding, 
using flow-cytometry analysis. Both Δ C1GT transfected F3 sh-C1GT (B7) and F3 sh-C1GT (E7) showed a statistically significant increase in anti-e-
cadherin and Fas-L accessibility when compared to control shRNA transfected F3 sh-con (F2) and F3 sh-con (C8). The expression level of e-
cadherin and fas were also compared between transfectants and were found to be similar. N=2, n=2, ANOVA with Dunnett’s test, ***= P<0.001 
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Figure 4.20: C1GT knockdown in MUC1 expressing SW620 cells leads to increased accessibility of anti-integrin beta antibody.  MUC1 expressing 
SW620 cells transfected with either the control or Δ C1GT shRNA were tested for cell surface binding of antibodies to Integrin β1and CD44 and 
analysed by flow-cytometry.  Δ C1GT transfected SW620 sh-C1GT showed a statistically significant increase in anti-integrin β1 accessibility 
compared to control shRNA transfected SW620 sh-con. Anti- CD44 accessibility between these cells was found to be non-significant. The 
expression level of integrin β1 and CD44 were also compared between transfectants and were found to be similar. N=2, n=2, ANOVA with 
Dunnett’s test, ***= P<0.001 
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Figure 4.21: C1GT knockdown in MUC1 expressing SW620 cells leads to increased accessibility of antibodies to E-cadherin antibody and Fas-
L. MUC1 expressing SW620 cells transfected with either the control or Δ C1GT shRNA were tested for cell surface binding of antibodies to E-
cadherin and Fas-L and analysed using flow-cytometry.  ΔC1GT transfected SW620 sh-C1GT showed a statistically significant increase both E-
cadherin and Fas-ligand accessibility compared to control shRNA transfectedSW620 sh-con.  The expression level of E-cadherin and Fas were 
also compared between transfectants and were found to be similar. N=2, n=2, ANOVA with Dunnett’s test, ***= P<0.001 
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4.6 Summary of results 
1) C1GT knockdown in HCT116 MUC1 full cells and SW620 cells leads to a 
reduction in TF expression and an increase in Tn expression, an effect not seen 
in MUC1 neo cells of same cell type 
2) C1GT knockdown in MUC1 expressing cells leads to a significant increase in 
anoikis in response to suspended culture  
3) C1GT knockdown in MUC1-expressing cells leads to increased caspase 8 
activity in response to treatment with Fas-L. 
4)  C1GT knockdown in MUC1-expressing cells increased accessibility of 
antibodies to cell surface integrin β1, E-cadherin and Fas receptor but not to 
CD44 in both HCT116 MUC1 full cells and MUC1-expressing SW620 cells 
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4.7 Discussion  
The results from this study show that suppression of C1GT, the glycosyl transferase 
that controls the biosynthesis of the Core 1 structure of mucin type O-linked glycans, 
is accompanied by increased expression of sialyl-Tn (as detected by VVA) and core 3 
structure (as detected by GSL-II binding). This supports our previous work which 
showed that there is a competitive modification of the GalNAc residue of GalNAcα-
Ser/Thr between C1GT, C3GnT and ST6GalNAc-T in the biosynthesis of complex O-
linked mucin type glycans (54). It was found in this study, that reducing the size of 
MUC1 extracellular domain, by reducing its glycosylation through suppression of 
C1GT, leads to an increase in cell anoikis of both HCT116 and SW620 cells.  Flow 
cytometry analysis of cell surface proteins showed that suppression of C1GT leads to 
an increase of the accessibility of antibodies to cell surface integrin β, E-cadherin and 
Fas, but not CD44. It also increased Fas-L cell-surface binding and induction of 
caspase-8 in subsequent anoikis culture. This highlights the significance of the size of 
MUC1 extracellular domain in MUC1-mediated cell resistance to anoikis and is in 
keeping with the ‘protective shield’ effect of MUC1 over-expression, as we reported. 
Suppression of the C1GT was seen in this study to result in marked increase of cellular 
Tn expression, as detected by VVA (figure 6 and 8). This indicates that the ultimate 
formation of cellular TF, Tn, sialyl-Tn and Core 3 glycans are controlled not solely by 
the activity of the competitive glycosyltransferases. The concentrations of nucleotide 
sugar-donor and the rate of substrate transport throughout the Golgi have been 
shown previously to contribute to the expressions of specific glycans. The relative 
positioning of the glycosyltransferases within the Golgi is also reported to be an 
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important determinant. Work by Kellokompu and colleagues (94, 95) and by 
Campbell et al (96) has shown that Golgi derangement occurs in epithelial cancers 
and can be mimicked by agents that block normal Golgi acidification, in both cases 
leading to increased formation of oncofoetal carbohydrate antigens. Furthermore, 
the expression and action of ER-localized molecular chaperones can also play a role 
in the expression of the oncofoetal glycans by controlling the folding and hence the 
activity of the relevant glycosyltransferases (48). Thus, the overall cellular expression 
of Tn, sialy-Tn, TF and Core 3 structures are the consequence of a range of complex 
factors that include competition between the relevant glycosyltransferases, the 
spatial arrangement of the glycosyltransferases within the Golgi, the availability of 
nucleotide sugar-donors in the Golgi apparatus and actions of relevant molecular 
chaperones. 
O-linked glycosylation, one of the most abundant post-translational modifications 
observed within the cell, plays crucial roles in creating and modifying the structure 
and function of the molecules. MUC1 is overexpressed and abnormally glycosylated 
in many epithelial cancers. Stable knockdown of C1GlT is shown to lead to increased 
anoikis in response to suspended culture. We had previously proposed that due to 
its massive size, overexpression of MUC1 on the surface of epithelial cancer cells, 
provides a protective microenvironment that prevents  activation of anoikis-initiating 
molecules in response to loss of cell-matrix contact (433). The increased 
accessibility/activation of antibodies to cell surface molecules Integrin β, e-cadherin 
and Fas-L following C1GT knockdown indicates that the ‘protective environment’ of 
MUC1 is severely compromised after reduction of its O-glycosylation.  
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In a mouse model of breast cancer, C1GT knockdown has been shown to decrease 
the incidence of tumour development.(84) While, presumably, loss of C1GT should 
favour formation of truncated glycans and tumor progression, loss of Core 1 glycans 
may favour formation of Core 3 or 4 structures that correlate with less aggressive 
tumours (99, 464, 465). This model also disrupted MUC1 expression and impacted 
downstream effectors, including extracellular signal-regulated kinase (ERK), RAC-
alpha serine/threonine-protein kinase (AKT), and phosphoinositide 3-kinase (PI3K) 
activation (84). This may also account for the observed decrease in tumour incidence. 
Conversely, overexpression of C1GT in breast cancer cells increased association 
between MUC1 and β-catenin by promoting the shedding of the MUC1 extracellular 
domain, which was correlated with increased migratory and invasive behaviour 
(466). Overexpression of C1GT may also potentiate increased formation of TF 
structures, as well as potential extension to form sialyl-Lewis moieties associated 
with metastasis. Interestingly, overexpression of MUC1 in human breast cancer lines 
as well as murine lines results in decreased expression of the extension enzymes core 
2 β1,6-N-acetylglucosaminyl transferase 1 (C2GnT1) and ST3 β-galactosidase α-2,3-
sialyl transferase 1(ST3Gal1) suggesting that MUC1 can potentiate expression of 
truncated glycans in a feed forward manner (467). 
Expression of specific glycans can play a critical role in the metastatic spread of 
tumour cells by allowing lectin interactions. Expression of the carbohydrate 
structures sialyl-LewisX and sialyl-LewisA on MUC1 enable the binding of MUC1 to 
both E-selectin and intercellular adhesion molecule (ICAM)-1 (467). Likewise, 
glycosylated forms of MUC16 have been shown to bind both E- and L-selectin (468). 
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As interactions with selectins on endothelial cells and other cell types are critical for 
extravasation of immune cells from vasculature and subsequent trafficking through 
tissues, these interactions are proposed to similarly affect extravasation, invasion, 
and metastasis of tumour cells (105). 
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5 Investigation of the 
impact of MUC1 
expression and MUC1- 
galectin-3 interaction on 
EGFR activation in 
epithelial cancer cells 
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5.1 Hypothesis  
MUC1 expression and its interaction with galectin-3 influences EGFR activation of   
epithelial cells in response to EGF 
5.2 Aims 
1. To assess the influence of the MUC1 intra- and extra-cellular domains on EGF-
induced EGFR activation in epithelial cancer cells 
2. To access the impact of MUC-1- galectin-3 interaction on EGF-induced EGFR 
activation.  
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5.3 Introduction  
Amongst the hallmarks of metastasising epithelial tumour cells are the pathological 
changes in MUC1 (440). In tumour cells, MUC is overexpressed, heavily glycosylated 
and is without apical polarization. This leads to a MUC1 ‘protective barrier’ around 
the cell (433). Given the length of MUC1 (up to 200 nm in some cells) and heavy 
glycosylation; combined with overexpression and loss of apical polarization; the 
‘protective barrier’ leads to reduced ligand accessibility to underlying cell surface 
molecules (433). It has been hypothesised that this is perhaps the reason why tumour 
cells have a low immunological profile and are more resistant to pharmacological 
treatment aimed at cell surface receptors (469). 
 
MUC1 is known to interact with a variety of cellular proteins, through both its 
intracellular (470) and extracellular domain (79), and has been shown to influence 
cell signalling essential in cell proliferation (471), adhesion (62, 472) and 
immunomodulation (473). MUC1 has been shown to interact with ERBB2/Her/Neu, 
beta catenin (110), growth factor receptor-bound protein-2 (GRB2), son of sevenless 
homolog 1 (SOS) (75) and has been thought to have a significant effect on cell growth 
and proliferation through these interactions.  The glycosylation profile of MUC1 is 
particularly important as it influences lectin binding affinity on the MUC1 
extracellular domain and influences cell surface ligand accessibility to underlying 
molecules. 
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A key protein which has been reported to be associated with MUC1 is Epidermal 
growth factor receptor (EGFR) (339, 430, 474). EGFR is a member of the ErbB family 
of receptor tyrosine kinases that includes EGFR/ ErbB1 (Her1), ErbB2 (Her2/c-Neu), 
ErbB3 (Her3) and ErbB4 (Her4) (219). EGFR is involved in regulation of multiple 
cellular process including proliferation and survival and its activity is directly linked 
with tumorigenesis and metastasis (219). EGFR normally exists in an inactive 
conformation. Binding to its extracellular domain by ligands such as EGF induces 
EGFR conformation change and enables its interaction with another member of ErbB 
family proteins to form homo- or hetero-dimers (219). This leads to activation of 
EGFR tyrosine kinase domain and autophosphorylation of specific tyrosine residues 
at its cytoplasmic domain. These phosphorylated residues then serve as binding sites 
for proteins containing Src homology and phosphotyrosine binding domains, leading 
to activation of downstream signalling pathways such as the Ras/extracellular signal 
regulated kinase (ERK) pathway, the phosphatidylinositol 3-kinase (PI3) pathway, the 
Janus kinase/Signal transducer and activator of transcription (JAK/ STAT) pathway  
(219), crucial in cell proliferation, migration and survival. 
 
In physiological conditions, EGFR activation is tightly regulated by its expression and 
the availability of binding ligands to ensure that cell proliferation matches tissue 
requirements for homeostasis. In tumours however EGFR activation is often 
increased due to either increased EGFR expression, EGFR mutation or increased 
availability of the EGFR ligand produced by the same cells that express the ErbB 
receptors or by surrounding cells (413),(414). Aberrant expression of EGFR by 
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tumours typically also confers a more aggressive phenotype and is an indicator of 
poor prognosis in several types of epithelial cancer (475-477). Not surprisingly, EGFR 
is currently a principal target for therapeutic intervention in cancer. 
 
Galectin-3 is a β-galactoside-binding protein expressed by many types of human cells 
and particularly by epithelial and immune cells. Galectin-3 is distributed in the 
cytoplasm, nuclei, cell surface, extracellular space and in circulation. Overexpression 
of galectin-3 commonly occurs in most types of epithelial cancers such as colorectal, 
breast, lung, prostate, pancreatic, head and neck cancer and melanoma (306). The 
level of circulating galectin-3 is also markedly elevated (up to 30-fold) in cancer 
patients and particularly in those with metastasis (478). Overexpression of galectin-
3 by cancer cells is increasingly shown to influence cancer cell-cell and cancer-
microenvironment communication and contributes to cancer development, 
progression and metastasis as a result of galectin-3 interaction with an array of 
galactose-terminated glycans carried by glycoproteins and glycolipids on the cell 
surface as well as in the extracellular matrix (479).  
 
Recently studies from our group (79) as well as others (480, 481) have revealed that 
galectin-3 is a natural ligand of MUC1 in epithelial cancer cells. The interaction 
between galectin-3 and MUC1, via binding of galectin-3 to the oncofetal Thomsen-
Friedenreich (T or TF) carbohydrate antigen on MUC1 (79), induces MUC1 cell surface 
polarization and exposure of the underlying smaller cell surface molecules. This leads 
to increased cancer cell homotypic aggregation (25) and cancer cell heterotypic cell 
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adhesion to vascular endothelium (337), two important steps in the cancer 
metastasis cascade. As MUC1 is also associated with EGFR in epithelial cancer cells, 
the effect of galectin-3 on MUC1 cell surface localization led us to examine the impact 
of galectin-3-MUC1 on EGFR activity in epithelial cells.  
 
5.4 Methods 
Immunoblotting  
Cellular proteins (cell lysate or immunoprecipitates) separated by SDS-PAGE were 
electro-transferred to 0.2 μm nitrocellulose membrane. The membranes were first 
incubated with specific primary antibodies [anti-p-EGFR (SC-23420), EGFR (SC-03), 
anti- pERK (SC-7383) and ERK (SC-94) at a concentration of 1:500.  Antibodies against 
MUC1 (B27.29 and CT2) or actin at a concentration of 1:5000 were applied for 16 hr 
at 40C. The blots were washed 3 times with 0.05% Tween-20 in TBS before incubated 
with peroxidase-conjugated secondary antibody (1: 3000) for 1 hour. After 6 washes 
with 0.05% Tween-20 in TBS, the protein bands were developed using 
chemiluminescence Super Signal kit and visualized with Molecular Imager® Gel Doc™ 
XR System (Biorad). The density of the protein bands was quantified using Imagelab 
version 3.0.1.  
 
EGFR activation 
Sub-confluent cells were incubated in serum-free medium containing 0.5 mg/ml BSA 
overnight. The cells were washed with PBS before incubation with EGF (20ng/ml), 
EGF (20ng/ml) and galectin-3 (2 μg/ml), galectin-3 (2 μg/ml), galectin-3C (2μg/ml) or 
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BSA (2 μg/ml) (control) in the absence or presence of EGFR inhibitor lapatinib (2mM) 
for various time at 370C and 5% CO2. The cells were washed immediately with ice cold 
TBS before lysed with SDS- sample buffer and analysed by immunoblotting. 
 
5.5 Results 
5.5.1 MUC1 extra- and intra-cellular domains both contribute to EGFR activation 
Interaction between MUC1 and EGFR has been shown to influence EGFR activity in 
breast cancer (338), endometrial cancer (339), non-small cell lung cancer cells (482) 
by unknown mechanisms. In this study, we first assessed the influence of MUC1 
expression on EGFR activation in human breast epithelial and colon cancer cells and 
then tested the influence of MUC1 intra- and extra-cellular domains to the effect.  
 
Following simulation by EGF, EGFR activation was significantly increased in MUC1 
transfected HCT116 MUC1-full and HCA1.7+ cells when compared to MUC1 
negatively transfected controls HCT116 Muc1-neo and HCA1.7- cells. The HCT116 
MUC1 full cells and HCA1.7+ cell react differently when subjected to 20 ng/ml of EGF 
with the highest EGFR phosphorylation being noted at 10 minutes for HCA1.7+ cells 
and 60 minutes for HCA1.7 MUC1 full cells. The EGFR phosphorylation almost reaches 
baseline level after 120 minutes of 20 ng/ml EGF simulation (figure 5.1 and 5.2). 
Comparing EGFR phosphorylation with EGFR level in MUC1 positive and negative 
transfected cells at different timepoints following EGF stimulation, EGFR is noted to 
be rapidly phosphorylated in full length MUC1-expressing cells HCT116 MUC1 full 
and HCA1.7+ but almost no EGFR phosphorylation is detected in control MUC1-
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negative cells HCT116 MUC1 neo and HCA1.7- (Fig 5.1 and 5.2).  In comparison to 
MUC1- negative cells, a 26-fold and 19-fold increase of EGFR phosphorylation were 
observed at 10 min and 60 min, respectively, for HCT116 MUC1 full and HCT1.7+ cells 
(Fig 5.1B and 5.2B).  
 
Figure 5.1: Both MUC1 extra and intra cellular domains influence EGF induced EGFR 
activation in colon cancer epithelial cells. MUC1 transfectants of human colon 
cancer (HCT116 cells) cells were treated with 20 ng/ml EGF for various times before 
EGFR phosphorylation was analysed by immunoblotting. The blots were also probed 
with anti-EGFR antibody to detect EGFR level and anti-actin antibody for protein 
loading. Densitometry scanning of the bands from three independent experiments is 
shown in B as fold-changes (mean ± SD) of p-EGFR/EGFR ratio. The cells transfected 
with full-length MUC1 showed rapid EGFR phosphorylation while MUC1 negative 
cells showed little response. Depletion of MUC1 extracellular domain had a bigger 
effect on MUC1 mediated EGFR phosphorylation compared to MUC1 intracellular 
domain deletion. Representative blots are shown in A. (N=
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Figure 5.2: The extracellular domain of MUC1 has a significant influence on EGF 
induced EGFR activation in human breast epithelial cells. MUC1 transfectants of 
Breast epithelial cells (HBL100) were treated with 20 ng/ml EGF for various times 
before EGFR phosphorylation was analysed by immunoblotting. The blots were also 
probed with anti EGFR antibody to detect EGFR level and anti-actin antibody for 
protein loading. Densitometry scanning of the bands from three independent 
experiments is shown in B and is shown as fold-changes (mean ± SD) of p-
EGFR/EGFR ratio. Like the HCT16 cells, HBL100 cells transfected with full-length 
MUC1 showed rapid EGFR phosphorylation while MUC1 negative cells showed little 
response. Depletion of MUC1 intracellular domain had a moderate effect on EGFR 
phosphorylation, with levels at early time points multiple folds higher than the 
MUC1 negative variants; suggesting that following simulation by EGF, MUC1 
extracellular domain has a bigger role in MUC1 mediated EGFR activation than 
initially thought. Representative blots are shown in A. (N=2) 
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Depletion of the MUC1 extracellular domain almost completely inhibited EGFR 
activation in HCT116 MUC1 ΔTR (Fig 5.1A and 5.1B) with MUC1 ΔTR cells showing 
similar level of EGFR activation as HCT116 MUC1 neo cells. Depletion of the MUC1 
intracellular domain resulted in less but still substantial EGFR phosphorylation in HTD 
and HCT116 MUC1 ΔCT. To get an indication of the level of contribution from 
different domains of MUC1, at 10-minute time points following the addition of 20 
ng/ml EGF, EGFR activation was recorded to be 12-, 7-, 2.8- and 1.64-fold higher in 
HCT116 MUC1 full, HCT116 MUC1 ΔCT, HCT116 MUC1 ΔTR and HCT116 MUC1 neo 
cells, respectively, compared to 0-time point. Although we did not have a MUC1 ΔTR 
variant for HBL100 transfected cells, we did notice similar intermediate level of EGFR 
activation for MUC1ΔCT variant when compared to MUC1 full and MUC1 neo variant 
as noted for HCT116 MUC1 transfected cells. At 10-minute time point following the 
addition of 20 ng/ml EGF, there was a 34.7-, 14.4- and 1.34- folds increase in EGFR 
activation in HCA1.7+, HTD and HCA1.7-  cells respectively when compared to 0-time 
point (figure 5.2).  
 
Collectively, these results suggest that expression of MUC1 is critical to EGF-induced 
EGFR activation and both the MUC1 intra- and extra-cellular domains contribute to 
the MUC1-associated increase of EGFR activity with predominant influence coming 
from the MUC1 extracellular domain. We had previously shown that galectin-3 is able 
to polarise MUC1 on the cell surface in both MUC1 full and MUC1 ΔCT variant cells 
(chapter 3). It has been proposed by ourselves (25) and by others (483) that 
polarization of MUC1 on the cell surface leads to exposure of underlying cell surface 
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molecules. Since MUC1 expression affects EGF-induced EGFR activation, we were 
interested in what effect, if any, galectin-3 mediated MUC1 polarization has on EGFR 
activation in our MUC1 transfected cells.  
 
We initially began by testing the effect of EGF on mutant MUC1 transfected cells. 
Once again, our results showed that the expression of MUC1 is associated with 
increased activation of EGFR compared to MUC1 neo transfected variant (figure 5.3 
compared to 5.4, 5.6. compared to 5.7) and this effect is lower in MUC1 ΔCT cells 
(figure 5.3 compared to 5.5). There is evidence in literature which shows galectin-3 
interacting with EGFR (474, 484, 485). There have also been speculations that 
perhaps galectin-3 may act as a ligand for EGFR, leading to its activation. We also 
tested this theory across our MUC1 transfects.  Addition of 2 μg/ml galectin-3 alone 
had no effect on EGFR activation on any of MUC1 full transfected HCT116MUC1 full 
and HCA 1.7+ cells. The same was also noted for HCT116MUC1 neo, HCA1.7- and HDT 
cells, suggesting that galectin-3 on its own is not able to activate EGFR. 
 
When galectin-3 was added in conjunction with EGF, galectin-3 presence caused  
substantially further (53 fold at 5 min) increase of EGFR activation to the MUC1-
positive HCA1.7+ cells (Figure 5.3B) but had no effect to the MUC1-negative HCA1.7- 
cells (Figure 5.5 B).  Similar results were observed with colon cancer HCT116 cells. 
When 20ng/ml EGF and 2 μg/ml galectin-3 were both introduced, a 30-fold further 
increase of EGFR activation was observed in the MUC1-positive HCT116 MUC1 full 
than that treated with EGF alone (Figure 5.6 A and B). MUC1 ΔCT transfected HTD 
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cells also showed similar effect. In comparison to HTD cells treated with EGF alone, 
the presence of galectin-3 along with EGF showed to cause 30-fold more increase of 
EGFR activation in response to EGF in the MUC1-cytoplamic domain depleted HTD 
cells (Figure 5.5 A and B). 
 
Comparing the activation of EGFR receptor in MUC1 full and ΔCT cells following 
simulation by either EGF alone or EGF in conjunction with galectin-3, galectin-3 
addition with EGF seems to not only enhance but also prolong EGFR activation. The 
EGFR phosphorylation was mostly higher at later time points, in cells treated with 
both EGF and galectin-3, compared to cells treated with EGF alone.  For example, the 
EGFR phosphorylation in HCA1.7+ cells treated with both galectin-3 and EGF at 90 
minute is 13.1 fold higher than 0 hour, which is higher than the 10.4 fold change 
noted for the same cells when treated with EGF alone at 60 minutes (figure 5.3 B). 
Similarly, for HTD cells EGFR phosphorylation for cells treated with both galectin-3 
and EGF at 90 minute is 14.7 fold higher than 0 hour, which compares to 15.3 % fold 
change noted for the same cells when treated with EGF alone at 10 minutes (figure 
5.5 B).  
 
Collectively these data show that galectin-3 on its own is not able to activate EGFR 
activation but enhances and prolongs EGFR activation induced by EGF.  
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Figure 5.3: Galectin-3 MUC1 interaction enhances EGFR activation in MUC1 full 
transfected breast epithelial cells. MUC1 full transfected HBL100 cells (HCA1.7+) 
were simulated with either 20 ng/ml EGF, 2 μg/ml galectin-3 or a combined 20 ng/ml 
EGF and 2μg/ml galectin-3 for various time points before EGFR phosphorylation was 
analysed by immunoblotting. The blots were also probed with anti EGFR antibody 
and anti-actin antibody for protein loading. Densitometry scanning of the bands from 
three independent experiments is shown in B as fold-changes (mean ± SEM) of p-
EGFR/EGFR ratio. A combined simulation with both EGF and galectin-3 enhanced and 
prolonged EGFR activation compared to simulation by EGF alone. Galectin-3 alone 
had very minimal effect on EGFR activation, suggesting that galectin-3 in presence of 
EGF promoted MUC1 mediated EGFR activation but not galectin-3 on its own. (N=3). 
Two-way ANOVA with Sidak post-hoc test (*P<0.05, ***P<0.001 and ****P<0.0001 
vs untreated control at the same time point). 
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Figure 5.4: MUC1 negatively transfected breast epithelial cells have very minimal 
EGFR activation. Compared to HBL100 MUC1 positive cell (figure 5.3) HBL100 
MUC1 neo cells showed minimal increase in EGFR activation following simulation 
with 20 ng/ml EGF. Addition of 2 μg/ml galectin-3 with EGF did not enhance EGF-
induced EGFR activation. Galectin 3 on its own had the least effect on EGFR 
activation. The fact that negatively transfected MUC1 cells had minimal effect on 
EGFR activation suggest that EGFR activation is boosted by the presence of MUC1 
and MUC1-galectin-3 interaction enhances and prolongs this effect.  Representative 
blots are shown in A and densitometry scanning of the bands from three 
independent experiments is shown in B, as fold-changes (mean ± SEM) of p-
EGFR/EGFR ratio. (N=3) 
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Figure 5.5: Galectin-3 interaction with MUC1 extracellular domain increases EGFR 
activation. HBL100 cells transfected with MUC1 ΔCT had a much higher EGFR 
activation, compared to MUC1 neo transfectant when simulated with 20 ng/ml of 
EGF. Simulation by both 2 μg/ml galectin-3 and 20 ng/ml EGF further enhanced this 
effect, with galectin-3 on its own having no effect, Representative blots are shown in 
A and densitometry scanning of the bands from three independent experiments is 
shown in B, as fold-changes (mean ± SEM) of p-EGFR/EGFR ratio.  (N=3). Two-way 
ANOVA with Sidak post-hoc test (*P<0.05, ***P<0.001 and ****P<0.0001 vs 
untreated control at the same time point).  
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Figure 5.6: Galectin-3 MUC1 interaction enhances EGFR activation in MUC1 full 
transfected colon cancer cells. MUC1 full transfected HCT116 cells (HCT116 MUC1 
full) were simulated with either 20 ng/ml EGF, 2 μg/ml galectin-3 or a combined 20 
ng/ml EGF and 2 μg/ml galectin-3 for various time points before EGFR 
phosphorylation was analysed by immunoblotting. The blots were also probed with 
anti-EGFR antibody and anti-actin antibody. Densitometry scanning of the bands 
from three independent experiments is shown in B as fold-changes (mean ± SEM) of 
p-EGFR/EGFR ratio. Like the effect noticed in HCA1.7+ cells (figure 5.4) a combined 
simulation with EGF and galectin-3 enhanced EGFR activation compared to 
simulation by EGF alone. Galectin-3 had very minimal effect on EGFR activation 
(N=3). Two-way ANOVA with Sidak post-hoc test (*P<0.05, ***P<0.001 and 
****P<0.0001 vs untreated control at the same time point). 
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Figure 5.7: MUC1 negatively transfected HT116 MUC1 neo cells showed much 
lower EGFR activation compared to MUC1 full version simulated with EGF. HCT116 
MUC1 neo cells showed small increase in EGFR activation following simulation with 
20 ng/ml EGF. Addition of 2 μg/ml galectin-3 with EGF did not enhance the EGFR 
activation. Galectin 3 on its own had no effect on EGFR activation.  Representative 
blots are shown in figure A and densitometry scanning of the bands from three 
independent experiments is shown in B, as fold-changes (mean ± SEM) of p-
EGFR/EGFR ratio. N=3 
 
 
 
5.5.2 MUC1 transfection has no effect on EGFR expression  
There is evidence in the literature to suggest that MUC1 expression influences EGFR 
expression (339) and a reciprocal effect was also reported in uterine adenocarcinoma 
and pancreatic cancer origins, where activated EGFR drive high level MUC1 
expression (430). Given the dramatic effect noted on EGFR activation across our 
MUC1 transfected cells, we also tested if MUC1 expression or MUC1 domain deletion 
influenced EGFR expression in our transfected cells.  
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Lysates from HCT116 MUC1 full, MUC1 neo, MUC1ΔCT and MUC1ΔTR cells and 
HCA1.7+, HCA1.7- and HDT cells were probed with anti-EGFR antibody to check for 
EGFR expression level (figure 5.8). The same lysates were probed for actin to ensure 
equal loading. When adjusted for actin, our result shows similar level of EGFR 
expression across the different transfects, suggesting that MUC1 transfection had 
little to no effect on EGFR expression on these cells.  
This, combined with the other data in this chapter, MUC1 expression increases EGF-
induced EGFR activation in epithelial cancer cells. 
 
 
 
 
Figure 5.8: MUC1 transfection does not influence EGFR expression. Lysates from 
HCT116 MUC1 transfectants and HBL 100 MUC1 transfectants were immunoblotted 
and probed with anti EGFR and anti actin antibody. EGFR expression were the same 
across the MUC1 transfectants of the same cell type, suggesting that MUC1 
transfection has minimal to no effect on EGFR expression. this suggests that 
difference in EGFR activation noted across different MUC1 transfectants is not due 
to altered EGFR activation in these cells. Representative image from 2 blots.  
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5.6 Summary of Results  
 
1. MUC1 expression increases EGF-induced EGFR activation in MUC1-positive 
human colon HCT116 MUC1 full and breast HCA1.7+ cells 
 
2. Both MUC1 intracellular and extracellular domains contribute to MUC1 
mediated EGFR activation. However, the greater influence is from the MUC1 
extracellular domain. 
 
3. The presence of galectin-3 with EGF increases and prolongs EGFR activation 
in HCT116 MUC1 full, HCA1.7+ and HTD cells but not in MUC1-negative cells. 
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5.7 Discussion 
 
This part of the study shows that EGFR activation in response to EGF binding in 
human breast and colon epithelial cells is substantially increased by expression of the 
transmembrane mucin protein MUC1. Both the MUC1 intracellular and extracellular 
domains are shown to contribute to the effect of MUC1 on EGFR activation but the 
predominate influence comes from the MUC1 extracellular domain. Addition of a 
combination of EGF and galectin-3 leads to a further increase in EGFR activation and 
this effect is seen in MUC1 ΔCT cells. 
 
MUC1 is a transmembrane mucin protein and is ubiquitously expressed on the 
surface of epithelial cells. Over-expression of MUC1 is a common feature of epithelial 
cancer cells (442). MUC1 is reported to be interacting with EGFR in epithelial cancer 
such as breast (338, 425), pancreatic (474), endometrial (339) and lung. Blocking 
MUC1-C dimerization or silencing MUC1-C expression has been shown previously to 
suppress EGFR activation-associated cell signalling and survival in non-small cell lung 
cancer cells (440). Interaction of MUC1 with EGFR in the nucleus of breast epithelial 
cancer cells was shown to promote accumulation of chromatin-bound EGFR and co-
localization of EGFR with phosphorylated RNA polymerase II (338). This study shows 
that MUC1 expression increases EGF-induced EGFR activation in human breast and 
colon cancer cells. Depletion of either the MUC1 intracellular or extracellular domain 
could only partly abolish MUC-associated effect on EGFR activation. This suggests 
that while both the MUC1 cytoplasmic and extracellular domains contribute to EGFR 
activation, the effect of MUC1 intra- and extra-cellular domain on EGFR activation 
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can be considered relatively independent. The fact that depletion of the MUC1 
extracellular domain resulted in bigger reduction of MUC1-associated EGFR 
activation than depletion of the MUC1 intracellular domain indicates that a 
predominate influence of MUC1 on EGFR may derive from its extracellular domain. 
MUC1 (486) and EGFR (487) have both been shown to be associated with lipid rafts 
on cell membrane. It is possible that the expression of MUC1 and its association with 
EGFR in the lipid raft on the cell surface may increase the proximity of inactive forms 
of EGFR in the lipid raft microdomains for them to be in a better position to form 
homo- and hetero-dimers in response to ligand banding. 
 
Galectin-3 is a chimera type galectin that binds to the Thomson-Friedenreich antigen 
(galactose beta 1,3 N acetyl galactosamine) on the MUC 1 extracellular domain. 
Earlier studies (25, 79) and studies presented in Chapter 3 have shown that galectin-
3 binding to MUC1 leads to MUC1 cell surface polarization. Polarization of MUC1 
exposes underling cell surface molecules. Galectin-3 addition only has an effect on 
EGFR activation in the presence of an EGFR ligand. The enhanced EGFR activation by 
galectin-3 only in MUC1 positive but not negative cells F suggests that this effect is 
likely linked to change of MUC1 cell surface localization in response to galectin-3 
binding. It is possible that galectin-3 mediated MUC1 polarization leads to a better 
accessibility of EGFR ligands (e.g EGF) to EGFR on cell surface leading to EGFR 
activation or perhaps MUC1 polarization on the cell surface enables EGFR receptors 
to come in close proximity to each other through MUC1-EGFR interaction, leading to 
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closer association and therefore a better chance to dimerize and phosphorylate 
following ligand binding.   
 
The effect of galectin-3 on EGFR signalling is rather controversial. It has been 
reported that galectin-3 expression enhances EGFR activation in mouse 
keratinocytes (485); in contrast, galectin-3 negatively regulates EGFR and ERK 
activation in a pancreatic cancer cell line, Capan-1 (474). Recent work done by Kuo 
et al (484) has shown that galectin-3 plays a positive role in EGFR activation in lung 
cancer cells., the effect of galectin-3 on the EGFR signalling pathway thus might be 
related to cell types. EGFR activity has been reported to be regulated by cell 
glycosylation (488). Galectin-3 has been shown to interact with EGFR through β-
galactoside-containing polysaccharide chains of EGFR (489). Kuo et al, has therefore 
proposed that the differential effects of galectin-3 on EGFR activation across 
different cell lines might be due to the different glycosylaytion status of EGFR in those 
cells. Our results here point towards a complex interaction between galectin-3, 
MUC1 and EGFR leading to enhanced EGFR activation in cell response to EGF.  
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6 Investigating the 
mechanism of the effect of 
MUC1-galectin3 
interaction on EGFR 
activation 
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6.1 Hypothesis  
 
MUC1-galectin-3 interaction-associated EGFR activation may be associated with 
change of MUC1 cell surface localization. 
6.2 Aim 
 
To determine the molecular mechanism and downstream signalling involved in the 
effect of MUC1-galectin3 interaction on EGFR activation.  
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6.3 Introduction  
 
Epidermal growth factor receptor (EGFR), also known as ERbB1, HER1 in humans, 
belongs to the ERbB family of receptor tyrosine kinases that contain 4 closely related 
members ERbB1-4. These transmembrane receptors couple the binding of 
extracellular growth factor ligands to intracellular signalling pathways that regulate 
various biological responses, including proliferation, differentiation, migration, 
adhesion and cell survival. At present, six EGFR ligands are known. These are 
Epidermal growth factor (EGF), Amphiregulin, Transforming growth factor alpha 
(TGF-alpha), Betacellulin, Heparin binding EGF-like growth factor (HB-EGF), and 
Epiregulin. 
EGF is a high affinity ligand and is the most studied ligand of EGFR. Binding of EGFR 
ligand to the extracellular domain of ERbB leads to receptor homo-or hetero-
dimerization. ErbB2 is a unique member of the ERBB family in that it does not bind 
any of the known ligands with high affinity. However, it is the preferred 
heterodimeric partner for other EGFRs (360, 490). The ligand induced receptor 
dimerization leads to autophosphorylation of tyrosine residues intracellularly, 
creating docking sites for various membrane-targeted proteins. Adapter proteins 
such as the SHC transforming protein 1 (Shc), Growth factor receptor-bound protein 
2 (GRB2), Cas-Br-M ecotropic retroviral transforming sequence (c-Cbl), Docking 
protein 2 (DOK2) and NCK adaptor protein (NCK1) along with enzymes such as 
Phospholipase C gamma 1 (PLC-gamma 1), v-Src sarcoma viral oncogene homolog (c-
Src) and PTK2 protein tyrosine kinase 2 (FAK1) are known to bind to EGFR 
phosphotyrosine residue. Following ligand mediated EGFR phosphorylation, these 
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adapter proteins lead to a signalling cascade which leads to cell proliferation and 
growth. 
Following the signal transduction by GBR2, GBR2 along with the adapter Shc, recruits 
the exchange factor SOS to form a complex consisting of Shc, GRB2 and SOS. 
Activated SOS activates small GTPase v-Ha-ras Harvey rat sarcoma viral oncogene 
homolog (H-Ras) by its conversion from the inactive GDP-bounding state to the active 
GTP-bounding state. The activated H-Ras stimulates v-Raf-1 murine leukemia viral 
oncogene homolog 1 (c-Raf-1) and Mitogen-activated protein kinase kinase 1 and 2 
(MEK1 and MEK2) which subsequently activates Mitogen-activated protein kinase 1 
and 3 (ERK1/2) kinase cascade. ERK activates a number of transcriptional regulators 
to induce cell growth and proliferation such as transcription factors ELK1, v-Myc 
myelocytomatosis viral oncogene homolog (c-Myc) and v-Fos FBJ murine 
osteosarcoma viral oncogene homolog (c-Fos). GRB2 also recruits PI3Ks, which 
convert Phosphatidylinositol-4,5-bisphosphate (PIP2) to Phosphatidylinositol-3,4,5-
trisphosphate (PIP3). PIP3 binds to AKT and recruits it to plasma membrane where 
activated AKT, through phosphorylation via PDK1, regulates the activity of various 
proteins that mediate cell survival.  
As well as the signalling cascade described above, EGFR activation also leads to 
generation of Inositol trisphosphate (IP3) and 1,2-Diacylglycerol (DAG). IP3 induces 
the release of Ca2+ from the endoplasmic reticulum to activate calcium-regulated 
pathways. DAG activates protein kinase C pathway (PKC). One of the signalling 
modules regulated by PKC in EGFR pathway is the NFkB signalling, NFκB is widely 
used by eukaryotic cells as a regulator of genes that control cell proliferation and cell 
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survival. EGFR also translocates from the plasma membrane to other cellular 
compartments including nucleus where it directly regulates the expression of several 
genes in cooperation with other transcriptional regulators such as STATs, PCNA and 
E2F family of proteins.  
As a growth, differentiation and cell survival factor; mutations and overexpression of 
EGFR and/or the defective regulation of its signal transduction pathways is associated 
with oncogenesis.   Aberrant expression of EGFR by tumors typically also confers a 
more aggressive phenotype and has been shown to be an indicator of poor prognosis 
in several types of epithelial cancer. Breast carcinoma, non-small cell lung carcinoma 
and colon carcinomas have all been shown to have high EGFR expression coupled 
with a higher expression of EGFR ligands (219). In glioblastoma multiforme tumors, 
EGFR is often mutated in the intracellular domain rendering the tyrosine kinase 
constitutively active (491). In addition, EGFR expression and mutation in tumor cells 
is often accompanied by production of transforming growth factor alpha (TGF-alpha) 
or other EGF family ligands (492). Thus, EGFR and its signalling components are 
promising targets for effective therapy for various cancers. 
MUC1 is known to interact with various cellular proteins, through both its 
intracellular and extracellular domains, and influences diverse signalling pathways 
that are important in cell proliferation, adhesion and immunodeficiency. EGFR is one 
of the proteins which has recently been reported to interact with MUC1. A potential 
link between MUC1 expression and EGFR activation was shown in the last chapter, 
which showed that MUC1 expression and presence of its extracellular domain, 
promotes EGF-induced EGFR activation. Presence of galectin-3, a natural ligand for 
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MUC1, along with EGF led to a significant increase and prolonged EGFR activation. 
The aim of this chapter is to investigate the molecular mechanism for the impact of 
MUC1-galectin-3 interaction on EGFR activation.   
 
6.4 Methods 
Cell surface protein crosslinking  
Sub-confluent cells were incubated in serum-free medium overnight. The cells were 
washed twice with Ca2+ and Mg2+ free PBS and then treated with serum free media 
containing BSA 2μg/ml (control), EGF (20 ng/ml) without or with galectin-3 (2 μg/ml) 
or galectin-3C (2 μg/ml) for 10 minutes at 370C and 5% CO2. The cells were then 
washed with ice-cold Ca2+ and MG2+ free PBS and incubated with 3mM BS3 cross-
linker in Ca2+ and Mg2+ free PBS on ice for 20 minutes.  Excess BS3 was quenched with 
250 mM glycine in PBS for 5 minutes at 40C. The cells were washed three times with 
ice-cold PBS, lysed in SDS-sample buffer and analysed by immunoblotting with 
antibodies against EGFR.  
 
Confocal microscopy 
Sub-confluent cells grown on glass coverslips in 24-well plates were incubated in 
serum-free medium at 370C overnight. The cells were treated with BSA (2 μg/ml) 
(control), EGF (20 ng/ml) without or with galectin-3 (2 μg/ml) for 10 minutes at 370 
C. The cells were washed with ice cold PBS and fixed with 4% paraformaldehyde. The 
cells were washed with PBS and probed with anti-MUC1 B27.29 (1 μg /ml) or anti-
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EGFR (D38B1) (2 μg/ml) for 2 hours at room temperature. After two washes with PBS, 
FITC-conjugated anti-mouse or Alexa fluor 643 conjugated anti-rabbit antibodies was 
applied for 1 hour at room temperature. The cells were washed twice before 
mounted using DAPI-containing fluorescent mounting media (Vector Laboratories, 
Burlingame, CA). The slides were analysed with 3i confocal microscope (Marianas 
SDC, 3i Imaging) and Slidebook 6 Reader version 6.0.4 (Intelligent-imaging). 
 
Immunoprecipitation  
Sub-confluent cells were incubated in serum-free medium containing 0.5 mg/ml BSA 
overnight. The cells were incubated in TBS with EGF (20 ng/ml), EGF (20 ng/ml) and 
galectin-3 (2 μg/ml), galectin-3 (2 μg/ml) or 20 ng/ml BSA (control) in serum-free 
media for 10 min at 370 C. The cells were washed with ice-cold PBS, scraped and 
collected into 1 ml PBS containing 1% triton-100 and protease inhibitors 
(Calbiochem). The cells were lysed on ice for 30 min followed by centrifugation at 
10,000 g at 40C for 15 minute. The supernatants were collected and pre-cleared by 
adding 20 μl of the protein A/G beads and incubating at 40C for 30 minutes with 
gentle agitation. One ml lysate (protein concentration 2 mg/ml) were incubated with 
B27.29 (1 μg/ml), anti-EGFR (DB81) (2 μg/ml) or isotype-matched normal IgG at 40C 
with continuous agitation for 16 hours. 30 μl of protein A/G plus agarose beads were 
added for 4 hr and the beads were washed five times at 40C with ice-cold PBS. 
Proteins were eluted from the beads by boiling in SDS-sample buffer for 10 minutes 
before applied to SDS-PAGE and subsequent immunoblotting. 
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6.5 Results  
6.5.1 MUC1-galectin-3 interaction-induced EGFR activation increases downstream 
ERK1/2 signalling 
It is known that EGFR activation on the cell membrane triggers an array of 
intracellular signalling pathways (493-495). One of the common signalling pathways 
triggered by EGFR activation is ERK signalling (496-498). To test whether galectin-3-
MUC1 interaction induced EGFR activation effectively transduces EGFR signalling to 
downstream EGFR effectors, we assessed ERK activation in cell response to EGF and 
galectin-3 in the MUC1- positive and -negative cells.  
 
Introduction of EGF to the cells induced rapid ERK1/2 phosphorylation in MUC1-
positive HCA1.7+ (Figure 6.1A). This increase of ERK1/2 phosphorylation peaked at 
10 min at which point a 3.6-fold increase of ERK1/2 phosphorylation was observed in 
HCA1.7+ cells. Introduction of EGF also induced ERK1/2 phosphorylation of the MUC1 
negative HCA1.7- and HCT116 MUC1 neo cells but to a much lower level in 
comparison to the MUC1-positive cells (Figure 6.1 B), consistent with the effect of 
MUC1 expression on EGFR activity recorded in chapter 3. At 10 min, a 1.9-fold 
increase of ERK1/2 phosphorylation was observed in HCA1.7- cells. When galectin-3 
was introduced, EGF showed a stronger (1.9- fold further increase at 10 min) and also 
prolonged ERK1/2 phosphorylation in the MUC1-positive HCA1.7+ (Figure 6.1A), 
while ERK1/2 phosphorylation in the MUC1-negative HCA1.7- (Fig 6.1B) cells 
remained the same as the cells treated with EGF alone. Moreover, without the 
 
 
181 
 
 
presence of EGF, introduction of galectin-3 alone did not show any influence on 
ERK1/2 phosphorylation. 
 
Further work done in our lab showed a similar effect for MUC1 positive HCT116 
MUC1 full and MUC1 negative HCT116 MUC1 neo cell (499). In contrast to the 
enhanced ERK1/2 activation by the full-length galectin-3/EGF in the MUC1 positive 
cells, it was also noticed that introduction of C-terminally-truncated galectin-3 form 
(galectin-3C) with EGF showed no further effect on ERK-1/2 phosphorylation in 
comparison to the cells treated with EGF alone.  
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Figure 6.1: MUC1- as well as MUC1-galectin-3 interaction-associated EGFR 
activation increases ERK activation. MUC1-expressing HCA1.7+ (A) and MUC1-
negative HCA1.7- (B) cells were treated with either 20 ng/ml EGF, 20 ng/ml EGF and 
2 µg/ml galectin-3, 2 µg/ml galectin-3 or 2 µg/ml galectin-3C for various times as 
before the expression of p-ERK1/2 and ERK1/2 were analysed by immunoblotting. 
EGF treatment increases ERK1/2 phosphorylation in the MUC1- expressing HCA1.7+ 
and HCT116MUC1full cells. Introduction of galectin-3 further enhances ERK1/2 
activation in the MUC1-expressing cells but not in the MUC1- negative cells. 
Representative blots from three independent experiments are shown. 
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These results suggest that, as predicted, EGFR activation on the cell surface induced 
by MUC1 expression and by MUC1-galectin-3 interaction effectively transduces the 
signalling to downstream EGFR effectors. The stronger and prolonged ERK1/2 
activation in the MUC1-positive cells induced by galectin-3 is in keeping with the 
stronger and prolonged activation of EGFR in those cells in the presence of galectin-
3 (Fig 6.2, Fig 6.3 and Fig 6.4). Compared to the marked effect on EGFR activation of 
full length galectin-3, the lack of effect of galectin-3C, in which its N-terminal ligand 
multimerization domain is depleted hence unable to crosslink MUC1 for cluster 
formation, indicates that MUC1 polarization is essential in galectin-3-MUC1 
interaction-induced EGFR activation.  
 
6.5.2 Activation of EGFR and ERK by galectin-3-MUC1 interaction is inhibited by 
EGFR inhibitor lapatinib 
To determine whether the effect of galectin-3-MUC1 interaction on ERK activation 
was the consequence of EGFR activation, we tested the effect of Lapatinib, an EGFR 
phosphorylation inhibitor (500) on activation of EGFR and ERK in these cells.  As 
shown above, the presence of EGF induced EGFR phosphorylation and the 
introduction of galectin-3 further increased EGF-induced EGFR phosphorylation of 
HCT116 MUC1 full (Figure 6.2A) and HCA1.7+ cells (Figure 6.3A). The presence of 
Lapatinib prohibited EGFR phosphorylation in response to EGF of HCT116 MUC1 full 
and HCA1.7+ cells and also abolished the increased EGFR activation/phosphorylation 
in these cells induced by the presence of galectin-3. A similar effect was observed for 
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ERK1/2 phosphorylation, with Lapatinib preventing activation of ERK1/2 
phosphorylation of HCT116MUC1full (Figure 6.2A) and HCA1.7+ cells (Figure 6.3A). 
The presence of galectin-3C did not show any effect on phosphorylation of either 
EGFR (Figure 6.2A and 3A) or ERK1/2 (Figure 6.2B and 3B).  These results suggest that 
the increased phosphorylation of ERK1/2 induced by MUC1 expression and by MUC1-
galectin-3 interaction is the consequence of EGFR activation. It also further confirms 
that the effect of MUC1 and galectin-3-MUC1 interaction on EGFR activation 
effectively enhances downstream EGFR signalling. 
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Figure 6.2: EGFR inhibitor Lapatinib inhibits EGFR and ERK activation induced by 
MUC1-galectin-3 interaction. HCA1.7+ cells were treated with and without EGF in 
the absence or presence of galectin-3, truncated galectin-3 galectin-3C, EGFR 
inhibitor lapatinib for 10 min before analysed by immunoblotting with antibodies 
against p-EGFR, EGFR (A) or pERK1/2 and ERK1/2 (B). Densitometry analysis of the 
bands from two independent experiments was quantified and was presented as 
mean percentage changes (± SD) of pEGFR/EGF and p-ERK1/2/ERK1/2, respectively, 
in comparison to the controls. N=2, n=2 
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Figure 6.3: Lapatinib inhibits EGFR and ERK activation induced by MUC1-galectin-3 
interaction. HCT116 MUC1 full cells were treated with and without EGF in the 
absence or presence of galectin-3, truncated galectin-3 galectin-3C, EGFR inhibitor 
lapatinib for 10 min before analysed by immunoblotting with antibodies against p-
EGFR, EGFR (A) or pERK1/2 and ERK1/2 (B). Densitometry analysis of the bands from 
two independent experiments was quantified and was presented as mean 
percentage changes (±SD) of pEGFR/EGF and p-ERK1/2/ERK1/2, respectively, in 
comparison to the controls. N=2, n=2 
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6.5.3 Galectin-3-MUC1 interaction increases EGFR homo- and hetero-dimerization 
In EGFR activation, an immediate event following ligand binding is EGFR dimerization, 
which is followed by EGFR auto-phosphorylation and internalization (501-503). As 
galectin-3-MUC1 interaction occurs on the cell surface and as the MUC1 extracellular 
domain plays a role in EGF-induced EGFR activation, we speculated that the effect of 
galectin-3-MUC1 interaction on EGFR activation might be linked with an effect of 
galectin-3-MUC1 interaction on EGFR dimerization.  To test this, we treated the cells 
without or with EGF or galectin-3 and then crosslinked the cell surface proteins with 
non-cleavable crosslinker BS3 and then analysed cell EGFR by immunoblotting.   
 
It was found that treatment of the cells with EGF induced EGFR dimerization in the 
MUC1-positive HCT116MUC1full (figure 6.5A) and HCA1.7+ (figure 6.4A) cells. EGFR 
dimerization predominately occurred as homo-dimers in HCT116 MUC1 full but 
hetero-dimers in HCA1.7+ cells in response to EGF.  The presence of galectin-3 further 
increased EGFR dimerization in both cell types. Interestingly, galectin-3-induced 
EGFR dimerization occurred both as homo- and hetero-dimers in HCT116 MUC1 full 
cells but predominantly as homo-dimers in HCA1.7+ cells (figure 6.5A and figure 6.4A, 
respectively). Consistent with the lack of influence on activation of EGFR and ERK in 
the MUC1-negative cells (figure 6.2-6.4), EGF, alone or with galectin-3, showed little 
effect on EGFR dimerization in the HCT116 MUC1 neo (figure 6.5B) and HCA1.7- 
(figure 6.4B) cells.  Moreover, although the presence of full length galectin-3 
increased EGFR dimerization (figure 6.4A and 6.5A) and EGFR phosphorylation, the 
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presence of the truncated galectin-3C did not show any effect on EGFR dimerization 
and the levels of EGFR homo- and hetero-dimers remained the same as the EGF 
alone-treated HCT116 MUC1 full (figure 6.5A) and HCA1.7+ (figure 6.4A) cells. 
 
 
Figure 6.4: Galectin-3-MUC1 interaction promotes EGFR dimerization in human 
breast epithelial cells. HCA1.7+ (A) and HCA1.7- (B) cells were treated with and 
without EGF in the absence or presence of galectin-3 or galectin-3C for 10 minutes 
before EGFR dimerization were analysed using BS3 cross linker and immunoblotting.  
The presence of galectin-3, but not galectin-3C, increased EGFR homo- and hetero-
dimerization in the MUC1-expressing, but not MUC1-negative, cells. Representative 
blots from 2 independent experiments, N=2. 
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Figure 6.5: Galectin-3-MUC1 interaction promotes EGFR dimerization in human 
colon cancer cells.  HCT116 MUC1 full (A) and HCT116 MUC1 neo  (B) cells were 
treated with and without EGF in the absence or presence of galectin-3 or galectin-3C 
for 10 minutes before  EGFR dimerization were analysed using BS3 cross linker and 
immunoblotting.  The presence of galectin-3, but not galectin-3C, increased EGFR 
homo- and hetero-dimerization in the MUC1-expressing, but not MUC1-negative, 
cells. Representative blots from 2 independent experiments, N=2. 
 
 
These results suggest that EGFR activation by galectin-3-MUC1 interaction is 
associated with its promotion of EGFR dimerization. The lack of effect of the 
truncated galectin-3C on EGFR dimerization in comparison to the full-length galectin-
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3 provides further support to an essential role of galectin-3-induced ligand clustering 
in EGFR activation.     
 
6.5.4 Galectin-3 increases interaction of MUC1 with EGFR  
To gain further insight into the action of galectin-3-promoted EGFR activation, we 
determined the association of MUC1 with EGFR in response to galectin-3.  It was 
found that treatment of HCA1.7+ cells with galectin-3, regardless of the presence or 
absence of EGF, resulted in more EGFR to be co-immunoprecipitated with MUC1 
(figure 6.6A and B) in comparison to the control untreated or the EGF-alone treated 
cells. Treatment of the cells with EGF did not have any effect on MUC1-EGFR 
interaction. This suggests that galectin-3-MUC1 interaction promotes physical 
interaction of EGFR with MUC1 and this increased MUC1-EGFR interaction is a key 
component of galectin-3-associated EGFR activation.   
 
As galectin-3 has been previously reported to be able to interact directly with EGFR, 
we also assessed whether direct interaction of galectin-3 with EGFR is involved in this 
action. Minimal galectin-3 was found to be co-immunoprecipitated with EGFR in 
these cells (figure 6.7 F). In comparison to EGF alone treated cells (figure 6.7F, lane 
2), introduction of galectin-3 and EGF did not increase galectin-3 presence in EGFR 
immunoprecipitates (figure 6.7F, lane 3), thus supporting a role of galectin-3 EGFR 
interaction in this action of EGFR activation. 
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We initially immunoprecipitated galectin 3 and immunoblotted for EGFR and found 
that galectin-3 has little to no interaction with EGFR. Using the same 
immunoprecipitates and immunoblotting them for MUC1 however shows that 
addition of galectin-3 with EGF (Figure 6.7A, lane 2) leads to an increased interaction 
of MUC1 with EGFR. Immunoprecipitating EGFR and immunoblotting for MUC1 
shows an increased MUC1 EGFR association in presence of galectin-3 (figure 6.7 B 
lane 3 and 4).  However, in sample treated with EGF alone, EGFR 
immunoprecipitation shows an interaction with both MUC1 and galectin-3, albeit to 
a lower extent, but still higher than control group. (figure 6.7B and C, lane 2). This 
suggests that there is an underlying interaction between MUC1, galectin-3 and EGFR 
which is enhanced in the presence of EGF and which is further enhanced in the 
presence of both EGF and galectin-3.  
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Figure 6.6: Galectin-3 enhances MUC1 interaction with EGFR.  HCA1.7+ cells were 
treated with PBS (control), EGF with or without galectin-3 for 10 minute followed by 
MUC1 immunoprecipitation of the cells with B27.29 anti-MUC1 antibody. The 
immunoprecipitates were analysed by immunoblotting with anti-EGFR or B27.29 
anti-MUC1 antibody. Representative blots from 3 independent experiments, N=3. 
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Figure 6.7: Galectin-3 enhances MUC1 interaction with EGFR. (A) HCT116 MUC1 full 
cells were treated with PBS (control), EGF with or without galectin-3 for 10 minute 
followed by EGFR immunoprecipitation of the cells with anti-EGFR antibody. The 
immunoprecipitates were analysed by immunoblotting with anti-EGFR or B27.29 anti 
MUC1 or anti galectin-3 antibodies. The same cells were treated with EGF in the 
presence or absence of galectin-3 for 10 minutes followed by galectin-3 
immunoprecipitation of cell with anti galectin-3 antibody. The immunoprecipitates 
were analysed by immunoblotting with anti-EGFR or B27.29 anti MUC1 or anti 
galectin-3 antibodies. Representative blots from 3 independent experiments, N=3. 
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6.5.5 MUC1 polarization increases EGFR internalization  
 
Following EGFR dimerization and auto-phosphorylation in response to ligand binding, 
EGFR internalization is an essential next step in EGFR signalling. In both HCT116 
MUC1 full and HCA1.7 cells, EGFR appeared both on the cell surface and inside the 
cells (figure 6.9 A and B). Addition of EGF resulted in disappearance of EGFR from cell 
surface and accumulation inside the cells in both HCT116 MUC1 full cells (figure 6.9A) 
and HCA1.7+ (figure 6.9B) cells.  MUC1 localization was uniformly spread on the cell 
surface and was not affected by the absence or presence of EGF (431). 
 
Introduction of MUC1 polarization inducing agents galectin-3 and anti-MUC1 
antibody 214D which has shown previously to induce MUC1 polarization (chapter 
3), changes MUC1 cell surface localization (as illustrated by disruption of the 
uniform localization). Presence of galectin-3 and 214D with EGF also increased EGFR 
internalization (more disappearance of EGFR from the cell surface and stronger 
appearance in the cytoplasm) in comparison to the cells treated with EGF alone. 
Interestingly, internalized EGFR induced by galectin-3/EGF or 214D/EGF was seen to 
be in a more clustered appearance inside the cells than that induced by EGF alone. 
Introduction of galectin-3 without addition of EGF did not show any effect on EGFR 
localization compared to the control cells.  This, together with the lack of effect of 
full length galectin-3 and 214D on EGFR activation in MUC1-negative cells along 
with the lack of effect of truncated galectin-3C on EGFR activation in the MUC1-
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positive cells, indicate that MUC1 polarization mediated EGFR activation is 
associated with its effect on alteration of MUC1 cell surface localization.  
- 
Figure 6.8: Galectin-3-MUC1 interaction enhances EGFR internalization in human 
colon cancer cells.  HCT116 MUC1 full cells were treated with PBS (control), EGF 
with or without galectin-3 for 10 minutes before localization of MUC1 (green) and 
EGFR (red) were determined by fluorescent immunohistochemistry and analysed by 
confocal microscopy. The cell nucleus was stained with DAPI (blue). Galectin-3 
changes MUC1 cell surface localization (as illustrated by disruption of uniform 
MUC1 localization). More intense and clustered EGFR localization were seen inside 
the cell in cells treated with both galectin-3 and EGF than in the EGF alone treated 
cells.  Representative images of 20 random field observations from 3 experiments 
(100 x magnification). 
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Figure 6.9: Galectin-3-MUC1 interaction enhances EGFR internalization in human 
breast epithelial cells.  HCA1.7+cells were treated with PBS (control), EGF with or 
without galectin-3 for 10 minutes before localization of MUC1 (green) and EGFR 
(red) were determined by fluorescent immunohistochemistry and analysed by 
confocal microscopy. The cell nucleus was stained with DAPI (blue). Galectin-3 
changes MUC1 cell surface localization (as illustrated by disruption of uniform 
MUC1 localization). More intense and clustered EGFR localization were seen inside 
the cell in cells treated with both galectin-3 and EGF than in the EGF alone treated 
cells.  Representative images of 20 random field observations from 3 experiments 
(100 x magnification). 
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Figure 6.10: Effect of 214D anti-MUC1 antibody on MUC1 polarization and EGFR 
internalization.  HCT116 MUC1 cells were treated with PBS (control), EGF with or 
without MUC1 polarizing 214D for 10 minutes before localization of MUC1 (green) 
and EGFR (red) were determined by fluorescent immunohistochemistry and 
analysed by confocal microscopy. The cell nucleus was stained with DAPI (blue). 
214D changes MUC1 cell surface localization (as illustrated by disruption of uniform 
MUC1 localization). More intense and clustered EGFR localization was seen inside 
cells treated with both 214D and EGF than in the EGF alone treated cells.  
Representative images of 20 random field observations from 3 experiments (100 x 
magnification). 
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Figure 6.11:  Effect of 214d anti-MUC1 antibody on MUC1 polarization and EGFR 
internalization in human breast epithelial cells.  HCA1.7+ cells were treated with 
PBS (control), EGF with or without MUC1 polarizing 214D for 10 minutes before 
localization of MUC1 (green) and EGFR (red) were determined by fluorescent 
immunohistochemistry and analysed by confocal microscopy. The cell nucleus was 
stained with DAPI (blue). 214D changes MUC1 cell surface localization (as illustrated 
by disruption of uniform MUC1 localization). More intense and clustered EGFR 
localization were seen inside the cell in cells treated with both 214D and EGF than 
in the EGF alone treated cells. Representative images of 20 random field 
observations from 3 experiments (100 x magnification). 
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6.6 Summary of results  
 
1. MUC-1-galectin-3 interaction-induced EGFR activation is associated with 
activation of downstream ERK1/2  
 
2. EGFR inhibitor Lapatinib inhibits galectin-3 -MUC1-mediated effect on 
EGFR activation and Erk1/2 activation 
 
3. Galectin-3 promotes EGFR homo- and hetero-dimerization induced by EGF 
 
4. Galectin-3 enhances MUC1 cell surface polarization and interaction with 
EGFR  
 
5. 214D anti-MUC1 antibody showed a similar effect on MUC1 polarization 
and EGFR internalization 
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6.7 Discussion 
Binding of galectin-3 to cell surface MUC1 is shown in this study to markedly increase 
EGF-induced EGFR activation. Interaction between MUC1 and galectin-3, and 
between MUC1 and anti-MUC1 antibody 214D, are known to induce MUC1 cell 
surface polarization (25, 79, 337). The effect of galectin-3 or 214D on MUC1 cell 
surface localization was clearly shown in this study (Fig 6.8 and 6.9 for galectin-3, Fig 
6.10 and 6.11 for 241D). Change of MUC1 localization in galectin-3-treated cells was 
seen in the absence or presence of EGF (Fig 6.8 and 6.9) but only in those with the 
presence of EGF did it enhance EGFR activation with subsequent induction of down-
stream signalling (Fig 6.2 and 6.3). This indicates that galectin-3-induced change of 
MUC1 cell surface localization alone is not sufficient to induce EGFR activation, the 
presence of EGFR ligand is essential. MUC1 co-immunoprecipitation showed an 
increase of MUC1 association with EGFR in galectin-3-treated cells, with or without 
the presence of EGF (Fig 6.6), but only those with the presence of EGF enhanced EGFR 
activation. This, together with the discovery that the presence of galectin-3 alone did 
not induce EGFR dimerization, suggests that galectin-3-MUC1 interaction is essential 
in galectin-3-mediated EGFR activation. The importance of galectin-3-mediated 
change of MUC1 localization in EGFR activation is further supported by the discovery 
that, in contrast to the presence of full length galectin-3, the presence of a truncated 
form of galectin-3 (galectin-3C), which lacks the N-terminal domain responsible for 
galectin-3-induced ligand clustering thus could not induce MUC1 polarization (Fig 
3.11), did not show any effect on EGFR dimerization (Fig 6.4 and 6.5), activation of 
ERK signalling (Fig 6.2 and 6.3), in the presence of EGF in MUC1-positive cells.  
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There was an earlier study reporting binding of galectin-3 to EGFR in pancreatic 
cancer cells to induce ERK activation (474). In our study, galectin-3 did not show any 
effect on EGFR phosphorylation, EGFR dimerization, or ERK activation in the MUC1-
postive cells in the absence of EGF, nor showed any effect on activation of the 
molecules in the MUC1 negative cells even in the presence of EGF. This suggests that 
a direct binding of galectin-3 to EGFR, even if exists, does not contribute to galectin-
3-mediated EGFR activation in those cells. It is noted that a recent study has reported 
a role of galectin-3 in promoting sphere formation activity of lung cancer cells 
through activation of EGFR (484). Although that study did not identify the galectin-3 
binding ligand in producing the effect, their discovery of the requirement of galectin-
3 carbohydrate recognition domain in the effect is broadly in keeping with an effect 
of galectin-3-MUC1 interaction on EGFR activation shown in the present study.  
 
EGFR activation on the cell membrane is known to trigger activation of an array of 
intracellular signalling pathways (219), commonly including Ras/MEK/ERK signalling.  
EGFR activation induced by either MUC1 expression or by MUC1-galectin-3 
interaction is shown in this study to be accompanied by an increase of ERK activation. 
This indicates that the MUC1 expression and MUC1-galectin-3-mediated EGFR 
activation effectively passes the signalling to downstream EGFR effectors. It is noted 
that galectin-3-MUC1 interaction-mediated EGFR activation is also associated with a 
prolonged activation of ERK phosphorylation (Fig 6.1). It is generally believed that 
EGFR activation is terminated primarily through endocytosis of the receptor-ligand 
 
 
202 
 
 
complexes which are either degraded in the endosomes or recycled to the cell 
surface. It has been shown that if recycled EGFR is unable to reach the cell surface or 
to the lysosomal compartment but accumulates in the early endosomes, it will lead 
to prolonged signalling and increased activation of ERK (504).  This notion seems 
supported by our study. We found that following EGFR activation, more EGFR was 
seen to be located in a clustered patter inside the cells in the galectin-3/EGF treated 
cells than in EGF alone treated cells (Fig 6.8 and 6.9). There was a much weaker EGFR 
cell surface localization in the galectin-3/EGFR treated cells than in the other groups 
including EGF-alone treated cells. This indicates that the galectin-3/MUC1/EGF-
mediated EGFR activation and subsequent EGFR endocytosis is associated with 
slower recycling of EGFR to the cell surface. This may provide an explanation to the 
prolonged activation of ERK in those cells (Fig 6.1). This conclusion is in keeping with 
an earlier study showing that MUC1 expression inhibits EGFR degradation in 
response to ligand binding but was accompanied by an increase of EGFR 
internalization in breast epithelial cells (505).   
 
As a key therapeutic target for cancer treatment, development of anti-EGFR 
strategies is a crucial area of clinical study for the treatment of solid tumours. 
Currently, main strategies include monoclonal antibodies directed towards the 
extracellular domain of EGFR, small molecule tyrosine kinase inhibitors targeting the 
catalytic kinase domain of EGFR and strategies to disrupt receptor trafficking to the 
cell surface. The discovery that the expression of MUC1 and its interaction with 
galectin-3 promotes ligand-dependent EGFR activation has implications in EGFR-
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targeted therapies in cancer treatment. MUC1 and galectin-3 are both well known to 
be commonly over-expressed by solid tumours. Overexpression of MUC1 and 
galectin-3 and their effects on EGFR activation may therefore not only have an 
influence on EGFR-mediated tumourigenesis and cancer progression, but may also 
have an impact on the effectiveness of EGFR-targeted therapy. It is conceivable that 
a closer localization of EGFR with MUC1 on the cell surface induced by galectin-3 may 
limit the access of anti-EGFR antibodies to cell surface EGFR due to the massive size 
of MUC1 that easily protrudes over EGFR on the cell surface. An enhanced EGFR 
dimerization induced by galectin-3-MUC1 may also limit the treatment effectiveness 
of anti-EGFR antibody as well as kinase inhibitors due to a slower recycling of EGFR 
to the cell surface. It is possible therefore that in cancer patients who have higher 
tumour expression of galectin-3 and/or MUC1, a combined treatment that targets 
EGFR as well as galectin-3 and/or MUC1 may improve treatment effectiveness.   
 
Thus, MUC1 expression and its interaction with galectin-3 make important 
contributions to EGFR activation in epithelial cells by promoting EGFR dimerizaton. 
As over-expression of MUC1 and over-expression of galectin-3 are both common in 
epithelial cancer, the influence of MUC1 and MUC1-galectin-3 interaction on EGFR 
activation likely contributes to EGFR-associated tumorigenesis and tumour 
progression and to the effectiveness of EGFR-targeted therapy. A combined therapy 
that targets EGFR as well as galectin-3 and/or MUC1 may improve effectiveness of 
EGFR-targeted cancer treatment.  
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7 General Discussion and 
future research 
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7.1 Key findings 
• MUC1 expression confers epithelial cell resistance to anoikis in response to 
loss of cell adhesion. 
• Inhibition of O-glycosylation by stable suppression of C1GT expression 
significantly increased anoikis of MUC1-positive, but not MUC1-negative 
cells. 
• EGF-induced EGFR activation is substantially increased by expression of the 
transmembrane mucin protein MUC1 in human breast and colon epithelial 
cells.  
• Binding of galectin-3 to cell surface MUC1 increases EGFR activation and this 
effect requires not only the galectin-3 C-terminal CRD domain but also its N-
terminal ligand polarization domain.  
• MUC1-galectin-3 mediated EGFR activation is translated downstream into 
ERK 1/2 activation 
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7.2 Discussion 
It was found in this study that MUC1 expression in epithelial cells leads to a significant 
decrease in anoikis compared to MUC1 null cells in melanoma, breast epithelial and 
colon cancer cells.  Both the intracellular and extracellular domains of MUC1 were 
found to contribute to this effect. My work shows that this effect is largely attributed 
to the elongated and heavily glycosylated extracellular domain of MUC1. The 
extracellular domain of MUC1 protrudes high above the cell membrane and hence 
prevents activation of the cell surface anoikis-initiating molecules such as integrins, 
cadherins and death receptors by providing them a mechanically 'homing' 
microenvironment. 
Both intrinsic and extrinsic apoptotic pathways are known to have an important role 
in anoikis and many of the intrinsic apoptotic signalling proteins (for example, Bcl and 
p53 family members) are involved in regulation of anoikis process (124). Several 
earlier studies have reported a role of the MUC1 cytoplasmic domain in regulation of 
apoptosis in cells growing under adhesion (anchored) conditions through interaction 
with a number of intracellular signalling proteins (30). For example, MUC1 
cytoplasmic tail has been reported to interact with mitochondrial membrane, p53 
and β-catenin and prevent mitochondrion-mediated apoptosis in cell response to 
DNA damage (108). Additionally, interaction of the MUC1 cytoplasmic tail with FADD 
have been reported to blocks caspase-8 recruitment to the death-inducing signalling 
complex in response to TNFα-induced apoptosis (508). Evidence of MUC1 expression 
having a potential role in anoikis is seen in the array results presented in chapter 3 
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where expression levels of P53, pro-capsase-3 and Fas/TNFSF6 were noted to be 
several folds higher in MUC1 expressing HCA1.7+ cells compared to MUC1 negative 
HCA1.7- cells. The ability to interact with key intracellular anoikis proteins is 
potentially one of the mechanisms MUC1 expression leads to anoikis resistance.  
Data presented in chapter 3 also highlights MUC1 extracellular domain has an 
inhibitory effect on anoikis. The extracellular domain of MUC1 is large and heavily 
glycosylated and its sheer size is able to dwarf many cell surface proteins. Normally 
the expression of MUC1 is controlled and is limited to a cells apical surface only.  
However, in cancer state this apical polarization is lost and MUC1 expression is 
substantially increased (up to 10 fold). Our earlier work has shown that this 
overexpression of MUC1, together with the large and heavily glycosylated 
extracellular domain, plays a key role in initiation of anoikis and on antibody 
accessibility to cell surface anoikis initiating molecule. The importance of MUC1 
extracellular domain is further highlighted by the shRNA suppression of C1GT, as 
detailed in chapter 4. C1GT is a key glycosyltransferase in the biosynthesis of O-linked 
mucin type glycans, responsible for the formation of the Core 1-related complex O-
glycans. Suppression of C1GT blocks Core-1 O-glycosylation and results in increased 
expression of the short glycans GalNAcα (Tn) and sialyl-Tn (51). Data presented in 
chapter 4 shows that suppression of C1GT in cancer cell line HCT116 MUC1 full and 
SW620 decreased the size of MUC1 by over 25%.  Using the C1GT knockdown variant 
and the control variant of the same cell line in anoikis (suspension) culture, this 
change led to a significant increase in anoikis in only the MUC1 positive cells but not 
the MUC1 negative cells.  Further analysis showed that under suspension conditions, 
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reduction of the MUC1 O-glycosylation increased ligand/antibody accessibility to cell 
surface anoikis-initiating molecules such as E-cadherin, integrinβ1 and Fas and 
increased caspase-8 activity in response to exogenous introduction of Fas-L to 
suspended cells. 
The extracellular matrix plays a key role in maintaining tissue homeostasis by 
ensuring that under proper adhesion conditions, a cell receives appropriate signals 
to grow and divide.  The extracellular matrix has an abundance of large and heavily 
glycosylated proteins such as laminins and fibronectins. In normal epithelium, 
interactions between these ECM glycoproproteins and cell surface anoikis initiating 
molecules acts as trigger/sensor for anoikis activation. MUC1 extracellular domain 
shares two key characteristics with these ECM glycoproteins; it is large and has 
complex glycosylation. It is likely that that overexpression and abnormal 
glycosylation of MUC1, noted in epithelial cancer cells, provides a similar ‘home’ 
microenvironment to anoikis initiating molecules on cell surface as the ECM 
glycoproteins, thereby preventing their activation following cell detachment and 
facilitating anoikis resistance. A model of proposed mechanism is presented in figure 
7.1. 
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Figure 7.1: Model of the MUC1-mediated epithelial cancer cell resistance to 
anoikis. In normal epithelia, MUC1 polarizes at the apical side and has no influence 
on activation of the cell surface anoikis-initiating molecule. Loss of cell-Matrix 
contact leads to the activation of anoikis initiating molecules leading to cell death. 
In epithelial cancer, MUC1 is overexpressed over the entire cell surface and thus is 
able to interact with the cell surface anoikis-initiating molecules, preventing their 
activation during loss of cell-matrix contacts, leading to anoikis resistance.  adapted 
from (506) (open access article distributed under the terms of the Creative 
Commons CC BY license) 
 
It is possible that other members of mucin transmembrane family which are large in 
size and are heavily o-linked glycosylated may also have a similar effect on anoikis of 
epithelial cancer cells. The work presented in this thesis highlights the importance of 
cell surface glycosylation, altered in majority of epithelial cancers, in cancer cell 
progression and metastasis.  
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One of the hallmarks of cancer is the ability to maintain sustained proliferative 
signalling. Increased EGFR phosphorylation has been reported in numerous epithelial 
cancers and is now understood to be one of way to ensure autocrine proliferative 
signalling. The present study (chapter 5 and 6) shows that MUC1 expression increases 
EGF-induced EGFR activation in human breast and colon cancer cells. Depletion of 
either the MUC1 intracellular or extracellular domain could only partly abolish 
MUC1-associated effect on EGFR activation. This suggests that while both the MUC1 
cytoplasmic and extracellular domains contribute to EGFR activation, some of the 
effect mediated by the MUC1 intra- and extra-cellular domain on EGFR activation is 
also relatively independent. The fact that depletion of the MUC1 extracellular 
domain resulted in greater reduction of MUC1-associated EGFR activation than 
depletion of the MUC1 intracellular domain indicates that the predominate influence 
of MUC1 on EGFR activation derives from its extracellular domain. MUC1 (487) and 
EGFR (488) have both been shown to be associated with lipid rafts on cell membrane. 
It is possible that the expression of MUC1 and its association with EGFR in the lipid 
raft on the cell surface might increase the proximity of EGFR molecules in the 
microdomains of lipid raft for them to be in a better position to form homo-/hetero-
dimers in response to ligand banding. 
Interaction of cell surface MUC1 with galectin-3 is seen in this study to induce 
changes of MUC1 cell surface localization and increases MUC1-EGFR interaction. This 
leads to an increase of EGFR homo-/hetero-dimerization and subsequently increased 
EGFR activation and downstream signalling. This effect of galectin-3 occurs only with 
the full length but not the truncated galectin-3 form that lacks its N-terminal domain 
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responsible for galectin-3-mediated receptor clustering. Thus, MUC1 interaction with 
galectin-3 enhances EGFR dimerization and activation in epithelial cancer cells. The 
effect of galectin-3 on MUC1 cell surface localization was indeed visible in this study, 
irrespective of the presence or absence of EGF. However, galectin-3 presence 
enhances EGFR activation only when EGF is also present. This indicates that galectin-
3 cannot activate EGFR without the presence of an EGFR ligand. MUC1 cell surface 
polarization induced by MUC1-galectin-3 interaction has been shown previously to 
expose underlying smaller cell surface molecules (24, 76, 334). The discovery that 
EGF showed much weaker effect on EGFR activation in the MUC1-negative than in 
the positive cells, irrespective of the presence of galectin-3 (Fig 5.3, Fig 5.4, Fig 5.6 
and Fig 5.7), indicates that exposure of cell surface EGFR for easy EGF access is 
unlikely a mechanism of the MUC1-galectin-3 interaction-associated EGFR activation.     
MUC1 co-immunoprecipitation showed a weak presence of EGFR in MUC1 
immunoprecipitates but a substantial increase after addition of galectin-3, with or 
without the presence of EGF. This, together with the discovery that the presence of 
galectin-3 alone did not induce EGFR dimerization, suggests that galectin-3-MUC1 
interaction is essential for galectin-3-associated, EGF-induced EGFR activation. The 
importance of galectin-3-mediated change of MUC1 cell surface localization in EGFR 
activation is supported by the discovery that the presence of a truncated form of 
galectin-3 (galectin-3C), which lacks the N-terminal domain responsible for galectin-
3-induced ligand clustering hence could not induce MUC1 polarization, did not show 
any effect on EGFR dimerization and activation or ERK signalling, in the presence of 
EGF in MUC1-positive cells.   
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An earlier study has proposed formation of a bridge formed by galectin-3 between 
MUC1 and EGFR in cancer cells (513). In our study, very minimal galectin-3 was co-
immunoprecipitated with EGFR and addition of exogenous galectin-3 also showed no 
effect on EGFR association with galectin-3 and in the cells (chapter 6). Addition of 
galectin-3 also did not show any effect on EGFR phosphorylation, EGFR dimerization, 
or ERK activation in the MUC1-positive cells in the absence of EGF, nor did it show 
any effect on EGFR activation in the MUC1-negative cells even in the presence of EGF. 
These findings indicate that a direct binding of galectin-3 to EGFR, even if it occurs, 
does not contribute to galectin-3-MUC1-associated EGFR dimerization and activation 
in those cells. It is noted that a recent study has reported a role of galectin-3 in 
promoting spheroid formation of lung cancer cells through activation of EGFR (490). 
Although that study did not identify the galectin-3 binding ligand related to the 
effect, their discovery of the requirement of the galectin-3 carbohydrate recognition 
domain in its effect is broadly in keeping with an effect of galectin-3-MUC1 
interaction on EGFR activation, which requires galectin-3 CRD domain, shown in the 
present study.  
EGFR activation on the cell membrane is known to trigger activation of an array of 
intracellular signalling pathways (214) including commonly Ras/MEK/ERK signalling 
activation.  EGFR activation induced by either MUC1 expression or by MUC1-galectin-
3 interaction is shown in this study to be accompanied by an increase of ERK 
activation. It is noted that in addition to increase EGFR activation, galectin-3-MUC1 
interaction also causes a prolonged activation of EGFR and ERK activation. It is 
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generally believed that EGFR activation is terminated primarily through endocytosis 
of the receptor-ligand complex which are either degraded in the endosomes or 
recycled to the cell surface. It has been reported that if recycled EGFR is unable to 
reach the cell surface or to the lysosomal compartment but accumulates in the early 
endosomes, it will lead to prolonged signalling and increased activation of ERK (506).  
This does seem to be supported in our study. We found that following EGFR 
activation, more EGFR was seen to be located in a clustered pattern inside the cells 
in the galectin-3/EGF treated cells than in EGF alone treated cells. There was a much 
weaker EGFR cell surface localization in the galectin-3/EGFR treated cells than in the 
other groups including EGF-alone treated cells. This indicates that the galectin-
3/MUC1-mediated EGFR activation and subsequent EGFR endocytosis is associated 
with slower recycling of EGFR to the cell surface. This may provide an explanation for 
the prolonged activation of EGFR and ERK in those cells. This is also in keeping with 
an earlier study showing that MUC1 expression inhibits EGFR degradation in 
response to ligand binding but was accompanied by an increase of EGFR 
internalization in breast epithelial cells (507).   
We noted that the presence of EGFR phosphorylation inhibitor Lapatinib completely 
inhibited EGFR phosphorylation but detectable level, similar as the controls, of ERK 
activity remained in the cells irrespective of the presence or absence of EGF. This 
indicates that endogenous, non-EGFR-related ERK activity exists in the cells. ERK is a 
one of the vital signalling pathways in cell proliferation and is known to be regulated 
by a variety of growth factors and molecules (516). Expressions of either galectin-
3(479, 517, 518) or MUC1 (454) in cancer cells has been shown to induce ERK 
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activation. It is most likely therefore the inability of lapatinib to completely inhibit 
ERK activity in the cells is due to the existence of non-EGFR-related actions of 
endogenous molecules such as galectin-3, MUC1 or other molecules expressed or 
secreted by the cells.     
 
7.3 Final conclusions  
MUC1 overexpression is a common feature in epithelial cancer cells and is shown in 
this study to enhance cancer cell resistance to anoikis. Overexpression of MUC1 has 
been shown previously to inhibit E-cadherin-mediated cell–cell interactions and to 
increase the ability of the cancer cells to detach from adjacent cells at primary 
tumour sites and to promote tumourigenesis (56, 476). Interaction of cancer-
associated MUC1 with circulating galectin-3, a galactoside-binding protein whose 
concentration is markedly increased up to 30-fold in the bloodstream of cancer 
patients (483), via expression of the oncofetal TF antigen on MUC1 (76), induces 
MUC1 cell surface polarization and exposure of the cell surface adhesion molecules. 
This consequently results in increased homotypic aggregation and heterotypic 
adhesion of circulating tumour cells to the blood vascular endothelium and tumour 
cell spread (24, 334). Thus, overexpression of MUC1 in epithelial cancer cells can 
influence several steps in tumourigenesis and metastasis and each of these is 
influenced not only by the MUC1 protein expression but also by the MUC1 
localization/depolarization, its glycosylation patterns and the presence of its 
interacting proteins in the tumour microenvironment.  
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MUC1 expression is also shown in this study to increase EGFR activation in epithelial 
cancer cells and this effect is further enhanced by its interaction with galectin-3. EGFR 
represents a key therapeutic target for cancer treatment. Development of anti-EGFR 
strategies is a crucial area of clinical study for the treatment of solid tumours. 
Currently, main strategies include monoclonal antibodies directed towards the 
extracellular domain of EGFR, small molecule tyrosine kinase inhibitors targeting the 
catalytic kinase domain of EGFR and strategies to disrupt receptor trafficking to the 
cell surface. The discovery in this study that the expression of MUC1 and its 
interaction with galectin-3 promotes ligand-dependent EGFR activation has 
implications in EGFR-targeted therapies in cancer treatment. MUC1 and galectin-3 
are both well known to be commonly over-expressed by solid tumours. Over-
expressions of MUC1 and galectin-3 and their increased interaction on EGFR 
activation may therefore not only have an influence on EGFR-mediated 
tumourigenesis and cancer progression, but may also have an impact on the 
effectiveness of EGFR-targeted therapy. 
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7.4 Implication for future research 
While this study has identified that MUC1-galectin-3 interaction leads to increased 
EGFR activation and reduction in MUC1 size (through reduced O-glycosylation) leads 
to increased anoikis, there are still a few unanswered questions. For example, I 
wasn’t able to assess if MUC1 polarization has any effect on anoikis and on caspase 
3/7 level following suspension culture. As noted in this thesis, MUC1 polarisation 
leads to an increased access to underlying molecules. This could in theory lead to an 
increased level of anoikis (as anoikis initiating molecule on cell surface will more 
readily be activated) or reduce anoikis due to formation of tumour emboli. This could 
shed further light on potential MUC1-galectin3 interaction on anoikis. Additionally, 
we still don’t know if reduction in MUC-1 O-glycosylation has an effect on EGFR 
activation, following simulation with EGF. Since depletion of the MUC1 extracellular 
domain resulted in greater reduction of MUC1-associated EGFR activation compared 
to intracellular domain, the finding from this experiment could further identify the 
underlying mechanism behind MUC1 and EGFR interaction.  
One of the key finding in that thesis is that MUC1-galectin-3 interaction leads to 
increased EFFR and ERk activation following simulation with the ligand EGF. There 
are still a few limitations with this finding. Notably, EGF is one of the seven known 
ligands for EGFR. Other ligands such as TGF-α and amphiregulin are also noted to be 
overexpressed in tumour state. Further work is needed to assess if MUC1-galectin-3 
interaction leading to increased EGFR phosphorylation can be replicated with these 
ligands, Additionally, this study has mainly focused on EGFR/ErbB1 interaction with 
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MUC1. Due to similarity in structure of ErbB family of proteins and their involvement 
in development of various cancers, further study is warranted to assess if other 
members of ErbB family interacts with MUC1. Finally, this study only focused on 
MUC1-galectin-3 interaction on EGFR activation/phosphorylation on cell surface and 
did not explore further into receptor internalization, recycling and degradation. 
Further work in this area could lead to a better understanding of MUC1-EGFR 
interaction.  
 
7.4.1 Potential for translation into clinical practice 
Work done in this study also has possible therapeutic potential that could be 
explored further. Both galectin-3 and MUC1 are reported to be overexpressed by in 
epithelial cancer. Work done in our lab has identified circulating galectin-3 to be 
increased by up to 30 folds in patients with metastasising tumours. These patients 
are also reported to have an increased level of autoantibodies against MUC1 in 
circulation along with fragments of shed MUC1 itself. These molecules in circulation 
presents a novel target to be used as biomarkers for early detection of potential 
metastatic tumours.  
Targeting MUC1 and galectin-3 in circulation also presents as a potential therapeutic 
target against metastatic tumour. MUC1 has already generated a lot of interest in 
the research community and currently ranks second among 75 antigen candidates 
for cancer vaccines. Combining anti-MUC1 treatment with anti-galectin-3 therapy 
presents a novel way to therapeutically combat tumour metastasis in future. Several 
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compounds including modified heparin, gold–nanoparticles and modified antibiotics 
are currently under development as a potential means to target increased galetin-3 
in circulation.  
Increased EGFR expression and activation, seen in many cancers is currently targeted 
by anti-EGFR therapy such as with tyrosine kinase inhibitors (TKI) gefitinib, erlotinib 
and afatinib. Most patients receiving anti-EGFR therapies benefit from the 
treatment, but in some cases and especially in patients with prolonged use of TKI, 
the tumor ultimately develops drug resistance (507). In these patients combining 
therapy with anti MUC1 and anti-galectin-3 therapy presents a triple target to 
supress tumour proliferation and could perhaps increase the effectiveness of the TKI.  
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